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RÉSUMÉ 
Le virus influenza a été la cause d’épidémies et de pandémies parmi les plus anciennes et 
meurtrières rapportées dans l’histoire de l’humanité. La vaccination est le moyen le plus efficace 
de prévenir les infections. Par contre, la fabrication actuelle des vaccins contre l’influenza se fait 
dans les œufs, avec des embryons de poulet, un procédé lent et laborieux qui limite la capacité de 
répondre efficacement en cas de pandémie ou suite à une forte demande pour la grippe 
saisonnière. De plus, ces vaccins induisent principalement une réponse humorale contre les 
antigènes dominants  hémagglutinine (HA) et neuraminidase (NA), deux protéines du virus, 
causant un manque de protection croisée contre certaines des nouvelles souches. Leur efficacité 
est également réduite chez certains groupes plus vulnérables (par ex. personnes âgées et jeunes 
enfants). Par conséquent, l’industrie se tourne vers le développement d’une nouvelle gamme de 
vaccins plus immunogéniques et produits à partir de plateformes plus efficaces. Les particules 
pseudo-virales (Virus-like particles en anglais, VLPs) constituent une alternative intéressante 
comme vaccin.  Les VLPs présentent une structure qui s’apparente à celle des virus de type 
sauvage, en permettant la présentation à leur surface des antigènes principaux, dans leur 
conformation native. De plus, les particules pseudo-virales sont non-infectieuses et incapables de 
se répliquer. Les cellules de mammifères offrent plusieurs avantages comme plateforme 
d’expression pour la synthèse de nombreux produits biopharmaceutiques; elles sont capables 
d’effectuer des modifications post-traductionnelles complexes, de croître à haute densité et de 
produire des VLPs en suspension et en bioréacteur. Jusqu’à maintenant, les études traitant des 
VLPs influenza (produites avec des cellules de mammifères) se sont concentrées principalement 
sur l’assemblage du virion et sur le mécanisme de bourgeonnement cellulaire, alors que 
seulement un nombre limité d’études porte sur leur production à grande échelle et leur emploi 
potentiel comme vaccin. Dans le cadre de cette thèse, un bioprocédé transposable à grande 
échelle pour produire des quantités importantes de VLPs chimériques Gag-influenza à partir de 
cellules HEK-293 (cellules de reins issues d’un embryon humain) a été développé. 
En premier lieu, nous avons généré une lignée cellulaire HEK-293 exprimant de façon stable les 
protéines HA et NA (souche H1N1 du virus Influenza) sous le contrôle d’un système inductible 
au cumate. Ensuite, la formation des VLPs chimériques a été induite et dirigée par la transfection 
de plasmides codant la protéine Gag du virus de l’immunodéficience humaine ou la protéine M1, 
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une composante de la matrice du virus de l’influenza. La protéine Gag a été fusionnée à la 
protéine fluorescente verte pour faciliter le suivi de la production des VLPs. Les protéines 
antigéniques ont été produites 7 fois plus efficacement en présence de la protéine Gag, ce qui 
indique qu’il s’agit d’une meilleure protéine structurale que M1 dans ce contexte. Par conséquent, 
la production de VLPs contenant HA-NA et Gag (par transfection) a donc été transférée à 
l’échelle d’un bioréacteur de 3L avec agitation. Les VLPs ont été recueillies par 
ultracentrifugation sur un coussin de sucrose, puis concentrées par filtration à flux tangentiel en 
employant une membrane ayant des pores d’une taille limite de 1000 kDa. Plusieurs techniques 
ont été employées pour caractériser les VLPs produites: immunodiffusion radiale simple, essai 
d’hémagglutination, immunobuvardage de type Western et dot blot, ainsi que la microscopie 
électronique à transmission. Par ailleurs, lors d’essais sur des animaux, l’immunisation 
intranasale à partir de VLPs a permis d’induire une réponse immunitaire spécifique en plus de 
conférer une protection totale à toutes les souris soumises à l’épreuve (100% d’efficacité) avec 
une souche homologue de l’influenza. 
Après avoir démontré l’efficacité des VLPs comme vaccin in vivo (démonstration de faisabilité), 
une nouvelle lignée cellulaire inductible a été développée, exprimant cette fois les trois protéines 
HA, NA et Gag fusionnée à la GFP. Le but de générer une telle lignée était de simplifier le 
procédé de production en éliminant l’étape de transfection transitoire, qui peut être laborieuse à 
conduire à grande échelle. Sans sacrifier la production spécifique, le procédé a été optimisé pour 
obtenir une plus grande production volumétrique en augmentant notamment la densité cellulaire 
au moment de l’induction et en employant un mode de perfusion. L’opération a été réalisée à 
l’aide d’un bioréacteur de 3L et d’une filtration à flux tangentiel subséquente permettant 
d’augmenter les rendements de VLPs de 60 fois (3x1011 Gag-GFP événements fluorescents/L de 
culture mesurés par cytométrie de flux) en comparaison à une production sans perfusion (5x109 
Gag-GFP événements fluorescents/L). Le procédé a été caractérisé en déterminant la cinétique de 
production des protéines d’intérêts présentes dans les VLPs (le procédé en amont) ainsi que le 
taux de récupération pour chaque opération unitaire de la purification (le procédé en aval). 
L’opération du bioréacteur, en mode de perfusion et avec la lignée stable 293-HA/NA/Gag-GFP, 
a permis d’obtenir 5 fois plus de protéines antigéniques HA dans les VLPs que le bioréacteur 
opéré sans perfusion où la transfection transitoire a été employée. Le nouveau procédé développé 
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a permis de générer des rendements supérieurs à ceux publiés jusqu’à ce jour pour des VLPs 
influenza produits à partir de cellules de mammifères. 
Finalement, dans le but de répondre à certaines préoccupations de biosécurité associées à un 
usage potentiel de VLPs comme vaccins (parce que ce sont des particules enveloppées qui 
bourgeonnent d’une cellule hôte et qui renferment des protéines cellulaires, de l’ADN et de 
l’ARN), nous avons effectué une caractérisation du protéome des VLPs Gag-influenza produites 
par transfection transitoire et des vésicules extracellulaires produites par des cellules HEK-293 de 
type sauvage. Les fonctions des protéines identifiées dans les VLPs et dans les vésicules 
extracellulaires ont été discutées. 
Le procédé développé dans le cadre de cette thèse devrait être efficace pour produire des VLPs 
exposant les protéines HA et NA issues de différentes souches d’influenza. Les VLPs produites 
pourraient être évaluées dans le cadre d’essais cliniques dans le but de conduire au 
développement d’un vaccin efficace et sécuritaire pour remplacer ou complémenter le procédé 
actuel de production dans les embryons poulets. 
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ABSTRACT 
Of the fatal infections noted in human history, influenza epidemics and pandemics are among the 
most ancient. Vaccination remains the most effective tool to prevent infection. However, the 
current production of influenza vaccines in embryonated chicken eggs has limited capacity 
during pandemics or high demand seasons, and is both labor-intensive and time-consuming. 
Furthermore, the seasonal egg-produced vaccines mainly induce humoral response to the 
Hemagglutinin (HA)/Neuraminidase (NA) dominant antigens, which leads to a lack of cross-
protection against other non-matching novel strains. In addition, the vaccines provide low 
protection in high risk groups (e.g., elderly and young children). Consequently, the industry is 
moving toward the development of novel, more immunogenic influenza vaccines as well as more 
efficient production platforms. Virus-like particles (VLPs) constitute a promising alternative as 
influenza vaccine. They mimic the particulate structure of wild-type viruses while they are non-
infectious, non-replicative particles, and the main antigens repetitively displayed on their surface 
maintain the native conformation. Mammalian cell culture offers several advantages for the 
production of biopharmaceuticals such as their ability to perform complex post-translational 
modifications and the high cell densities and productivities reached in suspension culture 
bioreactors. Up to now, the production of influenza VLPs from mammalian cells has been mostly 
addressed to study influenza assembly and budding mechanisms but little attention has been paid 
to its potential use for large-scale manufacturing of VLPs as influenza vaccine candidate. The 
aim of this thesis was to develop a scalable process to produce large quantities of chimeric 
influenza Gag-VLPs from stable human embryonic kidney HEK-293 cells in suspension culture.  
First, a HEK-293 cell line stably expressing HA and NA proteins of influenza (subtype H1N1) 
under the regulation of the inducible cumate system was established. Then, the formation of 
VLPs was mediated by transient transfection of plasmids encoding human immunodeficiency 
virus (HIV) Gag or M1 influenza matrix protein. Gag protein was fused to the green fluorescent 
protein (GFP) to facilitate the monitoring of VLPs production. VLP antigenic proteins were 
produced seven times more efficiently in the presence of Gag, indicating that Gag is a better 
scaffolding protein than M1 in this context. Subsequently, the production of HA-NA containing 
VLPs after transient transfection of Gag as scaffold protein was successfully implemented in a 3-
L controlled stirred tank bioreactor. VLPs were recovered by ultracentrifugation on a sucrose 
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cushion followed by concentration through tangential flow filtration (TFF) using a 1000 KDa 
cut-off membrane. Different techniques were employed to characterize the produced VLPs: 
Single radial immunodiffusion (SRID), hemagglutination assay, dot-blot, western-blot, and 
transmission electron microscopy (TEM). Of great significance, intranasal immunization of VLPs 
induced specific immunogenic response and provided complete protection in mice challenged 
with the homologous influenza strain.   
Once the proof of concept of VLPs as an efficacious influenza vaccine was demonstrated in vivo, 
we developed a new inducible cell line expressing the three proteins HA, NA and the Gag fused 
to GFP. This was performed in an effort to streamline the production process by eliminating the 
transient transfection step that can be cumbersome at large scale. The process was optimized to 
reach a high volumetric yield of VLPs by increasing the cell density at the time of induction 
without sacrificing the cell specific productivity. By operating a 3L-bioreactor in perfusion mode 
followed by TFF, the yields of VLPs were improved by 60-fold (3x1011 Gag-GFP fluorescent 
events/L of culture measured by flow cytometry) compared to a standard batch culture (5x109 
Gag-GFP fluorescent events/L). The process was characterized for the upstream kinetics of 
production of VLP proteins and recovery rates for each downstream step. The production of a 
single bioreactor, operated in perfusion mode, with the stable cell line 293-HA/NA/Gag-GFP 
yielded 5-fold more total VLP antigenic HA proteins than what was produced with the 3L-batch 
bioreactor using transient transfection. Our process provided unprecedented yields of influenza 
VLPs produced from mammalian cells. 
Finally, because VLPs are enveloped particles that bud from a host cell potentially enclosing host 
cell proteins, DNA and RNA, which could pose a safety concern, we performed a proteomic 
characterization of the influenza Gag-VLPs produced by transient transfection and also 
extracellular vesicles (EVs) produced from wild-type HEK-293 cells. The functions of all 
proteins identified within VLPs and EVs were critically discussed. 
The process developed in this thesis could support the production of VLPs harboring HA and NA 
of different strains for clinical trials and could potentially result in a better vaccine candidate with 
higher efficacy and safety to replace the current labor-intensive egg-produced influenza vaccines. 
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CHAPTER 1 INTRODUCTION 
 Research problem 
Influenza is still a major threat to human health causing high morbidity and mortality in humans 
Influenza outbreaks are among the most ancient and lethal infections in human history. The 
reason for the persistence of this disease is because the causative agent is a virus with high and 
fast mutation rates. The mutations occur in the dominant antigenic proteins exposed in the viral 
envelope, hemagglutinin and neuraminidase. Thus far, there exist 18 types of HA and 11 NA that 
conform different strain subtypes. The new mutant strains cannot be recognized by the host 
immune system and therefore can cause severe infections. Vaccination remains the most effective 
way to combat the disease. Influenza vaccines have been produced in eggs for more than 70 
years, but this system carries major drawbacks such as limited production capacity in case of high 
demand seasons or pandemics, egg allergies in some patients and low adaptability of some strains 
to eggs, which can result in mismatch with the circulating strains. Furthermore, the seasonal 
vaccines are highly efficacious in healthy adults but poorly immunogenic in high-risk groups 
(elderly, young children and pregnant women). With the great progress made in the development 
of cell culture process to produce biopharmaceuticals, many researches are now focused on 
switching the manufacturing of influenza vaccines to cell based production. Mammalian cells 
offer several advantages for the production of complex biomolecules such as superior post-
translational modifications and easy adaptability to grow in serum-free suspension cultures. 
Among mammalian cells, human cell lines provide a glycosylation pattern homologous to 
endogenous human proteins reducing the risk of reactogenicity of biopharmaceuticals for human 
use. On the other hand, there is a need for new generation of influenza vaccines that mitigate the 
limitations of current seasonal vaccines and induce cross-protective immune response. Virus-like 
particles constitute an attractive platform to present the dominant antigens HA and NA in their 
native conformational structure on a non-infectious, non-replicative particulate structure similar 
to wild-type virus. The repetitive high-density arrays of antigenic proteins elicit a strong humoral 
response while the particulate structure induces the uptake by professional antigen-presenting 
cells stimulating cellular immune response. The immunogenicity and efficacy of VLPs as vaccine 
candidates have been extensively proven by in vivo experiments. However, there are still 
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numerous challenges for the large-scale manufacturing of these nanoparticles and their approval 
as vaccines. There is lack of robust and scalable processes to produce sufficient amount of VLPs 
from mammalian cells. This fact has limited the development of efficient methods to purify and 
characterize influenza VLPs for use in clinical trials. As enveloped particles, VLPs bud from the 
host cell membrane taking up not only the viral antigenic proteins but also host cell proteins, 
DNA and RNA. In mammalian cells, VLPs are co-produced with extracellular vesicles (EVs) 
also containing host cell contaminants and having a similar size to the VLPs, which makes 
difficult the development of an efficient purification process.  
 Hypothesis 
To address the issues mentioned above, in this thesis we have made the following hypothesis. 
The design and development of a VLP producer HEK-293SF stable cell line adapted to 
suspension growth will allow to develop and characterize a scalable process to produce, and 
further characterize high yields of influenza VLPs that are immunogenic and protective. 
 Research objectives 
To demonstrate the veracity of the hypothesis, the following objectives were defined: 
 To develop a HEK-293SF inducible stable cell line expressing the main influenza 
antigenic proteins HA and NA and to compare the VLPs production yields after transient 
co-expression of M1 influenza matrix protein and Gag structural core protein of HIV-1. 
 To produce VLPs in a laboratory scale bioreactor and partially purify them to assess their 
immunogenicity and efficacy by in vivo experiments. 
 To develop and apply process intensification strategies to achieve high yields of VLPs 
aiming at large scale manufacturing. 
 To characterize the protein composition of VLPs and extracellular vesicles by LC-
MS/MS. 
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 Thesis organization 
Following this introduction, Chapter 2 provides a detailed literature review on the state-of-the-art 
of influenza vaccines, mammalian cells platform and virus-like particles; Chapter 3 presents the 
production process of VLPs in a 3L-bioreactor after transient transfection of a gag-containing 
plasmid and the results of the immunization with VLPs in an in vivo experiment. The 
methodology and results of this chapter have been published in the Vaccine journal and presented 
as a poster at the Cell Culture Engineering XV, Vaccine Technology VI and Virus-like particle & 
nanoparticle vaccines conferences. 
 Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, et al. (2016). 
“Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 
suspension culture: An effective influenza vaccine candidate”. Vaccine, 34:3371-80. 
Chapter 4 presents the process intensification strategies performed to increase the yields of VLPs 
produced from the stable cell line 293-HA/NA/Gag-GFP including a 3L perfusion bioreactor and 
the concentration of 9.5L harvest by tangential flow filtration. These results are presented in a 
manuscript entitled “Process Intensification for High Yield Expression of Influenza H1N1 Gag 
Virus-Like Particles using an Inducible HEK-293 Producing Cell Line” which has been 
submitted to the Vaccine journal. 
The proteomic composition of VLPs and EVs as well as a critical discussion of the function of 
each host cell protein identified in both nanoparticles species are presented in Chapter 5. This 
chapter is entitled “Proteomic characterization of influenza H1N1 Gag virus-like particles and 
extracellular vesicles produced in HEK-293SF”. 
Chapter 6 provides a general discussion of all the results obtained in each chapter; and, finally, 
Chapter 7 presents the main conclusions and recommendations. 
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CHAPTER 2 LITERATURE REVIEW 
 Influenza 
The name Influenza arose in the fifteenth-century in Italy, from an epidemic attributed to the 
“inﬂuence of the stars” (Barberis, Myles et al., 2016). In the years 1918-1920, influenza A virus 
caused one of the worst worldwide human pandemics in history. The so-called “Spanish flu” 
(H1N1) led to the death of at least 20 million people (Taubenberger, Reid et al., 1997). The 
“Asian ﬂu” (H2N2) in 1957 (70,000 deaths in North America) (Dunn, 1958; Neumann, Noda et 
al., 2009; Trotter, Dunn et al., 1959) and the “Hong Kong ﬂu” (H3N2) in 1967 (Cockburn, Delon 
et al., 1969) caused the second and third most important influenza A pandemics. Recently, the 
“swine ﬂu” pandemic of 2009–2010 provoked over 16,000 deaths worldwide (Garten, Davis et 
al., 2009). Most people call "flu" the “common cold” which is usually caused by some upper 
respiratory viruses such as rhinoviruses and coronaviruses, not by inﬂuenza viruses. Influenza is 
a severe acute disease that can occur in all age groups with symptoms such as sore throat, cough, 
high fever, headache, and muscular pains (Dermody & Chappell, 2011; Osterholm, Kelley et al., 
2012). The virus spreads quite rapidly through the air by droplets released from infected person 
sneezes or cough, and also by mucosal contact (eyes, mouth) with contaminated hands. The 
World Health Organization (WHO) reports approximately 3-5 million cases of severe illness 
worldwide and up to 500,000 deaths annually 
(http://www.who.int/mediacentre/factsheets/fs211/en/). Vaccination remains the best method to 
control and prevent seasonal and pandemic influenza. 
2.1.1 Classification and virus structure 
Influenza viruses have a genome of approximately 13.5 kb and belong to the Orthomyxoviridae 
family.  The viruses are classified into three types: A, B and C (Milián & Kamen, 2015; Noda, 
2011; Subbarao & Matsuoka, 2013; Zambon, 2014). Recently, a novel genus termed influenza 
virus type D has been isolated from cattle in the United States (Collin, Sheng et al., 2015) and in 
Europe (Ducatez, Pelletier et al., 2015). The main differences between influenza types A, B and 
C lie in the number of RNA segments, 8 in the case of type A and B and 7 segments for influenza 
C; unlike influenza A and B, influenza C only contains one envelope protein, the HEF 
5 
(hemagglutinin-esterase fusion) that binds to 9-O-acetylneuraminic acid receptors instead of the 
N-acetylneuraminic acid receptors recognized by influenza A and B (Gao, Brydon et al., 2008; 
Muraki & Hongo, 2010). Inﬂuenza type A viruses are the best-studied orthomyxoviruses causing 
the most serious infections in humans, and are also widespread in many avian and mammalian 
species (Steel, 2011). Inﬂuenza type B is limited to humans, although occasional infections to 
other mammalian species such as seals have been documented (Bodewes, Morick et al., 2013; 
Chen & Holmes, 2008). Two lineages of influenza B have been identified referred to as 
B/Yamagata and B/Victoria (Shaw, Xu et al., 2002). The influenza type C causes mild infections 
in both pigs and humans, thereby having less importance for public health (Zambon, 2014).  
Influenza A viruses are categorized into different subtypes based on the hemagglutinin (HA) or 
neuraminidase (NA). Recently, novel influenza viruses have been isolated from bats in Central 
America giving rise to a total of 18 different types of HA (H1-H18) (Tong, Li et al., 2012; Tong, 
Zhu et al., 2013) and 11 NA (N1-N11) (Jagadesh, Salam et al., 2016) identified to date. 
Combination of these proteins gives rise to several influenza virus subtypes with different 
antigenicity. The virus classification refers to the surface antigens exposed (e.g. H3N2, H5N1, 
H1N1). The nomenclature used to describe each isolated influenza viral strain is descriptive and 
includes: the type of virus (A, B, C), the original host (this parameter is not indicated in human 
isolations), the geographic site of origin, the registered strain number and the year of isolation. 
For influenza A viruses, the corresponding identified HA and NA subtype must appear (e.g. 
A/H1N1/PuertoRico/8/1934, A/Chicken/Pennsylvania/1370/83 (H5N2) (Horimoto & Kawaoka, 
2001). 
The influenza virions are enveloped with a negative-sense, single-stranded, segmented RNA 
genome. Influenza viruses type A contain eight RNA genome segments encoding at least 12 viral 
proteins. Each one of the first 6 segments mostly gives rise to one protein: PB2, PB1, PA, HA, 
NP, NA. The PB2 (basic polymerase 2), (PB1 basic polymerase 1), and PA (acidic polymerase) 
proteins form the RNA polymerase complex (Kawaoka & Neumann, 2012). Hemagglutinin (HA) 
is a type I transmembrane protein and is the most represented envelope glycoprotein. The 
nucleocapsid protein (NP) tightly wraps the genomic viral RNA. Neuraminidase (NA), type II 
transmembrane protein, is the second most represented envelope glycoprotein. There are some 
exceptions where some of these first 6 segments code for more than one protein. In some 
influenza A strains, the RNA segment that codes PB1 has a second open reading frame for the 
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protein PB1-F2 which have been involved in the degree of virulence of the virions (Conenello, 
Zamarin et al., 2007). Meanwhile, the 6th segment of influenza B virus also encodes a protein 
called NB that is not essential for viral replication in vitro (Hatta & Kawaoka, 2003) and 
structurally resembles the M2 protein of influenza A (Bouvier & Palese, 2008). The segments 7 
and 8 are spliced into two messenger RNA (mRNA) encoding two different viral proteins; 
segment 7 codes for the matrix protein (M1) and the third enveloped protein (M2), whereas 
segment 8 codes for two nonstructural proteins (NS1 and NS2). The highly conserved 5’ and 3’ 
ends of the viral RNA segments form a helical hairpin at which is bound the trimeric PB2, PB1, 
and PA RNA polymerase complex. Arginine-rich nucleoproteins with positive net charge coat 
the rest of the negative-charged RNA phosphate backbone, approximately one NP per 24 
nucleotides. These structures called the viral ribonucleoprotein (vRNP) are exported from the 
host cell nucleus and packaged at the plasma membrane to form the virion (Noda, Sugita et al., 
2012) (Figure 2-1). The shape of the virions can be either roughly spherical or ﬁlamentous with 
an approximated size of 80-120 nm in diameter, and a length of up to 20 μm in the case of 
filamentous particles. The morphology of the virions appears to be related to the source of 
isolation. Mostly filamentous structure virions are observed from clinical isolations and more 
spherical/rounded viruses are found during in vitro productions (eggs passage or cell culture) 
(Noda, 2011). The Table 2-1 summarizes the main functions of the viral proteins.  
 
Figure 2-1 Schematic representation of influenza virions. Hemagglutinin, Neuraminidase and M2 
ion channel are transmembrane proteins exposed in the viral envelope. The M1 matrix protein is 
found underneath the viral membrane. Inside of the enclosed lipid bilayer are the eight RNA 
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individual segments associated to the nucleocapsid protein and the RNA polymerase complex 
(PB1, PB2 and PA) forming the 8 helical vRNPs (adapted from (Dermody & Chappell, 2011)). 
Table 2-1 Inﬂuenza A virus strain A/PR/8/34 genome and proteins 
RNA 
segment 
Length 
(nucleotide) 
Encoded 
Proteins  
Protein 
size (aa) 
Protein function 
1 
2 
3 
2341 
2341 
2233 
PB2 
PB1 
PA 
759 
757 
716 
These three proteins form the heterotrimeric 
RNA-dependent RNA polymerase complex. The 
PA endonuclease generates the primers; the PB2 
binds the capped RNA and PB1 subunit 
performs the RNA synthesis (Stevaert & 
Naesens, 2016). 
4 1778 HA 566 The hemagglutinin is a homotrimeric 
transmembrane glycoprotein and the main 
antigenic determinant; it is crucial for the 
binding to sialic acid receptors at cell virus entry 
and membrane fusion at low pH in the 
endosome.  
5 1565 NP 498 The nucleoprotein encapsidates the viral RNA, 
control functions during RNA synthesis and is 
also involved in the virion morphology, probably 
through interaction with M1 (Bialas, Bussey et 
al., 2014). 
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6 1413 NA 454 The neuraminidase is a tetrameric surface 
glycoprotein and the second antigenic 
determinant. It cleaves terminal N-acetyl 
neuraminic acid (sialic acid) mediating the 
release of the new virions progeny. It also 
facilitates hemagglutinin-mediated fusion and 
viral spread in the respiratory epithelium 
(Jagadesh et al., 2016). Mostly, the HA:NA ratio 
in wild type virus is approximately 1:4. 
7 1027 M1 
 
 
 
 
 
M2 
252 
 
 
 
 
 
97 
The matrix protein (M1) interacts with the 
cytoplasmic tails of HA, NA, M2 (Chen, Leser 
et al., 2007) and also with the nucleocapsids in 
the vRNPs, and NS2 (Noda, 2011). M1 is 
involved in the virion assembly, budding and 
morphology as well as the nuclear export of the 
vRNPs. 
Integral membrane protein forming an ion 
channel crucial in the un-coating of virions 
inside the endosome and scission membrane for 
viral budding. The HA:M2 ratio is around 10 to 
100 M2 per HA molecule (Bouvier & Palese, 
2008). 
8 890 NS1 
 
 
NS2(NEP) 
230 
 
 
121 
The nonstructural protein 1 is an interferon-
antagonist that down-regulates host cell mRNA 
processing; reduces apoptosis of infected cells. 
The nonstructural protein 2 mediates the export 
of viral nucleocapsids from the nucleus; interacts 
with M1. 
9 
2.1.2 Infective replication cycle  
Influenza infection begins with the binding of hemagglutinin glycoprotein to the N-
acetylneuraminic (sialic) acid-containing receptors exposed on the host cell membrane. The term 
hemagglutinin arise from the protein’s ability to agglutinate red blood cells. HA is synthesized as 
a homotrimeric molecule (HA0) that is sensitive to cleavage from cellular serine-proteases. After 
cleavage, polypeptide HA0 is excised in two subunits: the immunodominant globular head HA1 
subunit that is responsible for the binding to sialic acid and the stalk domain HA2 that contains 
the fusion peptide involved in membrane fusion inside the endosome (Carr & Kim, 1993; 
Lorieau, Louis et al., 2013). The virus enters the cell via clathrin-mediated endocytosis. The low 
endosomal pH causes an important conformational change in the HA protein which is 
comparable to the opening of a coiled spring (Baker & Agard, 1994; Dermody & Chappell, 2011; 
Lorieau et al., 2013). The fusion peptide hidden within a hydrophobic region of HA moves out 
toward the membrane of the endosome causing the fusion of the virus envelope with the 
endosomal membrane (Ivanovic, Choi et al., 2013). After membrane fusion, the next step 
includes the release of the helical nucleocapsids from the virion to the cytoplasm mediated by the 
M2 ion channel present in the virus envelope. The hydronium protons enter into the virion 
through the M2 channel protein and this acidic environment in the inner virion causes weakening 
of the interaction between M1 and the helical nucleocapsids, provoking their release across the 
previously fused membrane to the host cell cytoplasm (Bouvier & Palese, 2008).  
Unlike most other RNA-containing viruses, influenza virus replication occurs in the nucleus 
(Pohl, Lanz et al., 2016). The RNA segments of infecting virions liberated to the cytoplasmic 
lumen are transported into the nucleus via the classical importin-α– importin-β1 (IMPα–IMPβ1)-
dependent nuclear import pathway (Eisfeld, Neumann et al., 2015). This is facilitated by nuclear 
localization signals present in the vRNPs. Once the viral genome segments get into the nucleus 
the negative-sense viral RNAs are transcribed to messenger RNAs. The subunit PB2 of the vRNP 
complex binds to cellular capped pre-messenger RNA while PA subunit cleaves them to generate 
primers for RNA synthesis. The PB1 polymerase transcribes the RNA terminating at 5’ poly U 
sequence found at the end of the RNA. These mature mRNAs are exported to the cytoplasm for 
translation in cellular ribosomes (Fodor, 2012). The polymerase also replicates the vRNA to a 
complementary RNA (cRNA) which serves as template for de novo vRNAs synthesis. Because of 
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their nuclear localization signals, NP and the trimetric polymerase are redirected again to the 
nucleus for the assembly of the ribonucleocapsids. Hence, the new progeny of vRNAs are 
assembled with NP and the RNA polymerase complex proteins newly synthesized inside the 
nucleus and then transported to the cytoplasm. This process involves the interaction with M1 and 
NEP. The transportation of mature vRNPs to the budding site is mediated by Rab11 vesicles 
(Eisfeld et al., 2015).   
The proteins of the viral envelope (hemagglutinin, neuraminidase and M2) take the secretory 
pathway through the endoplasmic reticulum (ER) and Golgi apparatus to the cell surface 
facilitated by the protein-trafﬁcking machinery. HA and NA head towards cellular membrane 
zones enriched in cholesterol, named lipid rafts, whereas M2 is not associated to these domains 
(Rossman & Lamb, 2011). M1 is one of the most abundant proteins in the virion and it is located 
throughout the inner side of the viral envelope. M1 interacts directly with the cytoplasmic tails of 
HA, NA and M2 and also binds to virus nucleocapsids giving it an important structural role in 
maintaining the morphology of the virus (Chen et al., 2007; Thompson, Petiot et al., 2015). The 
exact mechanism for viral budding initiation remains unknown. Studies on the formation of 
influenza virus-like particles revealed that the accumulation of HA at the lipid-rafts patches is 
sufficient to mediate membrane curvature and release of HA-containing vesicles (Chen et al., 
2007; Rossman & Lamb, 2011). Viral budding occurs on the apical membrane previously filled 
up with HA, NA, and M1 associated to the vRNP segments and M2 could mediate the membrane 
scission and viral release. The review of  Rossman, and Lamb (2011) proposed that, considering 
the inconsistencies encountered in the viral budding studies done with VLPs, there is not one 
single protein totally responsible of the influenza viral budding but rather it is a reduntant 
cooperation among them. Figure 2-2 shows the major steps in the infection cycle of influenza 
virus. 
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Figure 2-2 General steps in the infection cycle of influenza virus. First, the binding of virions to 
the cellular membrane and internalization in endosomes take place. Subsequently, there is release 
of the RNA genomes through the lipid bilayer after virus and endosome membrane fusion. 
Nucleocapsids enter into the nucleus for transcription and replication of the RNA segments. 
Finally, translation of the viral proteins, virus ribonucleoprotein assembly in the nucleus and viral 
budding at the host plasma membrane take place. 
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2.1.3 Influenza pathogenesis  
The pathogenicity of influenza is determined by both viral and host factors (Behrens, Stoll et al., 
2006). The amount of host cell receptors, the abundancy of enzymes responsible of virus entry 
and replication (e.g. availability of protease mediating the cleavage of HA0), and the 
immunocompetency of the individual are among the factors related to the host individual. Viral 
factors are determined by the affinity and ability of the virus strain subtype to bind to the host cell 
receptors, the susceptibility to antigenic mutation and reassortment with other co-infecting viral 
strains, and the capability to attenuate the host immune response, etc.   
In humans, the influenza virus infects and replicates in epithelial cells of both upper and lower 
respiratory tract (Taubenberger & Morens, 2008). Infected persons usually show asymptomatic to 
mild illness. The symptoms persist for 7-10 days and include fever, inflammation of the 
respiratory tract, cough, prostration, headache, etc. An experiment in healthy volunteers showed 
that a peak of influenza virus replication occurred 48 hours post-inoculation in the nasopharynx 
and little to no virus shedding was observed after 6 days (Barnard, 2009; Carrat, Vergu et al., 
2008). However, these results cannot be generalized since children or older persons were not 
included in the experiment, in whom the illness evolves differently. Since influenza virus infects 
epithelial cells, complications of the respiratory tract including tracheitis, bronquitis, 
bronchiolitis, otitis media, and sinusitis are commonly developed. Pneumonia and acute 
respiratory distress syndrome (ARDS) are the most severe complications of influenza infection 
(Li & Cao, 2016). The major reason of the high mortality during influenza pandemics is due to 
secondary bacterial infections mainly caused by Streptococcus pneumonia (Stegemann, Dahlberg 
et al., 2009). A strong overactivated immune response due to an uncontrolled production of 
cytokines have been reported in severe influenza infections causing lung damage (Li & Cao, 
2016). 
 Influenza vaccines 
The source of variation in influenza viruses arises from two phenomena: 1) the accumulation of 
point mutations in the coding RNA segments, which is known as antigenic drift and 2) the 
reassortment between RNA segments of two or more different virus subtypes co-infecting the 
same host cell, which is termed antigenic shift. The major variations introduced due to the 
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antigenic drift occur in the main antigenic determinants, the globular domain of HA (HA1) and 
NA. Consequently, the new mutant virions progeny cannot be recognized by the host immune 
system causing severe infections.  The antigenic shift occurs occasionally but can be extremely 
dangerous. By genome segments interchange, strains originally infecting one species may pass to 
another one appearing new to the immune system making the infection potentially highly fatal 
(Dermody & Chappell, 2011). 
These viral strategies used to escape the host immune system have made it very difficult for 
researchers to find an efficient vaccine to totally eradicate the disease. The first human influenza 
virus was isolated after propagation in ferrets in 1933 (Hannoun, 2013). The discovery of the 
causative agent of influenza triggered several investigations to develop an effective vaccine. The 
progress in the development of methods allowing large-scale cultivation in embryonated chicken 
eggs and methods for virus quantification by hemagglutination assay, made possible the 
production of the first inactivated vaccines in 1942, which showed protective efficacy against 
influenza A and B after evaluation in trials among US military recruits (Francis, 1953). 
Currently, after more than 70 years, the basic technology and principles of influenza vaccine 
production remain much the same (Sambhara & Stephenson, 2009).  
Thus far, influenza vaccines have to be annually updated to be effective against new emerging 
strains. Every year, through a surveillance system, the World Health Organization (WHO) 
identifies newly evolved antigenic strains most likely to predominate in the following influenza 
season. Twice a year, a committee assembled by WHO provides guidance to vaccine 
manufacturers on the viruses that will be included in the trivalent or quadrivalent influenza 
vaccines for the next seasons in the northern and southern hemispheres (Barr, 2014). Currently, 
vaccine companies have 6 months to produce their vaccines and provide them to public health 
systems. Two types of trivalent vaccines are approved for use: trivalent inactivated vaccine (TIV) 
and live attenuated virus vaccine (LAIV). These vaccines are composed of the 3 currently 
circulating seasonal influenza virus strains: two subtypes of influenza A virus (H3N2 and H1N1) 
and one strain of influenza B. The vaccine update is carried out by genetic reassortment between 
the field strains chosen by WHO surveillance and the backbone of A/PR8/34 master strain that 
has been shown to grow to high titers in embryonated eggs (HA and NA genes are exchanged). 
For influenza B, the field isolates are the seed strains for vaccine production because there is no 
evidence thus far of any master influenza B with high growth in the egg-based production 
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system. Once the seed strains are confirmed to be the reference strains by identity testing and 
sequence analysis, vaccine production begins. The TIVs can be prepared as whole inactivated 
virus- and split virus or subunit vaccines. Viruses are grown in the allantoic cavity of 
embryonated eggs, harvested, chemically inactivated by formalin or -propriolactone and 
purified by ultra-centrifugation (whole inactivated virus vaccine), then, viruses can be split using 
a nonionic detergent and the HA and NA are purified (split virus or subunit vaccines) (Gerdil, 
2003; Milián & Kamen, 2015). The LAIVs were produced in the 1960s by serial passage of the 
virus in eggs under suboptimal conditions at low temperature, selecting for variants that could 
grow in the cool nasopharynx but could not grow in the lung. Master donor strains were 
established for vaccine production (Shaw, 2012; Wong & Webby, 2013). Recently, quadrivalent 
inactivated vaccines have been approved by the Food and Drug Administration (FDA) including 
another influenza B-lineage leading to superior immunogenicity against the added B strain 
(Greenberg, Robertson et al., 2013; Tinoco, Pavia-Ruz et al., 2014).  
2.2.1 Immune response to current influenza vaccines 
The immunogenic efficacy of the licensed seasonal influenza vaccines is associated with the 
patient age, displaying less protection in young children and elderly. Current conventional TIVs 
stimulate strong serum antibody responses against the major envelope glycoproteins HA and NA 
but elicit poorly mucosal IgA influenza-specific antibody and cellular immunity (Cox, Brokstad 
et al., 2004). Due to the antigenic drift that takes place in influenza A viruses, the main surface 
proteins mutate almost every year leading to new strains that cannot be neutralized by the host 
immune system. Thus, the immunity induced by seasonal TIVs vaccines is subtype-specific 
providing short-time protection. 
The primary immune response to LAIV vaccines consists in serum IgA and IgM that peak two 
weeks post-vaccination while the IgG serum can last for at least 1 year post-vaccination. The 
nasal fluid IgA elicited is significantly higher than those elicited with TIVs. The LAIVs induce 
secretion of interferon-γ, proliferation of T lymphocytes including cytotoxic T-cells. Both 
vaccines have shown high rate of protection in human, but LAIVs can be more immunogenic in 
young children since a prior natural infection is needed for eliciting a potent humoral response 
against TIVs (Cox et al., 2004). Both vaccines offer low protection in the elderly. 
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Considering that cytotoxic T-cell immunity is responsive to more conserved internal proteins 
which could be efficient for mediating cross-protection and fast recovery from the disease, 
vaccine candidates stimulating influenza A virus-specific CD8+ T cells are very promising 
(Grant, Quiñones-Parra et al., 2016; Johansson & Brett, 2007; Kang, Yoo et al., 2009; Trollfors, 
2006). 
2.2.2 Limitations of current vaccine manufacturing process 
The egg-embryonated technology that supports production of seasonal influenza vaccines carries 
some drawbacks that are pushing the scientific community to find novel and more efficient 
vaccine production platforms. Disadvantages associated with the egg-based production platform 
include: 1) adaptation of virus to eggs can introduce mutations that alter the composition of the 
hemagglutinin and negatively affect its antigenicity, 2) some virus strains cannot be efficiently 
grown in eggs which leads to a time-consuming process with the risk of developing undesired 
reassortants 3) the supply of eggs in the cases of pandemics or high demand seasons can be a 
limiting factor (one or two high quality eggs are needed per dose of vaccine). Also, diseases 
affecting chickens such as avian influenza virus outbreak can disrupt the supply eggs for vaccine 
production; 4) local or systemic allergic reactions to egg-derived vaccine components in 
vaccinated persons and 5) the requirement of biosafety level 3 to manipulate highly pathogenic 
viral strains or non-human influenza viruses (Genzel, Behrendt et al., 2013; Quan, Steinhauer et 
al., 2008; Tree, Richardson et al., 2001). 
Therefore, there is a need to develop a new generation of influenza vaccines and a robust 
production system that takes advantage of recent progress in bioengineering, biotechnology, 
molecular and cellular biology. Most of the available expression systems have already been 
explored for the production of influenza vaccines: mammalian cell culture (Chu, Lugovtsev et al., 
2010; Le Ru, Jacob et al., 2010; Paillet, Forno et al., 2011); insect cells (Cox & Hollister, 2009; 
Pushko, Tumpey et al., 2005); plants (Landry, Ward et al., 2010); bacteria (Rudolph & Ben-
yedidia, 2011). An excellent review from Milián, and Kamen (2015) provides a very complete 
state-of-the-art on current influenza vaccines that have been approved by the FDA along with the 
expression system used. For example, the Flucelvax influenza vaccine, originally developed by 
Novartis and recently acquired by SeqirusTM (a CSL company), is produced in Madin Darby 
Canine Kidney (MDCK) suspension cells and the Flublok, manufactured by Protein Sciences 
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Corp., is produced in insect cells and both vaccines have been licensed by FDA, demonstrating 
the potential of cell culture technology as a modern and robust influenza vaccine production 
system. 
2.2.3 Recombinant influenza vaccines 
Influenza vaccines design is a key issue for achieving broader humoral and cellular immunity 
combined with improved safety. Different influenza vaccine strategies have been examined so far 
mainly looking for a universal vaccine that can prevent infections from new strains, and also for 
vaccine presentation formats and adjuvants to increase immunogenicity; and induce a long-
lasting response. The subunit vaccines mainly based on the engineering of the HA antigen have 
been extensively approached (He, Leyrer et al., 2016; Song, 2016). Toward a universal vaccine 
based on HA, chimeric globular HA domain containing the main conserved epitopes from 
different clades/subtypes based on computationally optimized broadly reactive antigens 
(COBRA) (Ducatez, Bahl et al., 2011; Giles, Bissel et al., 2012; He, Prabakaran et al., 2014) and 
headless HA vaccine candidates containing conserved epitopes of the stalk domain able to elicit 
broadly protective antibodies (Krammer & Palese, 2013; Neu, Dunand et al., 2016) constitute 
promising approaches. In the same direction of finding universal vaccines targeted to conserved 
epitopes of viral proteins, the highly conserved extracellular domain of the ion channel M2 
protein (M2e) has been studied (Deng, Cho et al., 2015). Considering the role of M2 during the 
viral infection, the antibodies raised against this protein could inhibit the virus growth. However, 
since this protein is the least represented in the viral envelope, little M2e-specific humoral 
response have been detected by natural infection. In general, vaccine candidates based on M2e do 
not induce neutralizing antibodies; they have to be enhanced with strong adjuvants and/or 
advanced antigen presentation formats to be efficacious  (Krammer & Palese, 2015; Shaw, 2012).   
As an alternative approach, DNA- and viral vector-based vaccines have shown to preserve the 
native structure of the antigens efficiently (Chen, Cheng et al., 2008; Laddy, Yan et al., 2008; 
Smith, Wloch et al., 2010; Van Kampen, Shi et al., 2005). Several other studies have focused on 
peptide-based vaccines by combining different conserved epitopes as synthetic peptides to 
enhance T-cells response (Alexander, Bilsel et al., 2010).  Finally, virus-like particle vaccines are 
becoming a promising way to safely elicit both humoral and cellular response in the host immune 
system. 
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2.2.4 Influenza virus-like particles as vaccines 
Influenza virus-like particles (VLPs) are usually formed by recombinant expression of the major 
viral proteins, e.g., HA, NA, M1, and M2. These proteins mediate the budding of particles that 
resemble native influenza virus as observed by electron microscopy. The VLPs do not contain 
viral genetic material; they are non-replicating and non-infectious particles displaying HA and 
NA antigens in the lipid envelope. The displayed viral glycoproteins keep their native 
conformational structure and intact biochemical functions (Haynes, 2009). VLPs are more 
immunogenic than subunit vaccines and induce an immune response similar to the wild-type 
virus, without the associated safety concerns. The repetitive display of the main antigens on 
VLPs and their particulate structure enhance phagocytosis such that they are easily taken up by 
antigen-presenting cells, especially dendritic cells. The antigenic epitopes are cross-presented 
through MHC I molecules resulting in the activation of cytotoxic T lymphocytes. Furthermore, 
VLPs can induce strong activation of B cell response in a T cell-independent mode. The high-
density of epitopes on the VLPs envelope induces the crosslinking of the B-cell receptor 
promoting the B cells proliferation, T-helper activation by MHC II presentation, 
immunoglobulins secretion and generation of long-lasting memory B cells (Chen & Lai, 2013; 
Rynda-Apple, Patterson et al., 2014).  
The viral proteins required for the formation of VLPs have varied in many studies. VLPs have 
been assembled from the co-expression of HA/NA/M1/M2 (Pan, Wei et al., 2010), HA/NA/M1 
(Pushko et al., 2005), HA/M1 (Song, Hossain et al., 2010), or by the single expression of M1 
(Gómez-Puertas, Albo et al., 2000), M2 (Rossman, Jing et al., 2010), NA (Lai, Chan et al., 
2010), and HA (Chen et al., 2007; D’Aoust, Couture et al., 2010). These inconsistencies 
observed in the production of VLPs have brought to light that the mechanisms of viral budding of 
influenza viruses are not completely understood. As mentioned previously, it appears that there is 
not a single protein responsible for the viral budding but rather there is a certain redundancy 
among them (Rossman & Lamb, 2011). It is worth mentioning that most of the studies done to 
elucidate viral budding mechanism have been performed in different expression systems and 
using different vectors to deliver the recombinant genes. The expression system may influence 
the budding mechanism, since the host cell provides the cellular machinery for the virus 
replication and budding. 
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The baculovirus/insect cell-expression system is the most widely used to produce influenza VLPs 
(Vicente, Roldão et al., 2011). Several studies producing influenza VLPs in insect cells have 
shown the efficacy of the VLPs to induce protective immunity against influenza virus challenges 
(Bright, Carter et al., 2007; Galarza, Latham et al., 2005; Kapczynski, Tumpey et al., 2016; 
Pushko et al., 2005; Pushko, Tumpey et al., 2007; Quan, Huang et al., 2007; Smith, Flyer et al., 
2013). Moreover, infuenza VLPs have been generated in Nicotiana benthamiana (a close relative 
to the tobacco plant) providing cross-protection in ferrets and promising immunogenicity in 
humans (Landry et al., 2010). Generation of influenza VLPs has also been achieved in different 
types of mammalian cells, including: HEK-293T (HEK-293 containing the SV40 large T-
antigen), HeLa (human cervical cancer derived cells), Cos-1 (monkey kidney cells), and Vero 
cells (derived from the kidney of an African green monkey) resulting in efficacious protection in  
in vivo challenge experiments (Carter, Darby et al., 2016; Tang, Lu et al., 2011; Wu, Yeh et al., 
2010). Various strategies have been followed to deliver influenza genes in mammalian cells to 
generate VLPs. Tang et al. (2011) carried out the production of VLPs using a unique BacMam 
containing individual expression cassettes of HA, NA, M1 under the control of the CMV 
promoter. In this work, very basic optimization of the transduction conditions was performed. 
The MOI, incubation time, and the addition of sodium butyrate (an additive used for enhancing 
gene expression in baculovirus transduced cells) were established. Following sucrose gradient 
purification, baculoviral DNA was detected but there was no detectable baculovirus in the 
purified VLPs. A positive hemagglutination assay and protective immunity in animals showed 
the efficacy of the produced VLPs. Wu et al. (2010) obtained VLPs from a stable Vero cell line 
expressing M1, M2, NA and HA using plasmids with the inducible system based on tetracycline 
operon. The work was focused on the characterization of VLPs recovered by ultracentrifugation. 
A detailed analysis of the VLP proteomic composition, glycosylation profile and demonstration 
of VLPs efficacy in animals was presented. These studies demonstrated the immune-protective 
efficacy of influenza VLPs derived from mammalian cells. However, more efforts are needed in 
order to develop and optimize a process to scale-up the influenza VLP production in mammalian 
cells with the ultimate goal that this approach can become seriously considered for large-scale 
vaccine manufacturing. 
Table 2-2 shows different types of VLPs, including influenza-like, that have been licensed and/or 
are in the process of acceptation as vaccines.   
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Table 2-2 Virus-like particles in development phase and/or licensed for use as human vaccine 
(Effio & Hubbuch, 2015). The expression system used is specified for influenza VLPs. 
Development stage Virus/pathogen/disease 
Preclinical Chikungunyavirus (Metz, Martina et al., 2013), Coxsackievirus B3 
(Koho, Koivunen et al., 2014), Cytomegalovirus (Vicente, Burri et al., 
2014), Dengue virus (Schmitz, Roehrig et al., 2011), Enterovirus 71 
(Chung, Chen et al., 2010; Ku, Liu et al., 2014), Group A Streptococcus 
(Chuan, Wibowo et al., 2014), Human B19 parvovirus (Chandramouli, 
Medina-Selby et al., 2013), Human immunodeficiency virus (Buonaguro, 
Tagliamonte et al., 2012; Negrete, Pai et al., 2014), Human 
papillomavirus (Gissmann, 2009), Rotavirus (Li, Lin et al., 2014) 
Phase 1 Allergenic rhinitis/Asthma (anti IgE Qβ-VLP), Chikungunyavirus 
(Chang, Dowd et al., 2014), Ebola virus (Mohammadi, 2014), Influenza 
H1N1 (Low, Lee et al., 2014; Ward, Landry et al., 2014) (produced in 
bacteria and plant Nicotiana benthamiana, respectively), Influenza H7N9 
(Fries, Smith et al., 2013) (produced in insect cells (HA,NA and M1), 
Respiratory syncytial virus (Glenn, Smith et al., 2013) 
Phase 2 Alzheimer’s disease (amyloid Qβ-VLP) (Bachmann & Whitehead, 2013; 
Caputo, Graf et al., 2014), Human B19 parvovirus (Bernstein, Sahly et 
al., 2011), Influenza H1N1 (López-Macías, Ferat-Osorio et al., 2011) 
(produced in insect cells HA, NA and M1), Influenza H5N1 (Ward et al., 
2014) (produced in plant Nicotiana benthamiana) , Norovirus 
(Sundararajan, Sangster et al., 2015) 
Phase 3 Human papillomavirus (Erickson, Landers et al., 2014; Hildesheim, 
Wacholder et al., 2014), Malaria P. falciparum (RTS,S) (Umeh, Oguche 
et al., 2014) 
Licensed Human papillomavirus (Gardasil®, Cervarix®) (Dochez, Bogers et al., 
2014), Hepatitis B virus (Recombivax HB®, Engerix-B®) (Lacson, Teng 
et al., 2005), Hepatitis E virus (Hecolin®) (Zhang, Wei et al., 2014) 
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2.2.5 Gag as a core protein for VLPs 
Gag is the major structural protein of HIV-1 and comprises about 50% of viral particle mass. 
This protein is sufficient to produce non-infectious virus-like particles in the absence of other 
viral proteins. The major structural components of HIV-1 are derived from Gag precursor 
polyprotein and consist in three polypeptides: matrix layer (MA), conical capsid or p24 (CA) and 
the nucleocapsid (NC) and spacer proteins SP, SP2 and p6 (Briggs, Simon et al., 2004) (Figure 
2-3). The gag gene is translated by the ribosomes, followed by post-translational myristoylation 
and it is translocated throughout the cytoplasm to the plasma membrane where Gag molecules 
assemble and bud as immature particles (Ganser-Pornillos, Yeager et al., 2008) . There is a 
preference of Gag-based particles to bud from lipid rafts domain facilitated by interaction with 
host cell proteins (Spearman & Freed, 2009). For example, the association with caveoline-1 has 
been related to this fact (Yu, Beer et al., 2006). This feature is very significant for the use of Gag 
protein as a budding trigger of pseudo-type VLPs, like influenza, where the main envelope 
proteins are accumulated in lipid rafts regions of the membrane. Concurrent with the assembly 
and budding, the protease mediate the cleavage of Gag polyprotein in 6 proteins that get 
rearranged inside the virion to form the mature particles.  The Gag core protein of retroviruses 
has been employed to produce influenza-pseudotype Gag VLPs in insect cells (Haynes, Dokken 
et al., 2009). The co-expression of Gag and the envelope proteins of influenza gave rise to 
abundant quantities of homogeneous sized particles with the antigens correctly displayed in the 
envelope. The immunization of mice and ferrets with these VLPs elicited robust immunogenicity 
and protection. 
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Figure 2-3. Structure of Gag protein of HIV-1 (adapted from (Ganser-Pornillos et al., 2008). 
 Mammalian cells as expression system 
Mammalian cell culture has become an efficient technology to sustain high yield production of 
therapeutic proteins or vaccines in the biopharmaceutical industry (Le Ru et al., 2010). One of 
the major advantages associated with this expression system is that mammalian cells can perform 
complex post-transcriptional and post-translational modifications which are important for protein 
stability, ligand binding, functionality and immunogenic responses (Liste-Calleja, Lecina et al., 
2013). Thus, the development of the platform arises as a need to efficiently produce high-quality 
biopharmaceuticals that are less immunogenic for human use than those obtained from traditional 
methods, e.g., protein expression in bacteria, yeast or production of inactivated viral vaccine by 
passages in animals or in embryonated eggs as in the case of influenza (Barrett, Mundt et al., 
2009). Since the approval in 1980s of insulin and the licensure of Inactivated Poliovirus Vaccine 
produced in cell culture many investigations have moved toward this direction. From 2003 to 
2010 more than half of approved biopharmaceuticals were produced in mammalian cell cultures 
(Liste-Calleja et al., 2013).   
In general, there are three types of mammalian cell cultures that have been used so far. The first 
culture to be used was primary cell culture, in which the cells were directly taken from a human 
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or animal tissue. The inconsistency of the starting material (it may be composed of mixtures of 
cell types), very short lifespan and concerns about contamination with a number of potential 
adventitious agents limited their use (Barrett et al., 2009). The second type of cell culture 
employed was diploid cell lines. They are defined as “having a finite in vitro lifespan in which 
the chromosomes are paired (euploid) and are structurally identical to those of the species from 
which they were derived” (Barrett et al., 2009). These cells are restricted to a limited number of 
passages before senescence, which is not suitable for large-scale production. Diploid cell lines 
need a more demanding growth medium and are not easy adapted to serum-free conditions. The 
third type of cell culture involves the use of continuous cell lines (CCLs) that are defined as 
immortalized cell lines with an infinite lifespan. They are either derived from tumorigenic cells or 
from a normal population with potential tumorigenicity. Due to the tumorigenic origin of CCLs, 
for many years, they were not considered suitable for the production of biopharmaceuticals. 
However, taking advantage of the development of new techniques in immunology, virology and 
molecular biology; WHO established requirements for using CCLs to produce biological 
products.  For a long time, the CCLs were grown in adherent culture and required the constant 
supplementation of animal serum (leading to increased production costs and lot-to-lot 
variability), which has hindered their use for large-scale production. Moreover, the serum is an 
animal derived product that is poorly characterized and can be contaminated by adventitious 
agents.  The successful adaptation of some CCLs to serum-free media allowed to reach higher 
cell densities, increased yields of biological products and reduced manufacturing costs (Werner, 
Walz et al., 1992).  
Currently, many CCLs are well characterized and have been widely used either for recombinant 
protein expression or viral production. Specifically for the production of influenza viral vaccines, 
Madin Darbin Canine Kidney (MDCK) cells (Voeten, Brands et al., 1999), human embryonic 
retinal cells (PER.C6) (Pau, Ophorst et al., 2001) or Vero cells (Paillet et al., 2011) are among 
the most widely used. Influenza VLPs have been produced in Vero cells (Wu et al., 2010) and 
HEK-293T (Chen et al., 2007; Tang et al., 2011). MDCK and Vero cells are the preferred host 
for influenza virus production because MDCK cells can produce infectious particles at levels 
comparable with eggs and Vero cells are recommended by WHO for meeting the established 
requirements to produce viral vaccines (Barrett et al., 2009; Belsey, Lima et al., 2006). However, 
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these cell lines must be grown adherently in serum-containing medium which can be 
cumbersome for large scale production (cells are grown attached to microcarriers).  
The HEK-293 cell line has been widely used in the last decades for the production of viral 
vectors for gene therapy (Dumont, Euwart et al., 2015; Le Ru et al., 2010). Several studies about 
metabolism, scalability, and viral transfection have validated the use of HEK-293 cells  as an 
efficient and well-documented platform for the large scale production of recombinant proteins 
and viral vectors (Ansorge, Transfiguracion et al., 2009; Durocher, Pham et al., 2007; Henry, 
Dormond et al., 2004; Henry, Jolicoeur et al., 2011; Petiot, Jacob et al., 2011; Shen & Kamen, 
2012). HEK-293 cells grown in suspension culture (batch mode) with serum-free medium (HEK-
293SF) can reach cell densities up to 107 cells/mL (Côté, Garnier et al., 1998).  When HEK-
293SF cells were infected with influenza virus, titers of infectious influenza viruses as high as 
those obtained with the MDCK reference cell line, up to 109 infectious virus particles (IVP)/ml, 
were achieved (Le Ru et al., 2010). Recently, after baculovirus transduction in several cell lines 
(including Vero, HeLa, MDCK and HEK-293T) to produce influenza VLPs, it was demonstrated 
that 293T was the most susceptible cell line and yielded the highest protein expression (Tang et 
al., 2011).The major concern about the use of HEK-293 cells has been associated to their 
potential tumorigenicity but a previous study clearly established a relationship between 
tumorigenicity and the viable passage number. The study concluded that using low-passages 
cultures (<52) should be acceptable to regulatory authorities (Shen, Gu et al., 2008). There are 
now various biotherapeutic products produced in HEK-293 cell that have been approved by the 
FDA or the European Medicine Agency, showing the possibility of fast regulatory clearance and 
good safety profile of these cells for manufacturing biopharmaceuticals (Dumont et al., 2015). 
2.3.1 Mammalian cells expression regulation systems 
Living organisms have the ability to adapt to the environment by internal changes allowing their 
continued survival on our planet. These internal changes known as regulation mechanisms have 
been identified for a long time, but it was not until 1961 that the first mechanism was described at 
the molecular level (Jacob & Monod, 1961). The lactose regulation system in Escherichia coli 
became a paradigm for understanding the general concept of gene regulation. It represents a 
recurring molecular principle for adaptation of life to changing environmental conditions, even 
for gene regulation systems of higher eukaryotes (Fussenegger, 2001). E. coli can redirect its 
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metabolism for utilization of lactose as carbon source by expressing a set of genes encoded by the 
lactose (Lac) operon. The mechanism works depending on the absence or presence of lactose as 
the only source of carbon.  
Analogous mechanisms to this system are found in mammalian cells and are able to integrate 
metabolic, hormonal and environmental signals and orchestrate vital regulatory networks such as 
the cell-cycle, programmed cell death (apoptosis) and development (Fussenegger & Bailey, 
1998). In general, inducible regulation systems have been widely used in biotechnology and gene 
therapy since their discovery. The potential applications of these systems are huge, e.g. the 
possibility to express a protein or set of proteins in a regulated manner helps the study of 
metabolic pathways and the understanding of specific functions of proteins. Additionally, it 
provides the possibility to regulate both the level and duration of the expression of some proteins 
that are toxic by constitutive expression (Mullick, Xu et al., 2006). Furthermore, for large-scale 
production of proteins, even for nontoxic proteins, inducible regulation systems seem better 
because of the facility to express the recombinant protein at the desired cell density. The 
constitutive overexpression of a foreign protein in the culture could reduce cell growth and 
decrease cell viability (Spitzer, Landthaler et al., 2012). Several studies to develop a very 
efficient and tightly controlled inducible system to regulate the expression of proteins in 
mammalian cells have been performed. The ideal inducible system should have a very low basal 
protein expression (“off” state) as well as reversible and very high expression (“on” state) after 
induction (ability to switch efficiently from on to off state, and vice versa). Furthermore, the 
inducer should not have a pleiotropic effect on host cells and the ability to induce protein 
synthesis rapidly (Russell, 1999). 
Currently, the most widely used mammalian regulation systems are ecdysone (insect hormone) 
system (Melito, Qiu et al., 2008) and (Tet) tetracycline resistance operon from E. coli modified to 
function in mammalian cells (several different versions of Tet system have been developed so 
far). However, some limitations are still found in these systems, which has motivated the need to 
develop other inducible systems to extend their use to other specific biological applications. 
Mullick et al. (2006) have developed an inducible transcription system (cumate switch), derived 
from the p-cym operon of Pseudomonas putida, for expression in mammalian cells. This work 
demonstrated that the cumate gene switch can tightly control gene regulation for both transient 
and stable expression. Later on, researchers have used the stable cell line with this inducible 
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transcription system to generate stable lentivirus (LVs) from a packaging cell line (293SF-
PacLV) with the capacity to produce high-titers (up to 3.4 × 107 transducing units (TU)/ml) of 
LVs in suspension culture and in serum-free medium (Broussau, Jabbour et al., 2008). This last 
work confirmed the feasibility of harnessing the regulatory elements of the p-cym operon from P. 
putida to regulate gene expression in mammalian cells. 
2.3.2 Cell line development 
The growing demand for biopharmaceuticals produced in mammalian cells has compelled 
researchers to improve media composition, optimize culture conditions and develop sophisticated 
manufacturing technology to sustain higher yields of biological products in a cost-effective 
manner. Substantial progress has been made in the development of mammalian cell lines for 
stable expression of recombinant proteins (Noh, Sathyamurthy et al., 2013). Once it is 
established, the cell line can be optimized for large-scale production without the variability 
typically associated with the type of method or the delivery vectors involved in transient 
transfection (Browne & Al-Rubeai, 2007). The general method used to create a stable cell line for 
protein expression consists of various steps (Figure 2-4). First, the gene of interest (GOI) should 
be cloned in an appropriate plasmid containing the selection marker cassette. Also, two 
independent plasmids can be used, one containing the selection marker and the other one the 
GOI. Subsequently, the plasmid (or plasmids) is transiently transfected in the target cell line and 
the expression as well as the correct folding of the protein are verified before continuing to the 
next steps. Once the GOI expression is validated, the cells are cultivated under selective pressure 
in medium containing a selective agent (e.g. antibiotic). Only those cells that have integrated the 
plasmid can survive. To generate clonal cells, it is necessary to obtain single and isolated high-
producer cells because large variability between the transfectants is observed. This phenomenon 
occurs due to random integration of the gene copies in the chromosomes giving rise to different 
phenotypes. The gene can be inserted in a genomic region disrupting endogenous genes and 
affecting the normal growth of the cells (Noh et al., 2013). The expression levels of the 
recombinant protein are variable between the clones, probably depending on the number of 
inserted gene copies or the site of insertion. However, it has been shown that this variability 
appears in both transfected cells that produce a recombinant protein and the untransfected 
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parental cell line, indicating that variability is an inherent characteristic of the cells and does not 
just arise as a result of the gene insertion (Browne & Al-Rubeai, 2007).  
Since stable cell lines usually take time to be generated, a lot of effort has been made to find 
more efficient, cost-effective and high throughput methods for the selection of high-producer 
clonal cells (Browne & Al-Rubeai, 2007). Traditional methods include limiting dilution cloning 
in 96 wells plates. This method is still widely used owing to its relative simplicity and low cost 
but is labor intensive, time-consuming, has a low-throughput and requires exhaustive 
downstream analysis of product levels. New methods allow an increase in the number of screened 
samples and a reduction of the time required to select cells with suitable characteristics. It is 
worth to mention, flow cytometry and cell sorting, as well as automated systems, such as, 
ClonePix (Genetix), and CellCelectorTM (Aviso), which permit to identify and pick higher 
producer clonal cells as early as seven days after seeding by pre-programmed software. Finally, 
after selection of the best clone, various passages are made with the selected clone to confirm 
insertion stability.  Then, the production from the stable cell line is scaled up and optimized for 
production. 
 
Figure 2-4 General method followed to create a stable cell line for large-scale production of 
recombinant protein. 1) To make the plasmid construction with the gene of interest-selection 
marker and pursues transient transfection in the host cell for checking functionality of the 
expression cassette. 2) To stress transformed cells under selective pressure with the antibiotic. 3) 
Traditional method of clone selection by limiting dilution cloning in 96 wells plates and 
downstream analysis to check the expression by different techniques. 4) Scale up to large-scale 
suspension (Noh et al., 2013). 
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 Challenges associated to the large-scale manufacturing of VLPs for 
vaccine 
As mentioned before VLPs constitute a promising influenza vaccine candidate. However, to 
finally validate these particles as vaccines, more work should be done to improve VLPs design, 
and develop the upstream and downstream processing. Due to the versatility of VLP functions 
and structures, many innovative and creative designs can be implemented toward more 
immunogenicity and cross protection. Also, the upstream process should be further developed 
and optimized to reach high VLP titers in a cost-effective manner. The downstream process of 
enveloped VLPs needs to be developed as well. Harvesting high-yields of VLPs-containing 
broths from the upstream process will allow to test several purification strategies in order to 
obtain highly purified VLPs for a better characterization of the final product. The process 
development should be supported by robust qualitative and quantitative analytical methods for 
production monitoring and characterization of polished VLPs (Thompson, Petiot et al., 2013; 
Vicente et al., 2011). 
2.4.1 VLPs design 
VLPs can be classified as enveloped or non-enveloped depending on the presence or not of the 
lipid bilayer. The intrinsic nature of the viral proteins involved in the VLP self-assembly will 
dictate the structure of the particle. Non-enveloped VLPs are classified as: single-protein (e.g. the 
Human Papillomavirus (HPV) licensed vaccine) and multi-protein (e.g. VLPs derived from 
poliovirus (Bräutigam, Snezhkov et al., 1993) and infectious bursal disease virus-like particles 
(Kibenge, Qian et al., 1999)). Single protein non-enveloped VLPs are quite simple in structure 
while multi-protein VLPs are far more complex forming two or three capsid layers as in the case 
of rotavirus VLPs (Crawford, Labbe et al., 1994). In enveloped VLPs, such as influenza and 
HIV-VLPs, the matrix proteins are enclosed with the host cell lipid membrane at the budding site 
while glycoproteins are embedded and exposed in the membrane. The presence of the lipid 
envelope makes these VLPs less structurally homogeneous than their non-enveloped counterpart 
(Donaldson, Al-Barwani et al., 2015; Lua, Connors et al., 2014). 
The structural and functional versatility of VLPs give room for innovative designs. One single 
VLP can harbor different antigens to combat different diseases and/or disease mutants. Also, 
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even though VLPs possess self-adjuvanting properties, the combination of VLPs with molecular 
adjuvants can further enhance their immunogenicity. VLPs can be used to deliver proteins, DNA 
or RNA to specific cell types which have application for gene therapy (Garcea & Gissmann, 
2004; Kaczmarczyk, Sitaraman et al., 2011; Robert, Lytvyn et al., 2016). Several studies from 
Medigen, USA have reported the expression of multiples HA subtypes within a VLP (triple and 
quadri-subtyped VLPs) which conferred protection in ferrets against the corresponding strains 
(Pushko, Pearce et al., 2011; Pushko, Sun et al., 2016; Tretyakova, Hidajat et al., 2016; 
Tretyakova, Pearce et al., 2013). Also, multiple studies have investigated chimeric VLPs, where 
foreign proteins or antigens from other viruses, together with a core/capsid protein are co-
expressed within the same cell through genetic engineering. In the last decades, the recombinant 
hepatitis B virus core (HBc) has been widely used as carrier of foreign epitopes from many 
viruses such as influenza A, papillomavirus, human and simian immunodeficiency virus, 
cytomegalovirus and also bacterial protein epitopes (López-Sagaseta, Malito et al., 2016; 
Pumpens & Grens, 2001). In fact, in the malaria vaccine candidates Malarivax (Nardin, Oliveira 
et al., 2004) and Mosquirix (Cohen, Nussenzweig et al., 2010), the epitopes from 
circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite are presented on 
chimeric nanoparticles using as capsid core the HBcAg or HBsAg (hepatitis B surface antigen), 
respectively. 
VLPs can serve as a robust presentation platform for proteins that are naturally less 
immunogenic. An interesting work done by Kim, Song et al. (2013) showed that the 
incorporation of a tamden repeat of M2e domain together with HA on VLPs elicited a significant 
higher immunogenicity and cross-protection in absence of adjuvant compared with the wild-type 
M2 VLPs, in mice. Also, the immunogenicity of VLPs has been enhanced by incorporation of 
flagellin and granulocyte-macrophage colony-stimulating factor (Liu, Liu et al., 2016). The 
immunization with these modified VLPs promoted stronger Th1 and Th2 responses along with an 
enhanced B cells proliferation. Original and efficient VLP designs will hopefully speed up the 
path toward universal vaccines and vaccines of new generation. The rational design of VLPs 
should take advantages of computational tools. More and more databases are available going 
from full sequences of isolated viruses genome (NCBI) to databases like Immune Epitope 
Database Analysis Resource (IEDB) where a compilation of reported immune T- and B-cell 
epitopes and MHC molecules are available (Wong & Ross, 2016).  
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2.4.2 Upstream process 
The demonstration that VLPs are immunogenic and efficacious in small in vivo experiments can 
be easily supported with laboratory scale productions. However, in order to produce sufficient 
amounts of VLPs to accumulate stronger pre-clinical data and perform clinical trials, the 
production process should be carefully developed to be scalable, robust, reproducible, cost-
effective and rapid. Several aspects can be looked up and improved during VLPs production in 
cell culture processes. If working with stable cell lines, the screening process should be 
implemented with high throughput screening techniques that allow to select clones with optimal 
VLPs protein expression and growth. Both, protein expression and cell growth rate and/or 
metabolism can be differently affected in each clone depending on the integration site of the gene 
of interest. Hence, a combination of high cell specific productivity and cell specific growth rate 
will provide a more suitable clone for large scale manufacturing. In the case of enveloped VLPs, 
like influenza, where more than one protein is involved in their formation, it appears more 
reasonable to employ an inducible system to reduce the extra metabolic burden during growth 
phase due to the expression of the recombinant proteins. 
Most of the VLP productions in mammalian cells found in literature have been commonly 
mediated through transient transfection of at least one of the genes of interest (Cervera, 
Gutiérrez-Granados et al., 2013; Chen et al., 2007; Robert et al., 2016; Wu et al., 2010). 
Transient transfection of recombinant genes is very efficient for fast expression of the 
corresponding heterologous proteins (Durocher, Perret et al., 2002). In the case of influenza 
VLPs, transient transfection has been efficiently used to elucidate budding mechanisms (Chen et 
al., 2007) and also for small laboratory scale productions to demonstrate immunogenicity and 
efficacy of VLPs in animal experiments (Wu et al., 2010). However, for large-scale 
manufacturing, having a transient transfection step in the production process requires the use of 
an extra closed vessel connected to the bioreactor to mix DNA with the transfection agent. 
Moreover, some transfection agents are toxic for the cells (Ansorge et al., 2009) and stocks of 
plasmids should be maintained. For a process based on transient transfection, the 
DNA:transfection agent ratio and cell density at the time of transfection has to be optimized 
(Cervera et al., 2013). In order to achieve high production yields, different media should be also 
evaluated at small scale (Vicente et al., 2011). Metabolic flux studies can help to implement 
rational feeding strategies based on the culture limitations (Henry, Perrier et al., 2005). Certainly, 
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the metabolic state of the cells may vary throughout the culture time, so the bioreactor parameters 
should be carefully controlled and methods for online monitoring of crucial cell physiological 
aspects and product formation should be implemented for an efficient process performance 
(Ansorge, Lanthier et al., 2011; Henry, Kamen et al., 2007; Liu, Wang et al., 2016).  
Fed-batch and continuous perfusion processes are the most common strategies employed to 
increase cell density and product yields in mammalian cell cultures. In the fed-batch operation 
mode, cell cultures are supplemented with nutrients that are being consumed by the cells, 
preventing their depletion in the culture medium. However, the accumulation of metabolic by-
products might also inhibit cell growth (Hiller, Ovalle et al., 2017). Finding an optimum feed 
requires a meticulous study of the cell line metabolism to identify the limiting factors and best 
timing to overcome these limitations (Henry et al., 2004; Petiot et al., 2011). The use of a 
perfusion process can alleviate some of the limitations of fed-batch cultures; by continuous 
removal and addition of conditioned and fresh medium, respectively, the growth inhibitors are 
eliminated and favorable culture conditions can be maintained (Tapia, Vázquez-Ramírez et al., 
2016). This mode of operation is particularly suited to products that are unstable, because they 
are sensitive to temperature and/or degradation by proteases (Ansorge et al., 2009). To our 
knowledge, there are no reports applying this process intensification strategy to influenza VLPs 
produced from mammalian cells. 
2.4.3 Downstream process 
The use of influenza VPLs as vaccine is not only limited by the upstream stages of the production 
process, but also due to the lack of efficient purification and characterization methods. With the 
increased interest on these nanoparticles, more efforts have been dedicated to determine and 
solve the challenges associated with their downstream processing.  
The contaminants present in the harvest broth collected from the upstream process can be 
classified as product and/or process-related contaminants. The process-related contaminants refer 
to host cell proteins (HCPs), DNA, RNA, endotoxins, extracellular vesicles, etc. while product-
related contaminants are aggregates, misfolding structures and unassembled VLPs (Effio & 
Hubbuch, 2015). The purification process of VLPs involves different steps: clarification, 
concentration, diafiltration, and finally chromatography for intermediate purification and 
polishing.  
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The clarification process consists in the separation of cells and cell debris from supernatant. For 
enveloped VLPs, cell separation has been mostly done by centrifugation. However, other 
approaches have been implemented to make the process scalable. Negrete et al. (2014) succeeded 
to remove cells from harvest broth containing insect cells-produced Gag-VLPs by microfiltration 
at low shear forces using hollow fiber membranes of 0.45 µm. Maintaining low shear forces 
during clarification is critical for cells integrity and avoid increasing contaminants due to cell 
lysis. Also, low shear forces are favorable for envelope VLPs since these particles are highly 
sensitive to shear stress. Depth-filtration methodology has also been employed for cell removal of 
non-enveloped VLPs such as rotavirus-like particles (Peixoto, Sousa et al., 2007). Digestion with 
benzonase endonuclease is a popular method used early at the clarification step to remove DNA. 
Stabilizers or protease inhibitors can also be added at this step. The cell culture platform, 
upstream process strategy and VLP type will all determine the downstream process strategy. For 
example, the harvest broths collected from perfusion processes are almost free of cells due to the 
cell retention device, but greater volumes need to be processed. Harvest broths collected from 
production process in insect cells cultures contain not only VLPs, but also high amount of 
baculovirus. 
Once the harvest broth is clarified and is free of cells, the second step in VLPs downstream 
processing is the concentration and diafiltration of the clarified material. Originally, the 
concentration and purification of VLPs were mainly performed through ultracentrifugation. 
However, this technique is difficult to scale up, laborious, time-consuming and also VLPs are not 
recovered completely pure due to separation inefficiency (Effio & Hubbuch, 2015; Morenweiser, 
2005). Ultracentrifugation is still used for bench scale research, but it is not practical for large-
scale manufacturing. Nowadays, the most used technique to concentrate VLPs is tangential flow 
filtration using membranes of different cut-off depending on the VLP size. This ultra- and 
diafiltration (UF/DF) step allows to remove small extracellular vesicles and cell debris reducing 
HCPs and DNA contaminants. HIV-Gag VLPs have been efficiently concentrated using 
membranes with cut-off of 300 KDa (Cruz, Peixoto et al., 2000) and 500 KDa (Negrete et al., 
2014). Precipitation by polyethylene glycol (PEG) can be an alternative method for VLPs 
concentration, however the technique has some drawbacks such as irreversible aggregation and 
co-precipitation with other contaminants like nucleic acids (Effio & Hubbuch, 2015).  
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Recovering highly pure enveloped VLPs containing only the heterologous viral proteins has 
become challenging for the downstream processing of VLPs. These large multimeric protein 
complexes surrounded by lipid membrane contain (inside and/or attached) HCPs, DNA and RNA 
that cannot be removed even with the most refined polishing methods. However, 
chromatographic methods could be efficient for the removal of extracellular vesicles (EVs) that 
are co-produced with VLPs in mammalian cell cultures. The removal of EVs will increase purity 
since EVs are nanoparticles involved in cell-cell communication and they also contain HCPs, 
DNA and microRNA. Affinity chromatography methods could be the most rational approach to 
separate both nanoparticles species. Most likely, different types of proteins are expressed on the 
surface of each nanoparticle, which, once identified, can be used as potential targets in affinity 
chromatography. The protein identification can be done by LC-MS/MS. Other kind of 
chromatography like size exclusion may not be very efficient in this case, because VLPs and EVs 
are similar in size. Anion-exchange chromatography has been often used to remove HCPs and 
DNA (Negrete et al., 2014; Pincus, Boddapati et al., 2010).  
Analytical methods play a crucial role in the development of a robust manufacturing process. So 
far, most of the studies employed for VLP quantification rely on analytical methods used for 
influenza virus such as hemagglutination assay and single radial immunodiffusion. These 
methods are not high throughput and are not suitable for online monitoring of influenza VLPs 
during upstream and downstream processing (Thompson et al., 2013). The fusion of reporter 
proteins like GFP will facilitate the monitoring of VLPs production from in-process samples 
(Gutiérrez-Granados, Cervera et al., 2013). 
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 Abstract 
Virus-like particles (VLPs) constitute a promising alternative as influenza vaccine. They are non-
replicative particles that mimic the morphology of native viruses, which make them more 
immunogenic than classical subunit vaccines. In this study, we propose HEK-293 cells in 
suspension culture in serum-free medium as an efficient platform to produce large quantities of 
VLPs. For this purpose, a stable cell line expressing the main influenza viral antigens 
hemagglutinin (HA) and neuraminidase (NA) (subtype H1N1) under the regulation of a cumate 
inducible promoter was developed (293HA-NA cells). The production of VLPs was evaluated by 
transient transfection of plasmids encoding human immunodeficiency virus (HIV) Gag or M1 
influenza matrix protein. To facilitate the monitoring of VLPs production, Gag was fused to the 
green fluorescence protein (GFP). The transient transfection of the gag containing plasmid in 
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293HA-NA cells increased the release of HA and NA seven times more than its counterpart 
transfected with the M1 encoding plasmid. Consequently, the production of HA-NA containing 
VLPs using Gag as scaffold was evaluated in a 3-L controlled stirred tank bioreactor. The VLPs 
secreted in the culture medium were recovered by ultracentrifugation on a sucrose cushion and 
ultrafiltered by tangential flow filtration. Transmission electron micrographs of final sample 
revealed the presence of particles with the average typical size (150-200 nm) and morphology of 
HIV-1 immature particles. The concentration of the influenza glycoproteins on the Gag-VLPs 
was estimated by single radial immunodiffusion and hemagglutination assay for HA and by Dot-
Blot for HA and NA. More significantly, intranasal immunization of mice with influenza Gag-
VLPs induced strong antigen-specific mucosal and systemic antibody responses and provided full 
protection against a lethal intranasal challenge with the homologous virus strain. These data 
suggest that, with further optimization and characterization the process could support mass 
production of safer and better-controlled VLPs-based influenza vaccine candidate. 
Keywords: Influenza vaccine; Virus-like particles; TFF; Stable cell line; Quantification; HEK-
293 
 Introduction 
Influenza is an illness that causes high morbidity and mortality to human population worldwide 
(Wurm, 2004). The antigenic “drift” and “shift” phenomena are the origin of the appearance of 
new strains that cannot be recognized by the host immune system causing severe infections 
(Herzog, Hartmann et al., 2009; Rossman & Lamb, 2011). Thus, every year, seasonal influenza 
vaccines are produced in embryonated chicken eggs depending on the circulating strains (Effio & 
Hubbuch, 2015). The production in hen’s eggs carries major drawbacks that have been described 
elsewhere (Genzel et al., 2013; Le Ru et al., 2010). Additionally, the egg produced seasonal 
vaccines do not provide full protection in all age groups (Hessel, Schwendinger et al., 2010; Pica 
& Palese, 2013). These facts are driving the scientific community to urgently develop a new 
generation of influenza vaccines that is supported by a robust production platform taking 
advantages of recent progress in the fields of immunology, molecular and cellular biology, and 
bioprocessing sciences. 
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Mammalian cells possess several attractive attributes as a robust production platform candidate 
due to their ability to perform complex post-translational modifications and the high cell densities 
reached in suspension cultures in bioreactors. This fact has allowed to increase the platform 
yields and produce bioproducts of very high quality (Genzel et al., 2013). Additionally, the 
required-time to develop stable cell lines has decreased considerably in the past decade. Inducible 
promotors have been developed in mammalian cells as well, mainly to deal with the 
overexpression of toxic proteins (Mullick et al., 2006). The use of inducible promotors also 
allows to separate the growth phase from the production phase, thereby reducing the metabolic 
burden during biomass growth (Aucoin, McMurray-Beaulieu et al., 2006; Pattenden, Middelberg 
et al., 2005). 
From the perspective of new generation influenza vaccines, different approaches have been 
investigated to overcome the disadvantages associated to egg produced vaccines (Jegerlehner, 
Schmitz et al., 2004; Kim, Lee et al., 2014; Lin, Huang et al., 2011; Nadeau & Kamen, 2003; 
Sedova, Shcherbinin et al., 2012; Shaw, 2012; Smith et al., 2010; Van Kampen et al., 2005). 
Virus-like particle (VLPs) constitute a promising alternative to safely elicit an effective immune 
response since they mimic native virus (Wurm, 2004). Influenza VLPs have been mostly 
produced in insect cells. However, this expression platform has the inconvenience of baculovirus 
contamination in final samples (Krammer, Schinko et al., 2010). With the aim of avoiding these 
drawbacks and exploit the advantages of a superior platform, previous works have explored the 
production of influenza VLPs in mammalian cells. Most of these studies have been focused in 
elucidating the virus budding mechanisms (Chen et al., 2007; Dunn, 1958; Gómez-Puertas et al., 
2000; Lai et al., 2010) or testing the protective immunogenicity of VLPs in animals by directly 
using the sucrose cushion preparations (Cockburn et al., 1969; Tang et al., 2011). From a 
bioprocessing perspective, influenza VLPs have been produced in human embryonic kidney cells 
(HEK-293) cells but the production levels were significantly lower in comparison with insect 
cells, and contamination with extracellular vesicles was observed in final samples (Thompson et 
al., 2015). In this work, we have developed and characterized an efficient procedure to produce 
influenza VLPs from a cell clone stably expressing the hemagglutinin (HA) and neuraminidase 
(NA) of influenza subtype H1N1 (293HA-NA cells).  It is demonstrated that HA and NA 
containing VLPs can be efficiently produced following transfection of the 293HA-NA cells with 
a plasmid encoding the gag gene of human immunodeficiency virus (HIV) whose product acted 
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as scaffold. The extracellular vesicles were efficiently removed from final preparation by 
tangential flow filtration (TFF). The Gag-made nanoparticles assembled from 293HA-NA cells 
showed the typical morphology and expected size for immature HIV-1 particles. An extensive 
characterization and quantification of the influenza VLPs produced was performed by using 
different analytical techniques. The immunogenicity and protective efficacy of the VLPs was 
demonstrated in mice. 
 Materials and Methods  
3.3.1 Cells, plasmids and antibodies 
The cells were cultured in Hyclone SFM4Transfx-293 supplemented with 4-6 mM of glutamine 
in a humidified incubator at 37 ºC with 5% CO2, at an agitation rate of 100-110 rpm. The gene 
for M1 (CY033578.1) was codon optimized to human cells and the restriction sites for Hind III 
were added at both ends of the gene (GenScript) for subsequent cloning in pKCR5 plasmid. The 
plasmids pUC-HA and pUC-NA H1N1 A/Puerto Rico/8/1934 described in (Thompson et al., 
2015) were used as template for PCR to introduce the Kozak sequence and enzymatic sites. A 
NheI site was introduced toward the 5’ end (forward primers 5’-
ACTAGCTAGCGCCACCATGAAGGCAAACCTACTGGTCCTG-3’HA and 5’-
ACTAGCTAGCGCCACCATGAATCCAAATCAGAAAATAATAACC-3’ NA) and HindIII 
site at the 3’ end (reverse primers 5’-ACCCAAGCTTAGATCTTCAGATGCATATTCTGCAC-
3’ HA and 5’-ACCCAAGCTTAGATCTCTACTTGTCAATGCTGAATG-3’ NA). The plasmid 
pKCR5 contains the CR5 promoter that has been described in (Mullick et al., 2006). The HIV-1 
(HBX2) gag DNA with the Kozak consensus sequence was synthetized by TOPGene 
Technologies (Canada) and cloned PmeI/NheI in pAdCMV5-GFPq (Garten et al., 2009) to give 
rise the plasmid pAdCMV5-gagGFP. The primary antibodies used for the immunofluorescense 
assay were: Anti-HA LS-C140660 (LifeSpan BioSiences, USA) (I) and  Anti-NA ref: 04-230 
(NIBSC, UK) (II); for Dot-Blot assay: anti-HA monoclonal produce in-house (III), universal 
rabbit anti-NA HCA-2 (IV) ; for SRID: anti-HA ref: 03/242 (NIBSC, UK) (V); for western blots: 
(III), (II), Anti-M1 antibody [GA2B] (ab22396) (Abcam, UK) (VI), and anti-GAG monoclonal 
2p24 Biotinylated (Hybridoma 31-90-25, ATCC) (VII). The secondary antibodies for the 
Immunofluorescense assay were #115-495-003 (Jackson Immunoresearch, USA) (VIII) and 
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Alexa Fluor® #594 A11005 (ThermoFisher Scientific, USA) (IX); for Dot-Blot: the infrared-
conjugated secondary antibodies IRDye (LI-COR Bioscience, USA); for western blots anti-
mouse and anti-sheep IgG-HRP (Jackson Immunoresearch, USA).  
3.3.2 Generation of 293CymR-rcTA cell line 
The 293CymR-rcTA cell line was constructed at the National Research Council of Canada 
(NRC) by stably transfecting the plasmid pMPG-CMV5-CymROpt and pKCMV5-CuO-rcTA in 
the 293SF-3F6 cell line adapted to serum-free culture (Côté et al., 1998). CymR is the repressor 
and rcTA is the reverse transactivator of the cumate regulation system (Mullick et al., 2006). The 
addition of cumate in 293CymR-rcTA cells triggers the synthesis of rcTA and its binding, 
resulting in the activation of the cumate responsive promoter (CR5). 
3.3.3 Generation of 293HA-NA stable cells 
293HA-NA cells were generated by transfecting 1x106 cells/ml of 293CymR-rcTA cells with 8µg 
total DNA of  XbaI-linearized plasmids pKCR5-HA, pKCR5-NA and pcDNA6/his-Blasticidin 
(amount of 3:3:2 µg) using PEIpro (Polyplus transfection, France). The selection with Blasticidin 
S HCl (Enzo Life Sciences, USA) was applied 48 hours post transfection (hpt). Cells were split in 
96-well plates with 8-10 µg/ml of Blasticidin. After 3 weeks under selection, several clones were 
isolated, induced with cumate and screened by Western Blot.  
The induction of protein expression for all productions in 293HA-NA cells was done at a cell 
density of 1x106 cells/m using 100 µg/ml cumate (stock of 100 mg/ml in Ethanol 70%) (Ark 
Pharm, Inc., USA). The cultures were stopped at 48-72 h post-transfection. 
3.3.4 Immunofluorescence assay 
To perform this assay, 293CymR-rcTA and 293HA-NA cells were seeded at 0.8x106 cells/ml in 
6-well plates. At 48 h post-induction the culture was centrifuged to discard the supernatant.  Cell 
pellet was washed with 1% ice-cold BSA/PBS (bovine serum albumin/phosphate buffer saline) 
and incubated in 750 l of this solution for 30 min. Then, 1.5 L of antibody (I) at 3,7 mg/ml and 
2 L of antibody (II) were added to the cells and incubated for 1h. The cells were washed twice 
in 1%BSA/PBS. 2.5 L of VIII and IX secondary antibodies were diluted in 500 l 1% 
BSA/PBS and added to the cells for 1h incubation in the dark at 4ºC. Three washes with 
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1%BSA/PBS were done. The cells were re-suspended in 200 l 1% ice-cold BSA/PBS and 
transferred to a glass bottom 4-chamber dish for confocal analysis using a Fluoview FV10i, 
Olympus microscope.  
3.3.5 3L-Bioreactor  
A 3-L Chemap type SG bioreactor (Mannedorf, Switzerland) was employed to produce the VLPs 
under controlled and monitored conditions. The bioreactor features have been previously 
published (Le Ru et al., 2010).  
3.3.6 Ultracentrifugation and concentration of VLPs by sucrose cushion 25% 
VLPs were concentrated following a protocol that has been previously described elsewhere 
(Thompson et al., 2015). All the sucrose cushion samples presented in this work had a 
concentration factor of 25X. 
3.3.7 Tangential Flow Filtration 
The Minimate™ TFF System (PALL Corporation) was used for the ultrafiltration of the 
influenza Gag-VLPs from the sucrose cushion sample. A Biomax cartridge (1000 kDa 0.005 m2 
PXB01MC50 | Pellicon XL Ultrafiltration Module) was employed in the purification of influenza 
Gag-VLPs. Before start the purification, the cartridge was sanitized with 0.5 M NaOH overnight. 
Subsequently, the system was neutralized with SuperQ water. The tubing size used was 16 SI and 
the retention volume of tubing was measured as 8 ml. Hollow fiber cartridges were used to 
concentrate control-VLPs and influenza Gag-VLPs recovered from TFF at 1000 KDa cut-off (ref: 
D02-E300-05-N, D02-E750-05-N, Spectrum Laboratories, USA).   
3.3.8 Cell lysate using RIPA buffer 
The cell culture was centrifuged at 1000 rpm for 5 min. The cell pellet was washed twice with 1 
ml of PBS1X. The washed pellet was incubated 30 min on ice with 100 µl of RIPA buffer (50 
mM Tris-HCl at pH8, 150 mM NaCl 0,1 % SDS, 1% NP-40, 0,25% sodium deoxycholate). Then, 
the mix was centrifuged at 12000 rpm for 5 min. Samples were analyzed by SDS-PAGE and 
Western Blot, as previously described (Thompson et al., 2015).  
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3.3.9 Dot blot 
The protocol followed in this study has been previously published (Li, Jaentschke et al., 2010). 
Briefly, the standards anti-HA and anti-NA employed were hemagglutinin H1N1/A/Puerto 
Rico/8/34, (Protein Science, USA) and neuraminidase H1N1/A/USSR/90/77, (Sino Biological 
Inc., China). The detection system used was Odyssey CLx imaging, (LI-COR Bioscience, USA). 
3.3.10 Single Radial Immunodiffusion 
The previously published protocol (Thompson et al., 2015) was used and the standard curve was 
constructed with the same material used for Dot-Blot.  
3.3.11 Hemagglutination assay 
The protocol for hemagglutination assay (Thompson et al., 2015) was used. The quantity of 
VLPs/ml was calculated with the equation: 
Viral particle/ml= [𝑅𝐵𝐶] ∗ 10(𝑙𝑜𝑔𝐻𝐴𝑡𝑖𝑡𝑒𝑟)  ; where RBC is red blood cells per well ~2x106 
cells/well 
The number of RBCs are proportional to the number of viral particles at the end point dilution.                  
1 virus=1 RBC (Donald & Isaacs, 1954; Thompson et al., 2013).  
3.3.12 Determination of host cell proteins and host cell DNA 
The HEK-293 host cell proteins (HCPs) ELISA kit (Cygnus Technologies, USA) was employed 
to determine the concentration of HCPs in the samples. The host cell DNA was estimated using 
the Quant-iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher Scientific, USA).  
3.3.13 Fluorescence intensity measurement and p24 quantification 
The supernatant from daily sampling was recovered by centrifugation at 1000 rpm for 5 min.  
The fluorescence intensity was measured using the Spectrophotometer Synergy H1 BioteK 
microplate reader set as follows: λem=485nm and λex=528nm. The values graphed were calculated 
by subtracting the fluorescence intensity values obtained for non-transfected 293CmR-rcTA cells 
used as negative control. The concentration of p24 was determined using the HIV-1 p24 ELISA 
assay cat# XB-1000 (XpressBio, USA). 
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3.3.14 Transmission electron microscopy (TEM) 
Transmission electron micrographs were obtained using a Hitachi H-7500 TEM, operating in 
high contrast mode at an acceleration voltage of 80kV and at a magnification between 30,000x 
and 200,000x. Briefly, a 10µL of sample solution was adsorbed to a glow-discharged carbon-
coated copper TEM grid (Cu-300HD, Pacific Grid-Tech, CA). Sample was then stained with 10 
µL of freshly prepared and filtered 2% uranyl acetate which is applied directly on the grid. After 
10 s, the stain was removed by touching the edge of the grid with a filter paper. The grid was 
dried at room temperature prior to the TEM observation. 
3.3.15 Immunization and viral challenge 
Six to eight-week-old female BALB/c mice were purchased from Charles Rivers Laboratories 
(St. Constant, Quebec). All immunizations were done intranasally at day 0, 14, 21 under lightly 
anesthesia with isofluorane and using as adjuvant 1 µg cholera toxin (CT, Sigma-Aldrich Canada 
Ltd., Canada). A group of mice (n=10) was immunized with 50 µl of influenza Gag-VLPs 
containing 2 µg of HA based on concentration determined by Dot-Blot. Two groups of 5 mice 
each were immunized with 2 µg of recombinant influenza H1N1 HA (rHA) (A/Puerto Rico/8/34, 
Sino Biological Inc., USA) or unimmunized (naïve). A group of 7 mice was immunized with 
control-VLPs containing the same Gag concentration of influenza Gag-VLPs dose. At day 42, 
five influenza Gag-VLPs immunized mice and 2 control-VLPs immunized mice were sacrificed 
for blood and nasal lavage fluid collection whereas non-terminal blood samples were collected in 
5 rHA-immunized and 5 naïve mice as described elsewhere (Collin et al., 2015). All samples 
were stored at -20ºC until assay. Five weeks after the last immunization, mice were intranasally 
challenged with 103 plaque-forming units (pfu) of the mouse-adapted influenza H1N1 virus 
(A/Puerto Rico/8/34) in 50 µl PBS. Challenged mice were observed daily for 12 days to monitor 
body weight and surviving rates. 
3.3.16 Enzyme-linked immunosorbent assay (ELISA) for HA-specific 
antibodies detection 
The 96-wells Immunolon 2R microplates (Thermo Electron Corporation, USA) were coated with 
0.2 µg rHA/well in 50 µl of bicarbonate buffer (pH 9.6) at 4ºC overnight. All the subsequent 
incubations were carried out at room temperature. The plates were blocked with 5% bovine 
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serum in PBS for 1 h, and washed three times with PBS-0.05% Tween 20. Duplicates of 100 μl 
pre-diluted samples (1:10 for nasal IgA, 1:100 for serum IgA, IgG1 and IgG2a) were added to the 
wells. After 3 h incubation, alkaline phosphatase-conjugated goat antibodies specific for mouse 
IgA, IgG1 and IgG2a (Caltag Laboratories, UK) were added and incubated for 1 h. Color 
reactions were developed by the addition of p-nitrophenyl phosphate (pNPP) substrate (KPL, 
Inc., USA), and optical density was measured at 405 nm with an automated ELISA plate reader 
(Synergy H1, Bio-Tek Instruments Inc, USA). Pooled samples collected from mice that had been 
intranasally immunized with the rHA+CT or from the naïve mice were used as positive or 
negative controls for the assays, respectively. 
 Results and Discussion  
3.4.1 Development of 293HA-NA stable cells 
To generate the 293HA-NA cells the HA, NA and Blasticidin containing plasmids were 
transfected into the parental cell line 293CymR-rcTA (Figure 3-1A). At 48h post-transfection 
(hpt) cells were maintained under blasticidin selection. Several cell clones were isolated, induced 
with cumate and the cell lysates were analyzed by Western Blot (data not shown). The clone 
exhibiting the highest expression levels of HA and NA was selected as our stable 293HA-NA 
cells. The expression of HA and NA proteins at the surface of the 293HA-NA cells was also 
confirmed by confocal fluorescence microscopy. The two secondary antibodies employed in the 
immunoassay were conjugated with two different fluorophore signals: green (NA) and red (HA), 
respectively (Figure 3-1B). The membrane of the cells expressing both proteins turned orange 
because of the two-color mixed effect. Some cells that are expressing only HA (red membrane) 
or NA (green membrane) can be observed as well. The non-transfected 293CymR-rcTA cells 
were treated in the same way and no evidence of non-specific antibody binding was detected 
(Figure 3-1B). 
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Figure 3-1 Development of the 293HA-NA stable cell clone and analysis of VLPs production 
efficiency. (A) Schematic representation of plasmids pKCR5-HA and NA transfection in the cell 
line 293CymR-rcTA to create the stable cells 293HA-NA under the cumate regulation system 
(Mullick et al., 2006) (B) 72 h post-induction with cumate, live cells (no fixation) were observed 
by confocal microscopy. The arrow points to cell membrane with an orange tone due to 
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simultaneous expression of the two proteins HA and NA. (C) The influence of M1 and Gag 
proteins on VLPs production from 293HA-NA cells. Lanes (1 and 5) non-transfected 293HA-NA 
stable cells; (2 and 6) 293HA-NA cells transfected with pKCR5-M1; (3 and 7) 293HA-NA cells 
transfected with pAdCMV5-GagGFP; (4 and 8) non-transfected parental cell line 293CymR-
rcTA as negative control; (C+) sucrose cushion of influenza virus H1N1 A/PR/8/34 produced in 
HEK-293 cells. The culture supernatants were 25× concentrated through a 25% sucrose cushion 
and the cells were lysed with RIPA buffer. The same total protein quantity was loaded in each 
lane, 6 µg for sucrose cushion pellets and 50 µg for cell lysates. 
3.4.2 Comparison of influenza matrix M1 and Gag proteins effect on 
influenza VLPs production 
The effect of two different proteins in triggering the release of VLPs from 293HA-NA cells was 
studied. There are discrepancies in the literature regarding the role of M1 protein as the driving 
force for virus budding and assembly (Chen et al., 2007; Gómez-Puertas et al., 2000). It appears 
that for influenza virus, the budding process is not driven by a single protein but rather is due to a 
redundant cooperation among them (Rossman & Lamb, 2011). For that reason, we evaluated in 
parallel the effect of HIV-1 Gag structural polyprotein, which is a well-known protein to promote 
viral budding of HIV and other viruses including influenza (Guo, Lu et al., 2003; Haynes, 2009; 
Haynes et al., 2009; Shaw et al., 2002). To facilitate the monitoring of Gag expression, the 
protein was fused with the green fluorescent protein.  
Thus, three different protein combinations were examined. Co-expression of HA-NA (non-
transfected 293HA-NA cells), co-expression of HA-NA-M1 (293HA-NA cells transfected with 
pKCR5-M1), and co-expression of HA-NA-Gag (293HA-NA cells transfected with pAdCMV5-
gagGFP). Since it is expected that VLPs will be released from the cells, a Western Blot analysis 
was performed to provide first evidence of VLPs presence in the supernatant. The cell lysate was 
also analyzed. The results showed that co-expression of HA-NA from non-transfected cells 
released HA in the supernatant while NA expression could not be detected (Figure 3-1C). With 
the combined expression of HA-NA-M1, the detection level of HA in the sucrose cushion was 
similar to that observed for HA-NA co-expression suggesting no positive impact on protein 
expression after transfection with M1. The matrix protein M1 was released from the cells, but a 
larger amount remained trapped within the cells. Our observations support the results obtained by 
(Chen et al., 2007) that M1 by itself is not the driving force of influenza virus budding. The 
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presence of M1 in the influenza VLPs seems to influence the functionality and morphology of the 
VLPs rather than its production (Chen et al., 2007; Thompson et al., 2015). Most likely the 
current discrepancies in the literature are due to the fact that different expression systems and/or 
delivery vectors have been employed, which makes it difficult to compare the results (Chen et al., 
2007; Gómez-Puertas et al., 2000; Li, Jaentschke, et al., 2010). The expression system employed 
may influence the budding mechanism since the host cell provides the cellular machinery for the 
viral budding, and many host proteins are found in the VLPs (Cockburn et al., 1969).  
In contrast with M1, transfection with a gag encoding plasmid was highly efficient to mediate the 
release of both NA and HA from the cells. This is supported by previous work in insect cells 
(Haynes et al., 2009). The expression of HA after HA-NA-Gag co-expression was 7-fold greater 
than in all previous combinations (HA-NA and HA-NA-M1). This experiment was performed in 
triplicate and the concentrations of HA and NA after sucrose cushion were estimated by Dot-Blot 
assay as shown in Table 3-1.  
3.4.3 Influenza Gag-VLPs production in shake flasks and 3L-Bioreactor 
The results obtained in Figure 3-1C and Table 3-1 provided evidences of VLPs production when 
HA, NA and Gag were co-expressed in the cells. With the goal to assess process scalability, 
influenza Gag-VLPs production was characterized and compared in shake flasks (50 mL working 
volume) and fully instrumented bioreactor (3L scale). The timeline for the production process is 
shown in Figure 3-2A. The experiment in shake flasks showed an increase in the fluorescence of 
supernatant and accumulation of HA protein following transfection/induction (Figure 3-2B). The 
corresponding results obtained in bioreactor are shown in Figure 3-2C. While culture 
performances were overall very similar at both scales, the fluorescence intensity and HA 
expression in the supernatant was slightly greater in the bioreactor due to better control of cell 
culture parameters. The transfection efficiency was found to be 81% in shake flasks and 86 % in 
bioreactor, as measured by flow cytometry analysis of GFP expressing cells 24 hpt (data not 
shown). At both scales it was observed a reduction in cell growth rate and viability after 
transfection/induction, probably due to a toxic effect of PEI (Ansorge et al., 2009) and/or Gag 
protein.  
 
45 
 
Table 3-1 Summary of HA, NA and Gag quantification 
Samples 
Dot-Blot (µg/ml) 
SRID  
(µg/ml) 
HA assay  
(HAU/ml) 
ELISA  
(ng/ml) 
Based on HA 
assay 
HA NA HA HA p24 VLPs/ml 
HA-NA 1.18 ± 0.14 0.05 ± 0.01 - - N/A - 
HA-NA-M1 1.19 ± 0.38 0.08 ± 0.00 - - N/A - 
HA-NA-Gag 7.59 ± 0.21 0.40 ± 0.02 - - - - 
TFF Feed  8.41 0.4 9.2 12589 28.8 2.52x1010 
Purified Gag-VLPs 6.05 0.16 3.4 8913 25.7 1.78x1010 
Purified Gag-VLPs 
conc. 
42 1.86 30.2 - 178.4 - 
Control-VLPs  N/A N/A N/A N/A 100.8 N/A 
H1N1 A/Puerto 
Rico/8/34 
80 19.62 - - - - 
*(N/A) non-applicable 
*(-) not measured 
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Figure 3-2 Gag-VLPs production in shake flasks and 3 L-bioreactor. (A) Diagram of the 
production process of influenza Gag-VLPs from 293HA-NA cells; (B) and (C) Time course of 
viable cell growth, cell viability, supernatant HA concentration, and GFP fluorescence intensity 
in shake flasks and 3 L-bioreactor, respectively. The production in shake flask was repeated twice 
and errors bars shown are standard deviations. The time of transfection was set as 0 h. The 
culture was stopped at 72 h post-transfection. 
3.4.4 Tangential Flow Filtration (TFF) of influenza Gag-VLPs 
The production of VLPs from mammalian cells is accompanied by extracellular vesicles that 
contain host cell proteins, DNA and RNA, which are undesired material in a vaccine (Barberis et 
al., 2016; Thompson et al., 2015). Therefore, purification of influenza VLPs is a critical issue to 
address (Vicente et al., 2011). In this work, we have evaluated TFF as an important step to 
remove small extracellular vesicles still present in sucrose cushion sample of Gag-VLPs 
produced in 293HA-NA cells. 
The influenza Gag-VLPs sucrose cushion from the 3L-bioreactor (Feed) was passed through an 
ultrafiltration cassette with 1000 KDa cut-off. The TFF feed employed was the sucrose cushion 
since after bioreactor production we aimed testing different purification methods while keeping 
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the aliquots of VLPs well-stored (data not shown). Better process scalability and higher 
recoveries could be obtained in the future by avoiding centrifugation steps (Morenweiser, 2005). 
Thus, the influenza Gag-VLPs sucrose cushion (32 ml) were diafiltered by 4 volume exchanges 
with a trans-membrane pressure (TMP) kept constant at 8psi. The three proteins HA, NA and 
Gag were clearly present in the retentate (Figure 3-3A). Interestingly, proteins with very low 
molecular weight were also observed in the TFF retentate suggesting that these small proteins are 
either part of the influenza Gag-VLPs or adsorbed to the influenza particles (Figure 3-3A SDS-
PAGE).  
The 25% sucrose cushion pellet from supernatant of non-transfected 293CymR-rcTA cells was 
observed by transmission electron microscopy (TEM) revealing the presence of very small 
vesicles (10-90 nm) (Figure 3-3B). This observation supports the need of more refined process to 
remove these contaminants from final samples. Figure 3-3C and D show the TEM images of 
influenza Gag-VLPs before and after TFF, respectively. The presence of vesicles clusters and/or 
cell membrane can be observed in the feed (Figure 3-3C). However, after ultrafiltration, the 
retentate recovered from TFF revealed more pure influenza Gag-VLPs by TEM (Figure 3-3D). 
The size of the influenza Gag-VLPs after TFF ranged from 50-220 nm. TFF using 1000 KDa cut-
off membrane appears as a novel approach in the purification of HIV-Gag VLPs, since other 
studies have reported 300 KDa (Hatta & Kawaoka, 2003) and 500 KDa (Negrete et al., 2014) 
cut-off.   
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Figure 3-3 Tangential flow filtration (TFF) of influenza Gag-VLPs. (A) SDS-PAGE and Western 
Blots for HA, NA and Gag detection in the purification steps by TFF. Lanes are (C+) sucrose 
cushion Influenza virus H1N1 A/PR/8/34 produced in HEK-293 cells; (1) The feed which is 
sucrose cushion from supernatant of 3 L-bioreactor influenza Gag-VLPs production; (2) 
Permeate; (3) Retentate which is referred as “purified influenza Gag-VLPs”. The reducing agent 
used was DTT at 168 mM and samples were boiled for 5 min at 95◦C. The position of the 
relevant proteins is marked with an arrow according to their expected molecular weight and the 
detection by Western Blot (B) Transmission electron microscopy (TEM) Image 20,000× of 25% 
sucrose cushion from parental cell line 293CymR-rcTA supernatant. TEM Images 20,000× (C) 
Feed and (D) Purified influenza Gag-VLPs. Black arrows highlight the influenza Gag-VLPs, 
white arrows point to vesicles and striped arrow indicates vesicle clusters. The VLPs are 
identified as the particles showing the classical dense core structure and morphology of HIV, 
whereas the vesicles are those lacking of the dense core with more irregular shapes. A total of 10 
different field images at different magnifications were taken of the purified influenza Gag-VLPs 
and none of them showed presence or traces of vesicles or vesicle clusters 
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Table 3-2 Recovery of the purification by TFF based on anti-HA Dot-Blot results 
Samples Volume (ml) HA (µg/ml) Total HA (µg) Recovery (%) 
Supernatant 3L-bioreactor 
(before clarification) 
800 0.54 432 100 
TFF Feed 32 8.41 269.12 62.3 
Purified Gag-VLPs 32.4 6.05 196.02 45.4 
3.4.5 Quantification, characterization and yield of influenza Gag-VLPs 
Different methods have been described to quantify HA and NA, the main antigens of influenza 
virus (Thompson et al., 2013). In this study, we have estimated the concentration of HA, NA and 
Gag proteins in our influenza Gag-VLPs before and after ultrafiltration. The concentration of HA 
in µg/ml was estimated by Dot-Blot, SRID and its biological activity in HAU/ml was assessed by 
Hemagglutination assay (Figure 3-4). NA and Gag concentrations were determined by Dot-Blot 
and HIV-1 p24 ELISA, respectively (Figure 3-4A). The amount of influenza Gag-VLPs/ml was 
estimated by correlation with the hemagglutination units. The results obtained from each 
quantification method are tabulated in Table 3-1. The slightly differences in concentration 
obtained by SRID and Dot-Blot could be simply due to intrinsic variability between the 
techniques or since SRID measures the antigenic conformation of HA (Li, Jaentschke, et al., 
2010), there might be less antigenic HA after TFF. The HA units values obtained by the HA 
assay (8913 HA units/ml) in our final VLPs preparation are greater compared with previous 
works producing influenza VLPs in mammalian and insect cells (Thompson et al., 2013; 
Thompson et al., 2015). The ratio of NA:HA on the purified Gag-VLPs estimated by Dot-Blot 
was approximately 1:40, while the ratio obtained for the sucrose cushion preparation of influenza 
virus H1N1 A/PR/8/34 produced in HEK-293 cells by using the same assay resulted in 1:4 (Table 
3-1). Based on the results of HA concentration by Dot-Blot, the recovery after each step of the 
influenza Gag-VLPs downstream processing is shown in Table 3-2. A total HA recovery of 45% 
was obtained after TFF.  
In order to assess the efficiency of the TFF step to remove host cell proteins (HCP) and host cell 
DNA, the concentration of these contaminants was measured before and after TFF. The results 
showed that the HCP concentration was 1.3 and 0.49 µg/ml whereas the host cell DNA was 3.7 
and 2.46 µg/ml before and after TFF, respectively. These data show that 62.3% of HCP and 
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33.3% of DNA were removed by TFF.  
Finally and with the aim to put our VLPs production process in context with other available 
recombinant vaccine approaches, the absolute yield and the overall timeline from the moment of 
receiving the sequence of the new circulating strain until the potential scaled up in a 100L 
bioreactor and purification has been predicted. Approximately 8 weeks would be required from 
receiving the DNA sequence until the final selection of the best expressing stable cell clone. 
Subsequently, it might take 5 weeks for cells amplification and VLPs production in a 100L 
bioreactor. The clarification, TFF and quantification analysis can be performed in one week. 
Thus, the production of the first bulk of VLPs might take approximately 14 weeks.  Certainly, 
this time could be shortened by further optimizing the production process and by developing a 
better method to isolate clones (Tong et al., 2013). The absolute yield of HA, by SRID, recovered 
by this process after TFF is 138 µg for 1L of culture volume.  
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Figure 3-4 Quantification of HA and NA on influenza Gag-VLPs before and after TFF. (A) Dot-
Blot using anti-HA and anti-NA antibodies. (Standard) Hemagglutinin recombinant protein from 
H1N1 A/Puerto Rico/8/34 (10 µg/ml top dot) and neuraminidase recombinant protein from H1N1 
A/USSR/90/77 (2.5 µg/ml top dot); (Feed) sucrose cushion from supernatant of 3 L-bioreactor 
influenza Gag-VLPs production used as feed in the TFF, dilutions from 1/2 to 1/256 (top to 
bottom); (Purified Gag-VLPs) Retentate from TFF; (Ctrl −) sucrose cushion from 293CymR-
rcTA cells supernatant, dilutions from 1/2 to 1/256 (vertical from top to bottom). (B) Single 
radial immunodiffusion (SRID) (Standard) same as for Dot-Blot anti-HA, horizontal dilutions 
from 30 to 7.5 µg/ml; samples horizontal dilutions from (2/3 to 1/8). The arrows are pointing to 
the periphery of the rings (C) Hemagglutination assay. Samples were diluted 1/10 in PBS, then 
sequentially diluted by 10. 
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3.4.6 Immunization and mice challenge protection study 
The immunogenicity and protective efficacy of the influenza Gag-VLPs containing HA and NA 
(H1N1 subtype) were evaluated in mice. Before start the experiment, the VLPs recovered after 
ultrafiltration by TFF were 8X concentrated using a hollow fiber cartridge of 300 KDa pore size 
(purified Gag-VLPs conc.) due to volume restriction for intranasal immunization in animals. The 
control-VLPs were produced in shake flasks as described in Figure 3-2A but by transfecting the 
pAdCMV5-gagGFP in the parental cell line 293CymR-rcTA instead, such a way there is not HA 
and NA on the VLPs. The control-VLPs sucrose cushion sample was ultrafiltered and 
concentrated using 750 KDa and 300 KDa cut-off hollow fiber cartridges, respectively. The 
concentration of the corresponding proteins in concentrated samples was tabulated in Table 3-1.  
Thus, mice were immunized following the schedule illustrated in Figure 3-5A. As shown in 
Figure 3-5B, HA-specific IgA were detected in the nasal lavage fluid of mice intranasally 
immunized with influenza Gag-VLPs while no or negligible amount of specific IgA was detected 
in the nasal lavage fluid of mice immunized with the control-VLPs. The fact that our VLPs 
induced mucosal IgA it is very significant since the respiratory tract is the natural route of 
influenza virus infection (Muraki & Hongo, 2010). The serum HA-specific IgA, IgG1 and IgG2a 
were only detected in mice immunized with influenza Gag-VLPs and the antibody levels were 
comparable to those in the mice immunized with rHA (Figure 3-5B). The detection of IgG1 is an 
indication of a T helper (Th) type 2 response which has been also observed after vaccination with 
rHA (Bright et al., 2007). Interestingly, the vaccination with influenza Gag-VLPs induced higher 
titer of IgG2a than the rHA H1N1 vaccinated mice which is associated to a dominant Th1 
response (Bialas et al., 2014; Tong et al., 2012). More importantly, the influenza Gag-VLPs 
immunized mice demonstrated impressive protection against a subsequent lethal intranasal 
challenge with the homologous virus strain in that the vaccinated mice showed little to no clinical 
signs or body weight loss throughout the course of infection and all the mice survived the 
challenge (Figure 3-5C). These results suggest that the influenza Gag-VLPs induce a potent 
protective immunity against lethal influenza virus challenge. 
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Figure 3-5 Immunity of influenza Gag-VLPs and mice challenge. (A) Vaccination schedule. (B) 
Sera IgG and/or nasal IgA specific to VLPs were evaluated by ELISA. At day 42, the nasal fluid 
and blood from sacrificed mice of groups immunized with (2 µg HA) influenza Gag-VLPs and 
control-VLPs were analyzed for nasal IgA and sera IgA, IgG1, and IgG2a response. Non-
terminal blood samples from 2 µg rHA H1N1-immunized and naïve mice were assayed for HA-
specific IgG sera antibodies. Each individual dot represents the value from a single mouse, and 
the horizontal line represents the median value for the group. The concentration of HA used per 
dose was based on the Dot-Blot assay results (C) Five weeks after last immunization, mice of all 
groups were intranasally challenged with 103 pfu of the mouse-adapted influenza H1N1 virus 
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(A/Puerto Rico/8/34). The percentages of body weight (BW) changes and survival were daily 
recorded for up to 12 days. Body weight data are the means for five mice per group ± SD. 
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 Abstract 
Influenza virus dominant antigens presentation using Virus like particle (VLP) platform is 
attractive for the development of new generation of influenza vaccines. Mammalian cell platform 
offers many advantages for VLPs production. However, limited attention has been paid to the 
processing of VLPs produced in mammalian cells. Better understanding of the production system 
could contribute to increasing the productivity and making large-scale VLPs vaccine 
manufacturing feasible. In a previous study, we have generated a human embryonic kidney HEK-
293 inducible cell line expressing Hemagglutinin (HA) and Neuraminidase (NA), which was 
used to produce VLPs upon transient transfection with a plasmid containing HIV-1 Gag. In this 
work, to streamline the production process, we have developed a new inducible cell line 
expressing the three proteins HA, NA and the Gag fused to GFP for monitoring the VLPs 
production in suspension and serum-free medium cultures. The process was optimized to reach 
high volumetric yield of VLPs by increasing the cell density at the time of induction without 
sacrificing the cell specific productivity. A 5-fold improvement was achieved by doing media 
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evaluation at small scale. Furthermore, a 3-L perfusion bioreactor mirrored the performance of 
small-scale shake flask cultures with sequential medium replacement. The cell density was 
increased to 14x106 cells/ml at the time of induction which augmented by 60-fold the volumetric 
yield to 1.54x1010 Gag-GFP fluorescent events/ml, as measured by flow cytometry. The 9.5-L 
harvest from the perfusion bioreactor was concentrated by tangential flow filtration at low shear 
forces. The electron micrographs revealed the presence of VLPs of 100-150 nm with the 
characteristic dense core of HIV-1 particles. The developed process shows the feasibility of 
producing high quantity of influenza VLPs from an inducible mammalian stable cell line aiming 
at large scale vaccine manufacturing. 
Keywords: Stable cell line; Process development; Perfusion; TFF; Gag-VLPs; Influenza vaccine 
 Introduction 
Well-assembled virus-like particles (VLPs) are highly attractive as vaccine candidates. The 
advantages of VLPs include: mimicry of the particulate structure of wild type viruses, absence of 
viral genome, and the repetitive display of major antigens on their surface while keeping the 
intact conformation (Haynes et al., 2009; Roldão, Mellado et al., 2010; Zeltins, 2013). An 
important step when proposing these nanoparticles as vaccine candidates is to demonstrate their 
immunogenicity and efficacy in preclinical in vivo experiments. Once the proof of concept is 
demonstrated, more efforts should be deployed to the establishment of a reproducible scalable 
production process that can support the vaccine candidate characterization for further preclinical 
and clinical studies (Effio & Hubbuch, 2015; Lua et al., 2014; Pattenden et al., 2005).  
The production of VLPs from mammalian cells has been commonly achieved via transient 
transfection or stable expression of the corresponding recombinant gene/s (Carter et al., 2016; 
Chen et al., 2007; Robert et al., 2016; Venereo-Sanchez, Gilbert et al., 2016; Wu et al., 2010). 
Developing a process based on transient transfection can be cumbersome for vaccine 
manufacturing at large scale. Transfection agents like PEI are toxic for the cells (Ansorge et al., 
2009), a complex bioreactor set-up is needed (one extra closed vessel for making the 
DNA:transfection agent polyplexes) and adequate plasmid stocks must be maintained. 
Meanwhile, stable cell line development has gained substantial progress with a significant 
reduction in the required time to obtain stable clones supported by robotic clone isolation (Caron, 
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Nicolas et al., 2009) and powerful flow cytometry cell sorters (DeMaria, Cairns et al., 2007). 
Once the cell line is established, it can be optimized for efficient protein expression, eliminating 
the drawbacks associated with methods relying on transient transfection.  
A review of the state-of-the-art on the optimization of virus production reveals that driving the 
cultures to high cell densities at the time of infection has the potential to significantly improve the 
virus volumetric yield (Cortin, Thibault et al., 2004; Ghani, Garnier et al., 2006; Henry et al., 
2004; Petiot et al., 2011). Similar scenario could be applied to stable cell lines producing VLPs 
under an inducible system in which the growth and production phases are separated. This 
approach of inducible expression seems very feasible for the production of enveloped VLPs, 
where more than one protein are often needed for the assembly. Accordingly, the cell biomass 
can be augmented to reach the targeted cell density at the time of induction without adding the 
extra metabolic burden imposed by heterologous protein expression. Perfusion culture process 
has been efficiently used to increase cell densities and productivities in mammalian cell cultures 
(Henry et al., 2004; Petiot et al., 2011). The perfusion mode allows to increase cell densities and 
extend culture times by continuously exchanging the culture medium with fresh one, and 
continuously removing by-products that might be toxic to the cells or inhibit the product 
formation. Perfusion process is very efficient in preserving quality and stability of products that 
may be negatively impacted if staying too long in the culture environment. However, in virus 
production, several studies have reported a decrease in the cell specific productivity at high cell 
densities (Maranga, Brazão et al., 2003; Nadeau & Kamen, 2003; Tapia et al., 2016).  
The challenges associated to the bioprocess engineering of influenza VLPs production from 
mammalian cells have been far less studied. Wu et al. (2010) studied the production of influenza 
VLPs HA-NA-M1-M2 from Vero cells in a 3L-bioreactor using microcarriers while Thompson et 
al. (2015) reported the production of influenza VLPs from HEK-293 suspension cells transduced 
with a BacMan-HA-NA-M1 also in a 3L-bioreactor but no further process optimization was 
performed. Likewise, the production of HIV Gag-VLPs from HEK-293 cells was investigated 
using transient transfection. The productivity was increased by 2.4 fold using an optimized 
production protocol based on the use of a supplemented Freestyle medium and by performing 
medium exchange prior to transfection (Cervera et al., 2013). 
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In previous work, we have characterized the production of influenza VLPs from a HEK-293HA-
NA stable cell line after transient transfection with a Gag-containing plasmid (Venereo-Sanchez 
et al., 2016). In the present study, to avoid the drawbacks related to transient transfection at large 
scale, we investigated the efficacy of a new HEK-293 stable cell line expressing the three main 
proteins involved in the formation of VLPs containing HA, NA and Gag-GFP, hereafter referred 
as “293-HA/NA/Gag-GFP”. The production process from the stable cell line was developed to 
achieve higher yields. Media evaluation, sequential medium replacement at small scale and a 
perfusion strategy in bioreactor were implemented to drive the cultures to higher cell densities at 
the time of induction and improve the volumetric yield. The VLPs produced from the perfusion 
bioreactor were semi-purified and concentrated by Tangential Flow Filtration (TFF). The VLPs 
were quantified and characterized by transmission electron microscopy (TEM), single radial 
immunodiffusion (SRID), Dot-Blot, and hemagglutination assay. To our knowledge this is the 
first work describing the bioprocess development of influenza VLPs production in suspension 
culture of inducible mammalian cells.  
 Materials and Methods  
4.3.1 Cells, plasmids and culture conditions 
The cells were cultured in a humidified incubator at 37 ºC with 5% CO2, at an agitation rate of 
100–110 rpm. The medium was supplemented with 4–6 mM of glutamine during cell 
maintenance. For the construction of the plasmid pKCR5-Gag-GFP, the gag-GFP gene was 
enzymatically isolated from the plasmid pAdCMV5-gagGFP (Venereo-Sanchez et al., 2016)  by 
digestion with Pme I and BamH I. Then, the gag-GFP gene was blunted and inserted in the 
plasmid pKCR5-3CuO-GFP (Mullick et al., 2006) previously digested with the restriction 
enzymes Age I and EcoR I.   
4.3.2 Generation of 293-HA/NA/Gag-GFP stable cell line 
The 293-HA/NA/Gag-GFP cells were generated by transfecting 1x106 cells/ml of 293HA-NA 
cells (Venereo-Sanchez et al., 2016)  with the XbaI-linearized plasmid pKCR5-GagGFP and a 
plasmid encoding the resistance to G418, pMPG/tk-Neo/CMV-CymR linearized with AscI to 
remove the fragment containing the promoter and CymR. The transfection was performed in a 
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six-wells plate with a total DNA of 2.5µg/well, 1.9:0.6 µg respectively, using PEIpro (Polyplus 
transfection, France) at a DNA:PEI ratio of 1:1. The selection with G418 sulfate (geneticin 
selectin, ThermoFisher Scientific, USA) was applied 48 hours post transfection at 200µg/ml after 
passing the cells to two plates of 96-well seeded at 1x104 cells/well. After 4-5 weeks under 
selection, 48 clones were isolated, induced with 100µg/ml of cumate and screened by flow 
cytometry for GFP and HA positive cells. The five pools showing the highest levels of HA and 
Gag-GFP expression were subjected to limiting dilution to isolate single clones. The cells were 
seeded in five 96-well plates at three different cell densities:  0.3, 1 and 3 cells/well. The plates 
were incubated until the clones reach 60-80 % of confluence. During this period 50 µL of 
medium was added twice. Three to four weeks later, subclones from plates seeded at 0.3 and 1 
cell/well were transferred in 24-well plates and tested for GFP and HA positive cells. The best 8 
subclones were expanded in 25 cm2 flasks and then cultivated in 125 ml erlenmeyer flasks. The 
production of VLPs was assessed in sucrose cushion preparations by detecting HA, NA and Gag 
proteins by Western Blot.  
4.3.3 Flow cytometry 
4.3.3.1 Cells  
The cells at 72 hours post-induction (hpi), including the corresponding positive and negative 
controls, were slowly re-suspended and transferred from a 96-flat bottom plate to a 96-V bottom 
plate. The cells were fixed by adding formaldehyde 10% to a final concentration of 2% under 
agitation. After 20 min incubation under agitation, the cells were washed with cold PBS and 
permeabilized with ethanol (70% final concentration); following two consecutive washes with 
cold PBS. The cells were incubated with blocking buffer for 15 min (4% Fetal Bovine Serum in 
PBS).  The primary antibody anti-HA ref: 03/242 (NIBSC, UK) was added at a final dilution of 
1:50 and incubated 30 min at room temperature. Two washes with cold PBS were done after each 
antibody incubation. Then, the secondary antibody Donkey anti-sheep Alexa Fluor 674 
(ab150179, Abcam, UK) at 1:2000 dilution was added, followed by an incubation time of 15 min 
in the dark. The cells were resuspended in blocking buffer, transferred to a 96-filter plate 
(Multiscreen 60µm Nylon Mesh, EMD Millipore), and spun at 230 x g for 1 min at room 
temperature. The cells were transferred to 96-V bottom plates for the analysis by Fluorescence-
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activated cell sorting (FACS) in the BD LSRFortessa-HTS, Biosciences (Becton-Dickinson, 
USA). 
4.3.3.2 Gag-GFP events count by flow cytometry 
The Gag-GFP fluorescent events per ml were quantified by detecting GFP green fluorescence and 
light scattering signals. The analysis of the samples was done using a BD LSR-Fortessa SORP 
flow cytometry system (Becton-Dickinson, USA) equipped with a 300mW 488nm laser and a 
Forward Scatter photomultiplier tube (PMT) detector. The volume passed in a given time was 
calculated using Becton-Dickinson TrucountTM Tubes (Becton-Dickinson cat nb: 340334) of 
52250 beads per tube. Based on 20 sec sample aspiration, the GFP fluorescent events counts were 
determined as the number of events per ml. SheroTM Nano Fluorescent particles (Spherotech 
Inc.USA) from 0.13 to 0.88 µm were used to choose the adequate instrument settings. 
4.3.4 Perfusion Bioreactor 
A 3L Chemap CF-3000 bioreactor (Mannedorf, Switzerland) was set-up as previously published 
in (Henry et al., 2004). The cells were inoculated in the bioreactor at around 0.3x106 cells/ml. 
The temperature, pH, dissolved oxygen and agitation were controlled at 37 ºC, 7.2, 40% and 90 
rpm, respectively. The pH was regulated by addition of 7.5% w/v NaHCO3 solution. Pure O2 was 
sparged from day 4 of culture when surface aeration was not sufficient. A cooling system was 
installed to maintain the VLPs-containing harvest bottle at 4 ºC during the collecting time. Each 
day, the harvest bottle was replaced and kept at 4 ºC in the refrigerator for subsequent 
downstream processing.            
4.3.5 VLP proteins quantification and characterization 
The Dot-Blot, SRID, Hemagglutination assay, Western Blot, determination of host cell proteins, 
host cell DNA and TEM techniques were performed under the same conditions published in 
(Venereo-Sanchez et al., 2016). 
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4.3.6 Clarification and Tangential flow filtration (TFF) 
The VLPs-containing supernatant collected from the bioreactor was pre-filtered through a 78 mm 
fiberglass pre-filter and then filtered through a 0.45 µm, 1000 ml funnel filter (Corning Inc., 
USA). The TFF was set-up using two P2B01MC01 | Pellicon® 2 Mini Ultrafiltration Modules 
Biomax®- 1000 KDa 0.1 m2 supported with the Pellicon 88cm2 and 0.11m2 cassette holder 
(EMD Millipore, USA). The ultrafiltration was performed by circulating the feed through the 
TFF membranes using a Masterflex I/P pump (Easy-Load model 77601-10) and a tubing 
Masterflex platinum-cured silicone 16 I/P. Two manometers (Anderson-Negele, Germany) were 
connected to the system to monitor the transmembrane pressure. The average flux across the 
membrane was estimated to be 310 L/m2/hour (LMH).   
The ultrafiltration and diafiltration of the supernatants collected from the shake flasks under 
medium replacement were performed using a hollow fiber cartridge (D02-E750-05-N, Spectrum 
Laboratories, USA). 
 Results and Discussion  
4.4.1 Stable cell line development  
To develop the 293-HA/NA/Gag-GFP cell line, that stably expresses HA, NA and Gag fused to 
the GFP, the gene Gag-GFP was cloned into a plasmid containing the cumate inducible CR5 
promoter. The resulting plasmid (pKCR5-GagGFP) was co-transfected with a plasmid containing 
the resistance to neomycin in the cell line 293HA-NA (Venereo-Sanchez et al., 2016). After 
selection, the neomycin resistant clones were screened by detecting Gag-GFP and HA by flow 
cytometry (Figure 4-1A). Different patterns were observed in the isolated clones; clones made up 
of cells expressing only Gag-GFP, only HA, or expressing both proteins. The eight subclones 
with the highest expression of both proteins were selected, cultivated in shake flasks (25 ml 
working volume) and induced with cumate for VLPs production. The subclone displaying the 
highest simultaneous expression of HA and Gag and with good cell growth characteristics (data 
not shown) was selected as our cell line 293-HA/NA/Gag-GFP. The presence of HA, NA and 
Gag-GFP in the chosen clone was confirmed by Western Blot analysis (Figure 4-1B).  
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Figure 4-1 Development of stable cell line 293-HA/NA/Gag-GFP. A) Different expression 
patterns were observed in the clones. B) Western blot analysis. Each lane contains the sucrose 
cushion preparation of: (C+) influenza virus H1N1 A/PR/8/34 produced in HEK-293 cells; 
(Subclone selected)   VLPs produced after induction of the highest producer stable clone 293-
HA/NA/Gag and (C-) the supernatant of parental cell line 293CymR-rcTA. 
4.4.2 Media evaluation at small scale 
Once the highest-producer cell subclone was selected, process development efforts were 
undertaken with the aim to improve the volumetric yield of VLPs by increasing the cell density at 
the time of induction without sacrificing the cell specific productivity. Firstly, two different 
commercial media: SFM4TransFx-293 and HyCellTMTransFx-H were evaluated in shake flasks 
(25 ml working volume) for VLPs production (Figure 4-2A). By using HyCellTMTransFx-H 
medium it was possible to induce the cells 293-HA/NA/Gag-GFP at a higher cell density (~3 x 
106 cells/ml) than when cells were cultured with SFM4-TransFx medium (~1 x 106 cells/ml). Cell 
viability was greater than 90% at the time of induction for both conditions.  
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The VLPs production was monitored by measuring the expression of HA via Dot-Blot and the 
quantity of Gag-GFP fluorescent events by flow cytometry. The results of production kinetics on 
supernatants revealed that the best production of Gag-GFP and HA was attained with HyCell-
TransFx-H medium, 5x107 Gag-GFP fluorescent events/ml and 0.3 µg/ml of HA (Figure 4-2B). It 
can be seen that after 48 hpi, the Gag-GFP fluorescent events count did not increase significantly. 
However, in the case of HA, the maximum quantity produced was at 72 hpi. The harvested 
supernatants from all conditions were 50X concentrated through a 25% sucrose cushion and the 
concentration values are shown in Figure 4-2C.  The yields after concentration showed a 
production improvement of 5.7-fold in terms of Gag-GFP fluorescent events/ml and 4.7-fold for 
HA concentration compared to the culture with SFM4TransFx. For following experiments, we 
considered the batch production in SFM4Transfx as our reference control condition since our 
previous work (Venereo-Sanchez et al., 2016) was run under the same conditions. 
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Figure 4-2 Media evaluation at small scale. A) Cell growth curves using 293-SFM4TransFx and 
HyCell-TransFx-H media. The production of VLPs was monitored in B) supernatants and C) 50X 
sucrose cushion concentrated harvests by the count of Gag-GFP fluorescent events/ml measured 
by flow cytometry and the concentration of HA (µg/ml) by Dot-Blot. The green marker indicates 
the day of induction. The error bars indicate the standard deviation for two replicates.  
4.4.3 Medium replacement at small scale 
As an attempt to increase further the volumetric yield of VLPs by increasing the cell density at 
the time of induction, a medium replacement (MR) strategy was explored at small scale.  This 
constitutes a simple way to mimic the perfusion mode. Two experimental conditions were 
considered: 1) medium exchange was done on a daily basis during the growth phase but not after 
induction (no MR post-induction) and 2) medium replacement was performed throughout the 
A 
B C 
69 
growth and production phases (MR post-induction). The cultures were performed in shake flasks 
(50 ml working volume) and consisted in exchanging 75 % of the culture volume with fresh 
medium every day. The growth curves corresponding to the two strategies are shown in Figure 
4-3A. The cultures reached much higher cell densities with medium replacement (~14-18x106 
cells/ml) in comparison with the corresponding batch culture (~3x106 cells/ml) (Figure 4-2A).  It 
can be observed that, when medium exchange was maintained after induction, the cell growth 
and viability declined at 24 hpi while for the condition with no medium exchange post-induction, 
cells continued to grow and cell viability decreased more slowly. This is probably due to a shear 
stress effect on the cells resulting from the centrifugation steps, since all the culture parameters 
were identical (e.g. working volume, temperature, agitation rate, etc.).  
The production in supernatant was monitored every 24 hpi (Figure 4-3B). The concentrations of 
HA and Gag-GFP fluorescent events in the supernatant are given as total cumulative values to 
consider the total volumetric yield per day. The Gag-GFP fluorescent events count increased after 
induction up to ~9.6x1010 at 96 hpi when medium replacement was continued during the 
production phase, compared to a maximum of 3.6x1010 at 72 hpi when feeding was restricted to 
the growth phase. Likely, the expression of HA continuously increased after induction for both 
conditions up to 93.2 and 25 µg total, respectively. Hence, the reduction in cell viability observed 
during the production phase does not seem to have a negative effect on productivity.  
The VLPs-containing harvest collected from both conditions were 50X concentrated by TFF 
using a hollow fiber of 750KDa cut-off. The total amount of HA protein (µg) and Gag-GFP 
fluorescent events produced in “MR post-induction” strategy improved by 2.9-fold and 2.2-fold, 
respectively, in comparison with the “no MR post-induction” condition (Figure 4-3C).  
Compared to the control batch SFM4TransFx, a volumetric yield improvement of 128 fold (Gag-
GFP events/L) and 17 fold for HA was achieved in the condition where medium exchange was 
maintained after induction (Table 4-1). The differences between the increasing fold factor for 
each gene, HA and Gag-GFP, could be due to the random integration of the genes in the cell 
chromosomes, which can lead to different expression levels of the protein of interest. The 
transgenes can be inserted in zones of the chromatin more or less active and/or the insertion of 
“multiple gene copies can unpredictably cross-interact” (Li, Vijayasankaran et al., 2010)  
influencing the protein expression (Wurm, 2004).  
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Figure 4-3 Production of VLPs in cultures with medium replacement (MR) at small scale A) Cell 
growth curves in medium HyCell-TransFx-H under two conditions: “MR post-induction” (the 
medium was exchanged from day 4 until the end of the culture) and “no MR post-induction” (the 
medium replacement was done on a daily basis from day 4 to 9 but not after induction). The MR 
consisted in an exchange of 75% of the culture volume with fresh medium by centrifugation at 
300 xg 5min. The green marker indicates the time of induction. The amount of VLPs proteins in 
B) cell supernatant of days post-induction and C) 50X TFF concentrated harvests was monitored 
by flow cytometry and by Dot-Blot to report total Gag-GFP events count and total µg of HA 
produced. The error bars indicate the standard deviation for two replicates. 
 
 
 
A 
B C 
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Table 4-1 Specific productivity, specific growth rate and productivity improvement factor from 
batch to perfusion 
4.4.4 Perfusion Bioreactor 
Considering the significant improvements achieved using the medium replacement strategy at 
small scale, we aimed to operate a laboratory-scale bioreactor operated in perfusion mode with an 
acoustic filter. The perfusion rate was started on day 4 of the culture and was kept at a flow rate 
of 2L/day (1.3vol/day). The perfusion rate was maintained after the induction. The bioreactor 
culture reached similar cell densities compared to the medium replacement at small scale and the 
induction was also done at 14*106 cells/ml (Figure 4-4A). The production in the supernatants 
reached a maximum of 6x1012 Gag-GFP fluorescent events and around 4 mg of HA at 96 hpi 
(Figure 4-4B). The total volume harvested from the bioreactor was around 9.5 L. This material 
was 50X concentrated by TFF as described in the following section. By doing perfusion in the 
bioreactor we could mirror the production obtained at small scale with medium replacement. 
Considering the concentration values obtained in the TFF semi-purified final material (Table 4-2) 
the volumetric yield was increased by 60-fold in terms of Gag-GFP events count and 17-fold for 
 Batch 
SFM4-TFx 
Batch HyCell-
TFx 
MR post-
induction 
Perfusion 
bioreactor 
Cell specific productivity (Gag-GFP 
events/cell based on viable cell density at 
the time of induction) 
5 12 136 22 
Cell specific productivity (µg of HA/cell 
based on viable cell density at the time of 
induction) 
8.9x10-9 1.5x10-8 3.5x10-8 1.2*10-8 
Cell specific growth rate before induction 
(h-1) 
0.015 
 
0.017 
 
0.018 0.019 
 
Volumetric yield (Gag-GFP events/L of 
culture) 
5.2x109 3.6x1010 6.6x1011 3.1x1011 
Volumetric yield (HA µg/L of culture) 10 46 167 165 
Volumetric yield improvement factor in 
comparison with the Batch control (for 
Gag-GFP events) 
1 ~7 ~128 ~60 
 
Volumetric yield improvement factor in 
comparison with the Batch control (for 
µg of HA ) 
1 ~5 ~17 ~17 
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µf of HA, with respect to the initial batch SFM4-TransFx condition. The higher productivity in 
terms of Gag-GFP events obtained in the medium replacement at small scale compared to the 
perfusion bioreactor might be due to the release of intracellular Gag-GFP as a result of the 
decrease in viability caused by the centrifugation steps to exchange the medium. The specific 
productivity estimated revealed an improvement of 4-fold (Gag-GFP events) in the perfusion 
process compared to the Batch-SFM4TransFx control (Table 4-1). 
 
Figure 4-4 Production of VLPs in a perfusion mode 3L-bioreactor. A) Viable cell growth. The 
grey region indicates the continuous perfusion period at a rate of 1.3 vol/day. B) The production 
of VLPs was analyzed in cell supernatant at days post-induction by doing flow cytometry to 
measure Gag-GFP events and by Dot-Blot to monitor HA protein expression. The error bars 
indicate the standard deviation for three measurements. The values measured for the 50X TFF 
concentrated harvest are reported in Table 3-2 along with the recovery yields. C) Negative 
stained electron microscopy of VLPs recovered in the TFF retentate after diafiltration.  
A.  
B.   
C.   
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4.4.5 Tangential Flow Filtration (TFF) 
The TFF is a gentle method to concentrate and semi-purify VLPs and viruses based on the size of 
the particles. We have shown in a previous study the efficiency of this method to remove cell 
debris and small extracellular vesicles from the sucrose cushion semi-purified material (Venereo-
Sanchez et al., 2016). However, having centrifugation steps during the downstream processing is 
not desirable due to the limitations and cost associated with scale-up. In this study, since the 
VLPs-containing harvest was collected after an acoustic filter separation system, very low 
amount of cells passed through the separation device (0.15x106 cells/ml).  Therefore, no 
centrifugation steps were needed prior to TFF for most of the harvest (only the residual 2.6L left 
in the bioreactor were centrifuged to separate cells from the supernatant). Thus, the whole harvest 
supernatant of 9.5 L was pre-filtered through a fiber-glass to remove the cells and cell debris 
remaining in the harvest. Thereafter, another filtration through a 0.45 µm filter was performed 
and this clarified material was the feed (9.3L) for the TFF system.  
Since enveloped viruses and VLPs are sensitive to shear stress, an important aspect to consider 
for TFF is to maintain low shear rate conditions during the run. Based on prior knowledge 
(Negrete et al., 2014) and experience accumulated in our lab on ultrafiltration of enveloped 
viruses, a shear force lower than 4000 s-1 does not cause significant damage on the viral particles. 
Thus, the TFF to concentrate the 9.3 L VLPs-containing harvest was set-up using two cassettes of 
0.1 m2, with a cross flow rate of 1.2 L/min at a flux of 310 LMH. Under such conditions, the 
expected shear force is around 2000 s-1. The schematic representation of the TFF set-up together 
with the permeate flow rate during the run is shown in Figure 4-5A, B. The overall recovery of 
the process is shown in Table 4-2. The higher loss observed, in terms of Gag-GFP events 
compared to HA after the clarification steps could be probably due to that some VLPs, exosomes 
containing Gag-GFP and/or Gag-GFP aggregates, which are bigger in size than HA protein, were 
retained in the fiber glass paper and/or the 0.45µm filter, while the HA free protein passed 
through. Actually, it can be observed that, after TFF, the loss in terms of Gag-GFP (5%) in 
comparison with HA protein (32%) was significantly lower because the cut-off used was 1000 
KDa, which allows the free HA protein to pass through the membrane to the permeate. We have 
compared the Gag-GFP fluorescent events value obtained by flow cytometry in the final material 
recovered after TFF (1.54*1010) with the VLPs/ml calculation from the HA units value by 
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hemagglutination assay of the same sample (1.78*1010) and similar values were obtained. 
However, we chose to describe the flow cytometry data as Gag-GFP fluorescent events/ml 
instead of VLPs/ml, since small GFP positive extracellular vesicles or protein aggregates could 
interfere with the measurement.  
The retentate VLPs were observed by transmission electron microscopy where particles of 100-
150 µm with a typical dense core were identified as the influenza Gag-VLPs (Figure 4-4C). The 
VLPs semi-purified and concentrated by TFF were also quantified by Single Radial 
Immunodifusion (SRID) and hemagglutination assay revealing a concentration of 9.9 µg/ml of 
HA and 8913HAU/ml, respectively. The concentration of NA was also estimated by Dot-Blot as 
2.1 µg/ml which means a NA/HA ratio on VLPs of 1/4. The host cell proteins (HCP) and host 
cell DNA in the final material were determined to be 29µg/ml and 3µg/ml, respectively. 
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Figure 4-5 Tangential Flow Filtration (TFF) of VLPs produced in the 3-L perfusion bioreactor. A) 
TFF set-up. B) The 7.3L of harvest contained in the feed bottle were concentrated through the 
reservoir bottle (2L), such that the total harvest volume (9.3L) was concentrated 50X.  The 
diafiltration consisted in the dilution of the retentate volume with 10 vol. of buffer 20 mM Tris-
HCl, 2mM MgCl2, sucrose 5% pH 7.5, which was then concentrated. 
Table 4-2 Recovery of VLPs during the downstream process of the perfusion bioreactor harvest 
in terms of Gag-GFP events/ml and HA concentration 
 
Total  
volume 
Gag-GFP fluorescent events count  
by flow cytometry 
 HA concentration by Dot-Blot 
(µg) 
Gag-GFP 
events/ml 
Total  
Gag-GFP 
events 
Recovery 
(%) 
 HA 
µg/ml 
Total HA 
(µg) 
Recovery 
(%) 
B. 
A. 
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Harvest 
broth 
9502 6.6x108 6.5x1012 100  0.43 4071.4 100 
Clarified 
material 
9300 3.3x108 3.1x1012 49.5  0.31 2904.4 71.3 
TFF 
retentate 
186.5 1.5x1010 2.9x1012 44.1  8.4 1564.7 38.4 
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CHAPTER 5 PROTEOMIC CHARACTERIZATION OF INFLUENZA 
H1N1 GAG VIRUS-LIKE PARTICLES AND EXTRACELLULAR 
VESICLES PRODUCED IN HEK-293SF 
One of the major concerns associated with the use of influenza virus-like particles (VLPs) as 
vaccine candidates is their heterogeneous composition. Enveloped VLPs take up the host cell 
membrane at the budding site carrying out with them not only the viral antigenic proteins but also 
host cell proteins. The intrinsic nature of the cells to produce membrane derived vesicles, which 
have similar size to the VLPs and can also contain the antigenic proteins, concomitantly to VLPs 
production makes the VLPs purification process challenging. Certainly, the expression system 
and the viral recombinant proteins employed will determine the nature of the proteins within the 
VLPs. To further characterize cell culture produced-influenza VLPs and contribute to enable their 
approval as vaccine candidates, the composition and biogenesis of VLPs needs to be better 
understood. In this chapter we have characterized, by nanoscale liquid chromatography tandem 
mass spectrometry (n-LC-MS/MS), influenza H1N1 Gag-VLPs produced in human embryonic 
kidney cells adapted to serum-free medium (HEK-293SF). The cells stably express HA and NA, 
and the VLPs production occurs following transient transfection with a plasmid containing the 
gag gene of HIV-1 fused to GFP.  Extracellular vesicles (EVs) produced by the unmodified 
HEK-293SF were also characterized by n-LC-MS/MS. A total of 73 host cell proteins were 
identified in the VLPs, whereas 98 were detected in the extracellular vesicles. From that number, 
32 host cell proteins were unique to VLPs while 41 proteins were found in both.  Importantly, 
nucleolin was the most abundant host cell differential protein identified in VLPs while 
lactotransferrin and heat shock protein 90 were the most present in EVs. This study provides a 
detailed proteomic description of the VLPs and EVs produced in HEK-293SF as well as a critical 
discussion of the function of each protein incorporated in both nanoparticles species. The 
outcome of this research sheds light on unique target proteins that could potentially be used for 
purification of both nanoparticles produced in HEK-293 cells. 
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 Introduction 
Virus-like particles (VLPs) constitute an attractive platform to present a repetitive array of 
dominant antigens while preserving the protein native conformation. VLPs lack viral genome and 
their structure mimics wild-type viruses, therefore they are safer and more immunogenic than 
virus-based and subunit vaccines, respectively (Haynes, 2009). Similarly to viruses, enveloped 
VLPs bud from the cell membrane taking up the host cell lipid bilayer at the budding site 
(Thompson et al., 2015) . In addition, the formation of VLPs relies on host cell protein machinery 
for gene transcription, translation, protein translocation throughout the cytoplasm, assembly and 
budding. Hence, released VLPs do not only contain the recombinant viral proteins of interest, but 
also several host cell proteins as well as genomic RNA and DNA (Vicente et al., 2011). The 
expression system employed for VLP production will determine the nature of the host cell 
derivatives within the VLPs.  
The production of influenza VLPs has been explored in several expression systems including 
insect cells (Pushko et al., 2011), plants (D’Aoust et al., 2010), and mammalian cells (Wu et al., 
2010). Within mammalian cells, the human embryonic kidney cell line HEK-293 seems attractive 
for VLP production since, in addition of offering human-like post-translational modifications, 
they are easy to transfect and show efficient growth in suspension culture in serum-free medium 
(Durocher et al., 2002). However, there remain some concerns about the use of HEK-293 cells 
for vaccine manufacturing and/or viral vector production for gene therapy. Being a human 
derived cell line introduces a risk of contamination with human-specific viruses and a 
tumorigenic potential has been attributed to this cell line (Shen et al., 2008; Stepanenko & 
Dmitrenko, 2015). Nonetheless, several biopharmaceuticals produced in HEK293 cells have been 
approved by the FDA for therapeutic use (Dumont, Euwart et al., 2016). 
Another aspect to consider when producing influenza VLPs in mammalian/human cells is the co-
production of extracellular vesicles which are very similar in size to VLPs. The secreted vesicles 
are diverse in nature and can be differentiated in three types: exosomes, shedding microvesicles 
and apoptotic bodies (Ha, Yang et al., 2016). The exosomes have an intracellular origin and a 
size in the range of 30 to150 nm. Shedding microvesicles bud from the cell membrane with a size 
ranging from 50 to 1000 nm and the apoptotic bodies (50-5000nm) have more irregular shapes 
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and arise from apoptotic cells outward membrane blebbings (Andaloussi, Mäger et al., 2013). 
Exosomes play an important role in cell-cell communication and have received a lot of attention 
in the last decades for different applications as cancer biomarkers, as well as drug delivery 
vehicles and chemotherapeutic sensitization agents (Katakowski, Buller et al., 2013; Nilsson, 
Skog et al., 2009). They contain intra-lumen proteins and genomic material that snapshot the 
metabolic state of the secreting cell (Akers, Gonda et al., 2013). The formation of exosomes 
starts with early endosomes that subsequently form multi-vesicular bodies (MVBs) containing 
intraluminal vesicles (ILVs). Then, the MVBs fused with the plasma membrane and the ILVs or 
exosomes are released to the extracellular milieu. The endosomal sorting complexes required for 
transport (ESCRT) mediate the formation and scission of MVBs (Ha et al., 2016). Enveloped 
viruses, like HIV-1, “hijack” this cell mechanism for its viral budding (Subra, Laulagnier et al., 
2007).        
In the light of these facts, and considering that the licensing process of human vaccines is 
becoming nowadays more and more rigorous; obtaining highly pure products with detailed 
specifications on vaccine composition is strictly required. Therefore, no component in the 
vaccine should be and/or have the potential to be hazardous for human health. Since enveloped 
VLPs are membrane-enclosed multimeric protein complexes, even after an intensive purification 
and polishing, host cell contaminants will not be completely removed since they are contained 
within and/or attached to the particles. Consequently, an extensive characterization of VLPs will 
provide more insights on the nature of their components and will allow to further elucidate the 
intracellular mechanisms (transport, assembly, and budding) associated with these nanoparticles. 
Furthermore, the analysis of the differential proteins content between VLPs and extracellular 
vesicles will help to identify targets for purification of both particle species. For this reason, in 
this study we have completed a proteomic analyses to characterize influenza H1N1 Gag-VLPs 
and extracellular vesicles produced in the human cell line HEK-293 cultured in serum free-
medium.  
 Methodology 
5.2.1 nLC-MS/MS of Tryptic Digests 
VLPs and EVs samples were reduced with 4 mM dithiothreitol for 1 hour at 56 oC, and then 
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alkylated with 20 mM iodoacetamide for 1 hour at room temperature in the dark. The samples 
were subsequently digested with trypsin at a 30:1 protein to enzyme ratio overnight at 37 oC.  
Peptides samples were then analyzed by reversed phase nLC-MS/MS, using a nanoAcquity 
UPLC (Waters) coupled to an Orbitrap XL mass spectrometer (Thermo Fisher) using 
electrospray ionization (ESI).   First, the peptides were loaded onto a 50 mm x 300 µm C8 
(Dionex) and a 20 mm x 180 µm C18 (Waters) trap columns in series, and then eluted onto a 100 
mm x 100 µm C18 analytical column (Waters). The elution gradient was linear: 1%-45 % solvent 
B over 18 minutes, 45%-85% solvent B over 3 minutes, 85%-1% solvent B over 1 minute. The 
columns were finally re-equilibrated at 1% solvent B for 8 minutes.  Solvent A was 0.1% formic 
acid in HPLC grade water; Solvent B was 0.1 % formic acid in acetonitrile. Data-dependent 
MS/MS analysis was performed, and the peak list files were searched against a database 
containing the Uniprot Human and influenza strain H1N1 A/PR sequences using MASCOT 
search engine (version 2.5; Matrix Science). Unique peptide matches were accepted when the ion 
score was greater than 30.  The significance threshold was set to p<0.05. 
5.2.2 Production of VLPs and EVs 
The VLPs analyzed in this study were produced in a HEK-293 inducible stable cell line 
expressing hemagglutinin and neuraminidase of H1N1 subtype. The VLPs formation was 
mediated by transient transfection of a plasmid containing Gag protein of HIV-1 fused to GFP 
(Venereo-Sanchez et al., 2016). The supernatant of cells, 72 hours post induction, was 
concentrated and semi-purified by ultracentrifugation through 25 % sucrose cushion. 
Subsequently, the recovered VLPs were ultrafiltrated through a membrane of 1000 KDa cut-off 
to remove smaller extracellular vesicles. 
The extracellular vesicles were isolated from supernatant of HEK-293CymRrcTA cells (Venereo-
Sanchez et al., 2016) at 72 hours post-induction with cumate. The supernatant was 25X 
concentrated through a 25% sucrose cushion. 
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 Results and Discussion  
5.3.1 Proteins identified in VLPs 
In the present study the proteins uniquely identified in the VLPs and EVs are presented and 
discussed in separate sections and tables. All proteins detected in VLPs sample are shown in 
Table 5-1 as differential and shared proteins with EVs. The proteins were grouped depending on 
their biological function. Mainly, proteins related to cell cytoskeleton, transport, RNA and DNA 
binding and processing, and post-translational modifications were identified in both species.  
- Heterologous proteins  
As differential VLPs proteins, the four recombinant proteins that mediate their formation were 
recognized within VLPs sample (HA, NA, Gag-GFP).  
- RNA binding and processing 
The nucleolin protein, one of the most abundant proteins in the nucleolus, was uniquely identified 
in VLPs with a MASCOT score of 324. This RNA-binding protein interacts with the 
nucleocapsid (NC) of Gag protein which is essential for the assembly (Bacharach, Gonsky et al., 
2000) and budding of HIV-1 particles (Ueno, Tokunaga et al., 2004). Nucleolin is also expressed 
on the cell surface (Hovanessian, Soundaramourty et al., 2010); cell-surface nucleolin and lipid 
rafts were shown to be involved in the virus entry process of HIV (Nisole, Krust et al., 2002).  
The heterogeneous ribonucleoproteins (hnRNPs) C1, C2 and U were also incorporated in the 
influenza Gag-VLPs, but not in the EVs. The hnRNPs bind to pre-messenger RNA protecting the 
RNA from being degraded by endo- or exo-nucleases and transporting it to the ribosomes for 
translation. This protein complex comprises a large family of over 20 members, some hnRNPs do 
not shuttle between the nucleus and cytoplasm (e.g. C1, C2 and U), which are those differentially 
identified in our Gag-VLPs. Other proteins, like A1 and K, stay attached during RNA export 
before shuttling back into the nucleus (Monette, 2011). The interaction between nucleolin and 
hnRNP C with the 3’-UTR of the amyloid mRNA precursor has been reported (Zaidi & Malter, 
1995). It is likely that Gag protein associates with these strong RNA binding proteins to 
guarantee the export of the vRNA into virions and reduce the release of empty virions. 
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- Cytoskeleton associated proteins  
Our analysis also revealed the presence of several proteins related to the cytoskeleton, some of 
which were unique to VLPs (Tubulin β-3 chain, Utrophin, Filamin-C, Rho guanine nucleotide 
exchange factor 4, the FYVE, RhoGEF and PH domain-containing protein 5, ADP-ribosylation 
factor-like protein 13B) and others were shared between VLPs and EVs (Tubulin β-chain, 
Tubulin α-1B chain, Tubulin β-4B chain, Actin, cytoplasmic 1, Actin, alpha cardiac muscle 1). 
From the differential cytoskeleton proteins in Gag-VLPs, the last three mentioned are not directly 
part of the cytoskeleton, but rather act as regulators. The Rho guanine nucleotide exchange 
factors mediate the activation of Rho GTPases by exchanging guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP). The Rho GTPases are involved in the regulation of actin-
dependent process such as migration and adhesion, and are also associated with the microtubule 
cytoskeleton, intervening in cell polarity and membrane transport, among other functions 
(Schmidt & Hall, 2002).  The FYVE, RhoGEF and PH domain-containing protein 5 also 
activates Rho/Rac GTPases family regulating actin cytoskeleton organization and cell shape 
(Nakada‐Tsukui, Okada et al., 2009). The ADP-ribosylation factor-like protein 13B, a member of 
ADP-ribosylation factor (ARF) family, is also essential in the stimulation of GTPases proteins 
being implicated in the intracellular vesicular trafficking (Brown, Gutowski et al., 1993).  The 
filamin protein has been previously identified in exosomes (Zhu, Chen et al., 2015). In general, 
the cytoskeletal proteins have been implicated in the transport of viruses throughout the cell 
cytoplasm to the assembly and budding site. Gag protein directly associates with actin 
microfilaments; in fact, the HIV-1 virions release depends on an intact actin-cytoskeleton 
(Mouland, Mercier et al., 2000; Sasaki, Nakamura et al., 1995). In the present study, some 
cytoskeletal regulator proteins were uniquely identified in Gag-VLPs and not in the EVs, which 
could be due to a more active translocation process promoted by Gag and/or the use of 
differential pathway for budding. 
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Figure 5-1 Differential and common proteins identified by nano LC-MS/MS in Gag-VLPs and 
extracellular vesicles (EVs).  
- Histones and Histone regulation proteins 
Several types of histones were identified within VLPs and EVs (Histone H4, Histone H2A, 
Histone H2B, Histone H3.2, Histone H1.2, Histone H2AX, Histone H2B type 1-J, and Histone 
H3) while histone regulator proteins (Protein SET similar protein, Protein SET, Histone 
deacetylase 4) were only found in VLPs. Histones are highly alkaline proteins rich in lysine and 
arginine that form a core around which DNA is wrapped, forming the nucleosome. In humans, 
this histone core is organized in octamers with a central tetramer of histones H3 and H4, flanked 
by two dimers of H2A and H2B.  The histone H1 acts as a linker between two nucleosomes 
(Marsman, Zeerleder et al., 2016). Histones play an essential role in regulating transcription and 
the condensation of chromatin. The presence of nucleosome fragments (histones and DNA) in the 
extracellular environment has been associated with cell death, cellular damage and apoptosis. 
However, it has been reported that different mechanisms are involved in the release of exosomes 
and apoptotic bodies and that both vesicle species are biochemically and morphologically 
different. The presence of histones in exosomes might be due to the co-production of apoptotic 
bodies in the cell culture (Théry, Boussac et al., 2001). The acetylation and deacetylation of 
histones has been involved with the regulation of transcription. The removal of the lysine acetyl 
group by the enzyme histone deacetylase causes the condensation of the chromatin. Regions of 
the chromosome with low level of acetylation are enriched with silent genes (Marks, Richon et 
al., 2000). The identification of histone deacetylase by LC-MS/MS has been previously reported 
in HIV-1 virions (Monette, 2011).  The Su(var)3-9, Enhancer-of-zeste, Trithorax (SET)-domain 
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protein family mediates the methylation of histone lysines regulating gene expression. Depending 
on the specific position in the chromatin of the methylated lysine, the genes will be repressed or 
activated (Dillon, Zhang et al., 2005; Nwasike, Ewert et al., 2016).  
- Heat shock proteins 
The heat shock proteins (HSPs) (Heat shock 70 kDa protein 1B, Heat shock cognate 71 kDa 
protein) were identified in both VLPs and EVs. This family of proteins have been found to be 
released under cellular stress and they are highly conserved among different organisms. The 
HSPs act as chaperones, participating in protein synthesis, folding, translocation and preventing 
protein aggregation. They also mediate ubiquitination of aberrant proteins cooperating with the 
proteasome system during quality control (Richter-Landsberg, 2009). The presence of heat shock 
proteins has been previously identified in exosomes, HIV-virions, influenza VLPs and influenza 
virus produced in Vero cells and Moloney murine leukemia virus (Ha et al., 2016; Monette, 
2011; Segura, Garnier et al., 2008; Shaw, Stone et al., 2008; Wu et al., 2010).  
- Post-translational modifications 
Furthermore, several proteins implicated in post-translational modifications were recognized in 
the VLPs and EVs (elongation factor 1-α 1 (EF1α), Eukaryotic initiation factor 4A-I, T-complex 
protein 1 subunit β, subunit γ, subunit θ, Peptidyl-prolyl cis-trans isomerase A), whereas other 
proteins such as Niban and Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase 
were uniquely identified in the VLPs. The EF1α is a crucial part of the cellular translation 
machinery. It is responsible for the GTP-dependent binding of aminoacyl-transfer RNA (aa-
tRNA) to ribosomes, guaranteeing fidelity and rate of elongation during translation. The EF1α 
interacts with actin filaments of the cytoskeleton, and is also involved in cell proliferation and 
compartmentalization of translation in the cytoplasm (Condeelis, 1995). This elongation factor 
specifically interacts with Gag protein of HIV-1, while it is not incorporated in non-lentivirus 
virions like Moloney murine leukemia virus (Cimarelli & Luban, 1999). However, in our study, 
this protein was detected in both VLPs and EVs, which suggests that the interaction with the 
actin cytoskeleton results in incorporation of EF1α into both nanoparticles species. In the case of 
VLPs, the EF1α most probably also interacts with Gag. The eukaryotic initiation factor 4A-I 
(eIF4-A) is required for the binding of ribosome subunits 40S to the mRNA during the initiation 
of protein biosynthesis. It has a single-stranded RNA-dependent ATPase activity, which mediates 
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the unwinding of the 5'-proximal mRNA secondary structure facilitating the attachment to the 
ribosomes (Rozen, Edery et al., 1990). The T-complex protein 1 is a hetero-oligomeric protein 
containing at least eight subunits that assists the correct folding and functional conformation of 
proteins in the cytosol of eukaryotic cells. It is involved in the folding of actin and tubulin 
(Kubota, Hynes et al., 1995). The Peptidyl-prolyl cis-trans isomerase A, also known as 
cyclophilin A, catalyzes the cis-trans isomerization of peptidyl-prolyl bonds in oligopeptides, 
accelerating the folding of proteins (Göthel & Marahiel, 1999; Takahashi, Hayano et al., 1989).  
The HIV-1 Gag protein specifically binds to cyclophilin A and B and this interaction appears to 
play an essential role in HIV-1 infection and replication cycle (Luban, Bossolt et al., 1993). The 
cyclophilin A was indentified in our Gag-VLPs with a significantly higher MASCOT score 
compared to the EVs (Table 5-1). This is likely due to the interaction with Gag, which enhances 
the presence of the protein within the VLPs. The cyclophilin A has also been detected in 
influenza virus produced in Vero cells (Shaw et al., 2008).  
Niban and Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase were uniquely 
identified in Gag-VLPs. The Niban protein is commonly expressed in renal tumors, therefore it is 
considered a marker of this type of carcinogenesis (Adachi, Majima et al., 2004). It regulates 
protein translation by phosphorylation of some eukaryotic translational initiation factors and is 
released under endoplasmic reticulum stress (Sun, Kobayashi et al., 2007). The Sia α-2,3, Gal-β, 
1,4-GlcNAc-R:α 2,8-sialyltransferase, also known as ST8SiaIII, catalyzes the polysialylation of 
membrane glycoproteins through the transfer of sialic acid from a cytidine monophosphate-linked 
sialic acid donor to an acceptor with alpha-2,8-linkages sialic acid ends (Volkers, Worrall et al., 
2015). The differential presence of the sialyltransferase in our VLPs could be part of the post-
translational modifications needed for the two glycoproteins hemagglutinin and neuraminidase.    
- Proteins transport 
As part of the transport proteins identified in VLPs, the ATP-binding cassette sub-family A has 
been differentially detected. This complex protein family is implicated in the export and import 
of complex molecules across lipid membrane, such as amino acids, sugars and proteins (Dean, 
Hamon et al., 2001). The ATP-binding cassette transporters superfamily has been involved with 
the assembly of HIV-1 virions (Zimmerman, Klein et al., 2002), and may be involved in the 
transport of Gag protein throughout the cytoplasm. The GTP-binding nuclear protein Ran and 
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ammonium transporter Rh type B (RHGB) were identified in VLPs and EVs. The GTP-binding 
nuclear protein Ran or Ras-related nuclear protein participates in the import and export of RNA 
and proteins between the nucleus and the cytoplasm and also its interaction with other proteins 
seems to play a role in the mitotic cycle (Klebe, Bischoff et al., 1995). The RHGB is a 
transmembrane protein mainly expressed in cells of organs related to the excretion, secretion of 
ammonia like the kidney. A previous study has shown the cellular localization of RHGB in the 
plasma membrane and intracellular granules (Liu, Peng et al., 2001).  
- Signaling transducer proteins 
The signaling transducer proteins, growth factor receptor-bound protein 10 (Grb10) and Guanine 
nucleotide-binding protein G(I)/G(S)/G(T) subunit β-1 were uniquely identified in VLPs. The 
Grb10 is an adapter protein that links tyrosine kinases receptors via phosphorylation, including 
the insulin and insulin-like growth factor receptors modulating several signaling pathways (Kabir 
& Kazi, 2014). The Guanine nucleotide-binding protein subunit β is part of the heterotrimeric G 
protein complexes. These subunits possess GTPase activity mediating the hydrolysis of GTP to 
GDP. The G proteins are activated by G protein-coupled receptors and this association regulates 
several signalling cascades for protein transport, enzymatic functions and a wide range of cellular 
functions (Neves, Ram et al., 2002).  The unique presence of these transducer proteins in the 
Gag-VLPs is most likely related to a more organized cell membrane translocation and budding 
orchestrated by the viral heterologous proteins.   
- DNA related proteins 
The DNA-dependent protein kinase catalytic subunit, Tumor protein 63, Transcription factor 
ETV7, and THAP domain-containing protein 6 were uniquely detected in Gag-VLPs.  The first 
two proteins mentioned are DNA-binding proteins that act as a response to cellular DNA damage 
stimulus. The transcription factor ETV7 (Tel-2) has been previously identified in human 
hepatocellular carcinoma being related with promoting chromosomal translocations in human 
cancers (Matos, Witzmann et al., 2009). The thanatos (the Greek god of death)-associated protein 
(THAP) domain is a DNA-binding protein that contains a zinc finger domain. The THAP domain 
containing proteins play an important role in cell proliferation, apoptosis, chromatin modification 
and transcriptional regulation (Bianchetti, Bingman et al., 2011). The N-glycosylase/DNA lyase 
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protein identified in VLPs and EVs is an enzyme that binds to damaged DNA and mediates DNA 
repair (Sharova, 2005).  
- Clearance of lipids 
Several proteins involved in the clearance of lipids were identified either in VLPs and EVs (Table 
5-1). The clusterin protein is a heterodimeric disulfide-linked glycoprotein that is implicated in 
several biological events, such as lipid transport, apoptosis, membrane lipid recycling and also it 
acts as a chaperone for correct folding and aggregation of secreted proteins (Koltai, 2014). The 
mitochondrial metalloendopeptidase OMA1, is part of the membrane-embedded quality control 
system in the inner membrane of the mitochondria. This protease plays a role in degrading and 
removing misfolded proteins from the organelles, and also in regulating the metabolism of lipids 
(Käser, Kambacheld et al., 2003; Quirós, Ramsay et al., 2012). The lactadherin (MFGE8) is a 
protein abundantly released in mammalian glands but it has also been identified in other types of 
tissues, such as lung, brain and kidney. It binds to phosphatidylserine and has been detected on 
the surface of apoptotic bodies and exosomes produced from murine dendritic cell line (D1) and 
monkey kidney cell line, COS-7 (Oshima, Aoki et al., 2002). The MFGE8 plays a role in the 
secretion of lipids.  
- Tetraspanins 
The tetraspanin member CD81 was found to be associated with the VLPs and EVs. Tetraspanins 
constitute a superfamily of proteins that have four transmembrane domains and two extracellular 
loops that are organized in the membrane as enriched-tetraspanin microdomains (TEMs). While 
tetraspanins are considered a biomarker for exosomes (Andreu & Yáñez-Mó, 2014), membrane 
zones enriched in tetraspanins are the areas from which HIV-1 assembles and buds (Thali, 2011). 
The tetraspanin CD81 is well known as a co-receptor for the entry of hepatitis C virus (Farquhar, 
Harris et al., 2011) and it has also been identified in several virus such as Moloney murine 
leukemia virus (Segura et al., 2008), feline immunodeficiency virus, canine distemper virus, 
influenza virus and influenza VLPs produced in Vero cells (Shaw et al., 2008; Wu et al., 2010). 
These findings suggest that these envelope viruses, VLPs and exosomes all follow similar path 
for budding through the TEMs spots.  
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- Glycolytic enzymes 
Three enzymes involved in ATP generating steps of the glycolysis were identified in the VLPs 
and EVs (GAPDH, pyruvate kinase and α-enolase). The presence of these glycolytic enzymes in 
viruses, VLPs and exosomes has been previously reported (Arslan, Lai et al., 2013; Monette, 
2011; Shaw et al., 2008; Wu et al., 2010). It is still unclear why these proteins remain in the 
VLPs and exosomes, however alternative functions related to the regulation of virus RNA 
transcription have been reported for these proteins (Shaw et al., 2008). In addition, it has been 
shown that the administration of mesenchymal derived-stem cells exosomes after myocardial 
ischemia/reperfusion injury increased ATP levels, decreased oxidative stress and activated 
cardioprotective pathways, thereby significantly reducing infarct size. The increase of ATP levels 
in the injured zone was claimed to be mediated by the glycolytic enzymes which reverted the 
depletion of ATP characteristic of this type of injury (Arslan et al., 2013). Perhaps the presence 
of glycolytic enzymes in the EVs and VLPs has to do with the life span and/or bioactivity of 
these nanoparticles. 
- Other proteins 
Other proteins with diverse functions were identified in both VLPs and EVs. The fatty acid 
synthetase has been previously detected in influenza virions (Shaw et al., 2008) and is a 
multifunctional enzyme that catalyzes the formation of long-chain fatty acids from acetyl-CoA, 
malonyl-CoA and NADPH. It has been reported that the infection with human cytomegalovirus 
(HCMV) upregulates the host cell metabolism (glycolisis, TCA and fatty acid biosynthesis) to 
provide energy for virus replication and the inhibition of fatty acid biosynthesis during HCMV 
and influenza A infection leads to the supression of viral replication (Munger, Bennett et al., 
2008). Lactotransferrin (LTF) was also detected in the influenza-Gag VLPs and EVs analyzed in 
this study. The protein has antiviral and antibacterial activity. Interestingly, LTF was the most 
abundant protein in the EVs evidenced by a highest MASCOT score among the proteins 
identified in extracellular vesicles. LTF has been previously identified in vesicles derived from 
urinary exosomes of both prostate cancer patients and controls (Øverbye, Skotland et al., 2015). 
It is worth to note that the use of LTF as an additive in the medium 293-SFM4TransFx employed 
to grow the HEK-293 cells, was demonstrated by MS/MS after cutting a high intensity 80 KDa 
band from an SDS-PAGE run with the medium (data not shown). However, considering that the 
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extracellular vesicles were isolated by ultracentrifugation through sucrose cushion, there should 
not be free LTF protein remaining in the final pellet, unless the protein forms aggregates and/or 
gets attached to VLPs. 
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Table 5-1 Proteins identified by n-LC-MS/MS in VLPs sample 
 Gag-VLPs unique proteins Shared proteins between VLPs and EVs 
  MASCOT 
Score 
Predicted 
MW (Da) 
Sequence 
Coverage (%) 
 MASCOT 
Score 
Predicted 
MW (Da) 
Sequence 
Coverage (%) 
Heterologous 
proteins 
Pr55(Gag) [Human 
immunodeficiency virus 1] 
3535 55894 70.6     
Green fluorescent protein 229 26869 34.9 
Hemagglutinin [Influenza A 
virus (A/Puerto 
Rico/8/1934(H1N1))] 
148 63341 12.5 
Neuraminidase [Influenza A 
virus (A/Puerto 
Rico/8/1934(H1N1))] 
61 50111 4.2 
Cytoskeleton 
associated proteins  
Tubulin β-3 chain  326 50400 20.7 Tubulin β-chain 641/1015 49639 40.3/62.2 
Rho guanine nucleotide 
exchange factor 4  
99 108145 2.2 Tubulin α-1B chain 595/995 50120 39.9/49.4 
Utrophin  53 394220 0.5 Tubulin β-4B chain 488/1078 
 
49799 36.9/62 
FYVE, RhoGEF and PH 
domain-containing protein 5 
41 159791 0.8 Actin, cytoplasmic 1 724/752 
 
41710 56/56 
Filamin-C  36 290841 0.5 Actin, alpha cardiac 
muscle 1 
280/281 41992 22/24.9 
ADP-ribosylation factor-like 
protein 13B  
35 48613 3     
RNA binding and 
processing  
Nucleolin  324 76568 13.7 Heterogeneous nuclear 
ribonucleoprotein K 
88/96 41781 3.2/3.2 
Heterogeneous nuclear 
ribonucleoproteins C1/C2  
161 31929 12.8 Heterogeneous nuclear 
ribonucleoprotein A1 
62/95 19460 5.2/17.9 
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Heterogeneous nuclear 
ribonucleoprotein U  
49 27387 3.3     
U1 small nuclear 
ribonucleoprotein A  
41 14635 7.8     
Cleavage and polyadenylation-
specificity factor subunit 1  
49 23670 3.9     
Histones and 
Histone regulation 
proteins 
Protein SET similar protein 54 33625 3.4 Histone H4 767/599 11360 51.5/51.5 
Protein SET  51 31105 12 Histone H2A 493/484 18470 37.9/27.2 
Histone deacetylase 4  45 118966 0.6 Histone H2B 386/637 13898 41.3/41.3 
    Histone H3.2 217/238 15379 40.4/43.4 
    Histone H1.2 176/386 21352 15/19.7 
    Histone H2AX 366/221 15135 47.6/47.6 
    Histone H2B type 1-J 307/690 13896 40.5/41.3 
    Histone H2A.Z 242/390 13545 35.2/53.9 
    Histone H3  113/144 14905 41.7/44.7 
Heat shock proteins     Heat shock 70 kDa 
protein 1B 
773/1292 70066 32.2/45 
Heat shock cognate 71 
kDa protein  
221/237 20000 21.2/9.7 
Post-translational 
modifications 
Protein Niban 43 103070 1.1 Elongation factor 1-
alpha 1 
136/189 47853 10.2/23.1 
Sia-alpha-2,3-Gal-beta-1,4-
GlcNAc-R:alpha 2,8-
sialyltransferase  
43 43942 2.1 Eukaryotic initiation 
factor 4A-I 
122/96 20675 6.9/6.9 
    T-complex protein 1 
subunit β 
101/194 56771 4.2/6.9 
    T-complex protein 1 65/158 55639 2.2/6.2 
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subunit γ 
    T-complex protein 1 
subunit θ 
41/97 35457 3.4/4.6 
    Peptidyl-prolyl cis-
trans isomerase A 
322/37 18001 44.8/32.8 
Proteins transport ATP-binding cassette sub-
family A member 12  
37 293049 0.3 GTP-binding nuclear 
protein Ran 
94/78 26799 13.7/18.4 
    Ammonium transporter 
Rh type B 
44/53 10570 11.3/11.3 
Proteins involved in 
clearance of lipids 
    Clusterin 157/222 52461 11.8/20.9 
    Metalloendopeptidase 
OMA1, mitochondrial 
48/42 37799 2.7/2.7 
    Lactadherin 79/316 29149 4.9/30.7 
Signaling transducer 
proteins 
Growth factor receptor-bound 
protein 10 
34 67189 3.4     
Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-1 
33 25918 4.2     
DNA related 
proteins 
DNA-dependent protein kinase 
catalytic subunit 
42 468788 0.5 N-glycosylase/DNA 
lyase 
41/46 19056 4.8/4.8 
Tumor protein 63 41 76736 1.8     
Transcription factor ETV7 36 38973 4.4     
THAP domain-containing 
protein 6  
35 11087 10.2     
Tetraspanin     CD81 71/158 24423 7.1/16 
Glycolytic enzymes     Glyceraldehyde-3-
phosphate 
dehydrogenase 
341/511 36030 36.1/51.6 
95 
    Pyruvate kinase  155/508 53011 8.9/24.1 
    α-enolase 201/648 
 
47139 
 
9.9/29.3 
Ribosomal proteins 40S ribosomal protein S20  46 5426 23.9 40S ribosomal protein 
SA 
39/55 33293 2.7/7.7 
Other proteins Cyclin-dependent kinase 
inhibitor 2A 
42 12076 18.1 Protein TRAJ56 49/50 2220 38.1/38.1 
Proline-rich basic protein 1 41 106852 1 Fatty acid synthase 76/102 273026 0.9/2.3 
Zinc finger protein 774 37 55032 2.7 26S proteasome non-
ATPase regulatory 
subunit 2 
67/43 
 
100136 
 
1.7/1.7 
Norrin 35 15033 16.5 Protein Dok-7 59/57 53064 3.6/3.6 
  
Pecanex-like protein 3  39 221898 0.4 Lactotransferrin 83/ 4003 76577 5/61.5 
Pecanex-like protein 2  30 237127 0.9 Creatine kinase B-type  99/256 24101 7.4/24.7 
Amine oxidase  30 15162 15.3     
 
Protein N-terminal asparagine 
amidohydrolase  
48 34656 2.6     
*MASCOT score and sequence coverage in “shared proteins between VLPs and EVs” are shown as VLPs/EVs value      
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5.3.2 Extracellular vesicles unique proteins 
The proteomic analysis of EVs revealed the presence of a total of 98 proteins and 57 unique 
proteins Table 5-2. From the differential proteins identified in EVs, the HSP90 was the most 
abundant based on the MASCOT score value and number of peptides identified. The HSP90 
protein binds to a wide variety of client proteins being implicated in several biological processes 
and was identified in exosomes derived from different tumorogenic cell tissues (Hegmans, Bard 
et al., 2004; Prodromou, 2016). It has been reported that the chaperone HSP70 is the one that is 
specifically incorporated in HIV-1 virions through interaction with Gag protein (Gurer, Cimarelli 
et al., 2002; Segura et al., 2008). Influenza viruses produced in Vero cells did not incorporate 
either HSP70 and/or HSP90 (Shaw et al., 2008) while influenza VLPs produced in the same cell 
line incorporated both (Wu et al., 2010).  
Within the group of proteins involved in signalling transduction, members of 14-3-3 proteins 
(epsilon and theta) were differentially detected in the EVs. The 14-3-3 proteins are a family of 
highly conserved acidic proteins comprising several isoforms (α-η) (Aitken, 2006). They play a 
role as modulators of Ras signalling pathway (Ji, Erfani et al., 2008). The Ras protein family are 
small GTPases involved in cellular signals transmission in the cytoplasm. Different members of 
the family have been identified in extracellular vesicles released from several cell types and it is 
considered an EV membrane marker in the Exocarta database.  
In addition, typical proteins associated to the ESCRT complex were differentially detected in the 
EVs produced in HEK-293SF, such as the programmed cell death 6-interacting protein, alias 
ALIX from apoptosis-linked gene 2-interacting protein X. The ESCRT complex is formed by 
four components: ESCRT-0, I, II, and III. The ESCRT-0 complex is recruited to the early 
endosome which at the same time recruits ESCRT-I and ESCRT-II. The complexes ESCRT 0, I 
and II bind ubiquitinated membrane proteins to be degraded in lysosomes, recycled or released to 
the extracellular milieu. Then, the endosomal membrane undergoes an inward budding to 
generate ILVs which requires the ESCRT-III complex for the final membrane bend and scission. 
The ALIX protein interacts with the ESCRTIII complex via the subunit CHMP4 (charged 
multivesicular body protein 4a) to mediate the scission of the ILVs, inside MVBs. ALIX also 
interacts with the ESCRT-I subunit TSG101 (tumor susceptibililty gene 101 preotein), linking 
ESCRT-I and ESCRT-III (Bissig & Gruenberg, 2014). ALIX has also been implicated in the viral 
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budding of HIV-1. The fact that proteins related to ESCRT complex were not identified in the 
influenza Gag-VLPs suggests a budding mechanism independent of ESCRT.  
Table 5-2 Proteins uniquely identified in extracellular vesicles produced in HEK-293 cells 
 Protein Description and database MASCOT 
Score 
Predicted 
MW (Da) 
Sequence 
Coverage (%) 
Cytoskeleton 
associated 
proteins 
MARCKS-related protein  71 19517 6.7 
Dystroglycan  50 97381 1 
PDZ and LIM domain protein 3  45 21741 5.6 
Fibrous sheath-interacting protein 2  40 789391 0.4 
Leucine-rich repeat and calponin 
homology domain-containing protein 2  
42 84536 1.6 
RNA binding 
proteins 
Lupus La protein  107 21429 7.6 
Nucleolysin TIAR  39 14607 6.1 
Serine/arginine-rich-splicing factor 2  49 15518 6 
rRNA methyltransferase 3, 
mitochondrial  
42 19683 12.4 
Histones Histone H2A type 1-A  218 14225 35.1 
Histone H1.3  251 22336 19 
Histone H2A type 2-B  206 13987 52.3 
Histone H1x  55 22474 5.6 
Heat shock 
proteins 
 
Heat shock protein HSP 90-alpha  523 84607 25.5 
Heat shock protein HSP 90-beta  490 83212 26.8 
Heat shock cognate 71 kDa protein  237 68763 9.7 
Putative heat shock 70 kDa protein 7  205 40220 18.3 
Post-translational 
modifications 
T-complex protein 1 subunit epsilon  223 55314 10.1 
T-complex protein 1 subunit alpha  145 46880 12.5 
T-complex protein 1 subunit zeta  38 57988 4 
Elongation factor 2  185 95277 9.3 
Elongation factor 1-gamma  103 50087 4.6 
Transport 
proteins 
Sodium/potassium-transporting ATPase 
subunit alpha  
114 78857 2.5 
98 
lipid metabolism 2-oxoglutarate and iron-dependent 
oxygenase domain-containing protein 3  
47 35624 2.8 
Prostaglandin F2 receptor negative 
regulator  
47 98495 2 
Phospholipase B1, membrane-
associated  
34 18491 9.9 
Signalling 
transducer 
proteins 
14-3-3 protein epsilon  236 29155 22 
14-3-3 protein theta  194 27747 28.6 
Serine/threonine-protein phosphatase 
2A 65 kDa regulatory subunit A alpha 
isoform  
95 45575 9.3 
Ankyrin repeat and SAM domain-
containing protein 3  
44 57992 2.8 
Citron Rho-interacting kinase  40 187298 0.4 
DNA related 
proteins and 
transcription 
factors 
X-ray repair cross-complementing 
protein 5  
83 82652 7.4 
X-ray repair cross-complementing 
protein 6  
77 64243 5.7 
T-box transcription factor TBX4  51 60166 2.4 
Poly (ADP-ribose) polymerase family, 
member 9, isoform CRA_b  
32 45623 3 
Cyclic AMP-responsive element-
binding protein 3-like protein 2  
31 57379 10.6 
Glycolytic and 
TCA enzymes 
Phosphoglycerate mutase 2  78 28748 9.9 
ATP-citrate synthase  64 120762 1.4 
Phosphoglycerate kinase  45 44586 4.1 
Ribosomal 
proteins 
40S ribosomal protein S3  61 14994 9.6 
40S ribosomal protein S8  58 21866 5.9 
ESCRT 
associated 
proteins 
 
Ubiquitin-like modifier-activating 
enzyme 1  
286 117774 10.8 
Coiled-coil domain-containing protein 
180 
53 190979 1.2 
Programmed cell death 6-interacting 
protein (ALIX) 
52 95963 1.7 
Cell-cell 
interaction and 
Integrin alpha-X  42 128456 1.3 
Matrix extracellular 40 55630 3.2 
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intercellular 
signalling 
phosphoglycoprotein  
Protocadherin alpha-6  54 102652 1.9 
Basigin  46 20529 7.4 
Olfactory receptor 4F3/4F16/4F29  30 35050 10.3 
Other proteins Protein AHNAK2  115 616242 0.2 
Brain acid soluble protein 1  82 22680 22.9 
Adenosylhomocysteinase 48 47685 5.1 
Breast cancer type 1 susceptibility 
protein  
39 69926 1.4 
RING finger protein 121 (Fragment)  32 16795 20.5 
Uncharacterized protein  383 88324 13.9 
F-box only protein 17 (Fragment) 36 12099 11.9 
Lamina-associated polypeptide 2, 
isoform alpha 
32 75446 2.9 
 Conclusions 
In a previous study we have shown the feasibility of producing influenza VLPs in HEK-293SF 
cells (Venereo-Sanchez et al., 2016). In the present work, the proteomic composition of the 
influenza Gag-VLPs generated using an inducible HEK-293 producing cell line (Venereo-
Sanchez et al., 2016) and extracellular vesicles (EVs) produced from non-transfomed HEK-
293SF was analysed by nano-LC-MS/MS. As expected, several host cell proteins were 
incorporated in influenza Gag-VLPs and EVs. The identified proteins are multifunctional 
proteins mostly involved in cell signalling pathways, protein translocation and folding, and were 
associated to the cell cytoskeleton and nucleic acids. The RNA-binding protein nucleoline was 
uniquely incorporated in the VLPs, probably through a specific interaction with the Gag protein. 
On the other hand, lactotransferrine was the most abundant protein in EVs, as well as the HSP90. 
In addition, important proteins associated to the endosomal sorting complexes required for 
transport (ESCRT) were identified in the exosomes, whereas they were not detected in VLPs. 
This observation could suggest a possible different mechanism where VLPs budding is 
independent of ESCRT. Further studies will be focused on determining the RNA composition 
within both nanoparticles species and in vivo experiments to confirm that there is no potential 
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hazardous components. In addition, proteins differentially identified either in VLPs and EVs will 
be exploited for the development of novel purification protocols to separate EVs from VLPs. 
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CHAPTER 6 GENERAL DISCUSSION 
While VLPs have emerged as a promising influenza vaccine platform, there are still numerous 
challenges associated with their large-scale manufacturing and more work needs to be devoted to 
bioprocess development, purification and characterization. Mammalian cells offer several 
advantages as a platform for enveloped VLPs production, including superior post-translational 
modifications that are important for preserving the conformation and glycosylation of the 
antigens. In addition, mammalian cells are easy to grow in serum-free medium in suspension 
cultures allowing large scale production and high productivity yields. In this thesis, to address 
some of the significant difficulties associated to the large-scale manufacturing of VLPs, we have 
developed a production process to produce these nanoparticles in a human cell line. Human cell 
lines provide a glycosylation profile and folding consistent with human endogenous proteins, 
which alleviates the potential antigenicity of recombinant biopharmaceuticals for human use 
(non-human mammalian cell lines can introduce glycosylation patterns that can be antigenic in 
humans). Since the formation of influenza VLPs involved more than one protein, the VLPs 
production was driven in an inducible manner, such that there is no extra metabolic burden 
during the cells growth. We have proposed the use of a stable cell line for large-scale vaccine 
manufacturing, thus bypassing the need for transient transfection which can be technically 
cumbersome at large scale production.   
The production of influenza VLPs is usually mediated by the co-expression of HA, NA, M1 and 
M2, although other studies were successful at producing VLPs by expression of HA, NA and M1 
(Pyo, Masic et al., 2012); HA and NA (Chen et al., 2007); HA and M1(Quan et al., 2007); HA 
(Chen et al., 2007; D’Aoust, Lavoie et al., 2008) ; NA (Lai et al., 2010); M1 (Gómez-Puertas et 
al., 2000); and M2 (Chen et al., 2007). After decades of intensive research on influenza virus 
assembly and budding mechanisms, it appears that these processes are mediated by a redundant 
interaction between the four proteins, and not by a single protein as for other types of viruses.  
The review of Rossman, and Lamb (2011) proposes a model for influenza assembly and budding 
where the accumulation of HA and NA in lipid raft zones may initiate the viral budding by 
altering the membrane curvature. Then, the cytoplasmic tails of HA and NA recruits the M1 
protein at the budding site enhancing the budding process. The non-raft channel protein M2 
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interacts subsequently with M1, mediating the scission of the virions. NA mediates the final 
release of the virions from the cell surface by cleaving the sialic acid on receptors to prevent the 
binding of HA.  
Considering the uncertainty as which proteins mediate virus budding in influenza and the need 
for a production process able to generate high yields of VLPs, we assessed the use of two 
proteins as driving force for viral budding: M1 matrix protein of influenza and Gag protein of 
HIV-1. At first, a stable cell line expressing HA and NA was transfected with the plasmid 
containing the corresponding proteins. Since the production of VLP proteins was significantly 
higher (7X) using Gag protein, the production process of VLPs was implemented in a lab-scale 
bioreactor by transient transfection with the plasmid containing Gag. The yields of HAU/ml 
(8913) and VLPs/ml (1.78x1010) estimated in the material recovered from the ultrafiltration were 
higher than those reported by other studies producing VLPs either in insect cells (Thompson et 
al., 2015)  or mammalian cells (Cervera et al., 2013). However, it should be emphasized that 
direct comparisons are difficult due to differences in the methodology and/or analytical 
techniques employed in each laboratory (Thompson et al., 2013). Thus, the VLPs production 
process using transient transfection of Gag was our first approach to produce influenza Gag-
VLPs and their immunogenicity and efficacy were demonstrated by in vivo experiments. The 
positive control group (CT+), included in the mice experiment, was immunized with a 
recombinant HA protein from the same strain H1N1 A/Puerto Rico/8/34. The levels of anti-HA 
specific antibodies IgG1 elicited in animals from CT+ were higher than mice vaccinated with the 
influenza Gag-VLPs. This immunoglobulin is related to a T helper (Th) 2 response, which is 
characteristic of immunization with soluble recombinant protein (Bright et al., 2007). 
Interestingly, most of the mice vaccinated with the influenza Gag-VLPs elicited higher titers of 
IgG2a, which is an immunoglobulin characteristic of a Th1 response. This type of response is of 
great importance against viral infections since it promotes viral clearance and induces strongest 
protection (Huber, McKeon et al., 2006). It has been shown that immunization with the whole 
influenza virion generates a significantly higher IgG2a in comparison with recombinant protein 
(Bright et al., 2007).  Furthermore, it has been reported that VLPs directly activate B cells and 
promote their differentiation in IgG2a producer plasma cells (Zhang, Cubas et al., 2009). 
Although both mice groups (CT+ and influenza Gag-VLPs vaccinated) were protected against a 
challenge with the homologous strain, it appears that VLPs generate a more active immune 
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response capable of clearing the viruses and mediate a professional presentation of antigens that 
activate cellular immunity. Further studies should be performed in other animal models, like 
ferrets, to test different concentrations of VLPs for immunization and challenge animals with 
different strains to verify the capacity of the vaccine to elicit a broader response.  
Once the proof of concept of HEK-293-produced influenza Gag-VLPs was demonstrated by in 
vivo experiments, the production process was reassessed, aiming to develop a strategy that can be 
suitable for large scale manufacturing. In the first production approach implemented, the 
formation of VLPs was mediated after transient transfection with a plasmid containing the Gag-
HIV-1 protein. However, in the context of large-scale operation, the additional steps required for 
the transient transfection are not desirable. Taking into account that the Gag protein is the core 
protein of the VLPs, there is no need to do transient transfection for every bulk production. 
Therefore, a production process using a stable cell line expressing the three genes involved in the 
VLPs formation was developed.  
The process was further optimized in an effort to increase the volumetric yield (without affecting 
the cell specific productivity) by increasing the cell density at the time of induction. Interestingly, 
we found that, by maintaining medium replacement after the induction at small scale, the total 
VLP proteins volumetric yield was increased by 128 fold (Gag-GFP events) and 17 fold (HA µg) 
compared to the batch control. This strategy was also found to improve the total volumetric yield 
by 2.9 fold (Gag-GFP events) and 2.2 fold (HA µg) compared to cultures without medium 
replacement after induction. Through medium exchange, toxic waste metabolites and growth-
inhibitory cell factors are diluted and, simultaneously, the fresh medium added provides a 
constant supply of nutrients to avoid limitations (Hiller et al., 2017). To achieve the same level of 
productivity, three bioreactor runs without medium replacement post-induction need to be 
performed, which has a significant impact on cost and labour. A reduction in cell viability and 
growth was observed in the shake flasks where medium replacement was maintained after 
induction due to a shear stress effect on cells as a result of the centrifugation steps. However, the 
productivity was not affected by this (Figure 4-3).  
A 3L-bioreactor in perfusion mode was successfully implemented using the cell line 293-
HA/NA/Gag-GFP. The protein HA productivity values were comparable to those of small scale 
cultures, whereas higher Gag-GFP event count was obtained in medium replacement condition at 
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small scale compared to the perfusion bioreactor. This could be due to the release of intracellular 
Gag-GFP associated with the decrease in viability resulting from cell centrifugation. The cell 
specific productivity, compared to the batch control, was increased for both genes by a factor of 4 
for Gag-GFP events and by 500 fold for HA. The observed differences can be due to the region 
of insertion of the genes in the chromosome and how their expression is affected or favored by 
the high cell density (Wurm, 2004). The acoustic filter used for cell separation was highly 
efficient, as low cell counts were measured in the harvest stream. Therefore, no centrifugation 
steps were needed to clarify the harvest (only the residual 2.6L left in the bioreactor were 
centrifuged) which is highly advantageous when operating at large scale. Once the perfusion 
bioreactor was stopped, it took only 3 hours to process the 9.5 L harvest, including clarification 
and ultrafiltration/concentration. This scenario was significantly better to what we showed in our 
first production process approach where VLPs concentration was performed by 
ultracentrifigation through a 25 % sucrose cushion followed by a diafiltration.  
With the aim to better compare the productivities obtained from our first process approach where 
VLPs were produced by transient transfection with Gag and the production process from the cell 
line stably expressing the three genes (293-HA/NA/Gag-GFP stable cell line), Table 6-1 shows 
the VLP protein yields based on different assays. The production of HA per liter of culture 
measured by dot-blot was higher in the transient transfection approach, while HA productivities 
based on SRID were higher in the stable cell line 293-HA/NA/Gag-GFP cultivated in a perfusion 
bioreactor. The differences can be due to intrinsic variability between the techniques or since 
SRID measures the antigenic conformation of HA (Li, Jaentschke, et al., 2010), there might be 
less antigenic HA produced in the transient transfection production process approach. Since 
SRID is the established method used to quantify seasonal influenza vaccines, we relied on this 
method to compare the processes and calculate the vaccine doses produced.  The expression of 
NA was higher in the production using the stable cell line 293-HA/NA/Gag-GFP leading to a 
HA:NA ratio of 1:4 which is the same ratio obtained with the sucrose cushion preparation of 
influenza virus H1N1 A/PR/8/34 produced in HEK-293 cells (Venereo-Sanchez et al., 2016). 
The transient transfection approach was more efficient in the sense that similar VLP protein 
production was obtained at a lower cell density. However, 5-fold more total HA protein was 
produced from one single bioreactor run operated in perfusion mode with the stable cell line 293-
HA/NA/Gag-GFP. The concentrations of host cell proteins (HCPs) and host cell DNA were 
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measured in the final material recovered from the two processes. The concentration of host cell 
DNA was similar between the two processes; however, a higher HCPs concentration was 
obtained in the VLPs produced from the stable cell line 293-HA/NA/Gag-GFP. The FDA 
provides guidelines with the purity requirements for vaccines establishing concentrations of DNA 
lower than 10 ng per dose. Considering that the dose in humans is 15 µg, with our current 
production we could expect around 5 µg of DNA in the final dose, which is considerably higher 
than the maximum residual DNA amount allowed. At the same time, very low amounts of HCPs 
concentration are accepted in the final product, and although biopharmaceutical companies do not 
release their lot specifications, more than 95% purity was required by the WHO for the late-stage 
VLP malaria vaccine from GlaxoSmithKline. For therapeutic proteins like antibodies, the 
specifications on HCPs levels are set below 100 ppm (Effio & Hubbuch, 2015). Certainly, future 
works on VLPs produced either by transient transfection or using stable cell lines need to address 
these important issues by implementing more refined purification and polishing methods that can 
effectively remove these product-related contaminants.   
The electron micrographs obtained from sucrose cushion preparations that revealed the presence 
of small extracellular vesicles (Figure 3-3) and also the detection of total HCPs by ELISA 
underscored the need to characterize in more details the proteomic of VLPs and extracellular 
vesicles (EVs) produced by HEK-293 cells. The results of the nano-LC-MS/MS analysis revealed 
the presence of 98 and 73 proteins within EVs and VLPs, respectively, of which 41 were shared 
between them. Most of the proteins identified in both nanoparticles species are multifunctional 
proteins which play important roles in signaling pathways, intracellular trafficking of molecules, 
cytoskeleton organization, protein folding, transcription and translation. Based on the MASCOT 
scores, we found that nucleolin was the most abundant HCP within VLPs, while lactotransferrin 
and HSP90 were the majority in EVs. Nucleolin is an RNA binding protein that interacts with 
Gag-HIV during the HIV replication cycle. Cell-surface expressed nucleolin, together with lipid 
rafts have been implicated with the viral entry process of HIV in the host cell (Nisole et al., 
2002). 
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Table 6-1 Summary of the production performances of the two processes employed to produce 
VLPs 
 Transient transfection 
(3L-batch bioreactor) 
Stable cell line  
293-HA/NA/Gag-GFP  
(3L-perfusion mode bioreactor) 
Cell density at the time of induction 
(x106 cells/ml) 
1 14 
[HA] µg/L of culture by dot blot 243 165 
[HA] µg/L of culture by SRID 138 194 
HAU/ml of final product after TFF 
concentration  
8913 8913 
[NA] µg/L of culture by dot-blot 8 41 
Gag-GFP events count by flow 
cytometry (x1011 Gag-GFP events/L 
of culture) 
6 3 
Host cell proteins (µg/ml) final 
product after TFF concentration 
0.49 29 
Host cell DNA (µg/ml) final product 
after TFF concentration 
2.46 3 
Ratio HA/NA 1 :40 1 :4 
Total HA produced ( µ by SRID) in 
one single 3L-bioreactor run 
370 1843 
Human dose (15 µg of HA measured 
by SRID) 
25 123 
The fact that nucleolin is expressed on the cell surface makes this protein a potential attractive 
target for VLPs purification. On the other hand, the reason why lactotransferrin was abundantly 
incorporated in the EVs remains unclear. The protein has antimicrobial properties and has been 
identified in different types of exosomes, like urine exosomes (Øverbye et al., 2015) and other 
secreted fluids like seminal plasma (Batruch, Lecker et al., 2011) and saliva (Ambatipudi, 
Swatkoski et al., 2012). The HSP90 is a chaperone commonly identified in exosomes isolated 
from different tissues (Prodromou, 2016). The protein ALIX, that plays an important role in 
assisting the ESCRT complexes, was identified in the EVs but not in the VLPs, suggesting that 
perhaps the VLPs are not using this pathway for budding. However, this would require further 
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investigation given the low MASCOT score of this protein identification and the fact that several 
proteins could interact with the particles during their formation inside the cell. 
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CHAPTER 7 CONCLUSION AND RECOMENDATIONS  
 Conclusions 
The traditional production approach for manufacturing influenza vaccines in embryonated eggs 
has limited capacity, is labor-intensive and time-consuming. Furthermore, current seasonal 
vaccines do not provide complete protection in all age groups. Therefore, vaccines with more 
immunogenic efficacy manufactured in high-production capacity platforms need to be developed. 
Virus-like particles (VLPs) can be formulated into promising vaccines to prevent influenza 
infection. In addition to having a structure that mimics the wild type virus, VLPs are safe since 
they are devoid of viral genes and consequently are not infectious. The surface antigens of VLPs 
synthesized in mammalian cells, will have human-like post-translational modifications similar to 
the wild type virus, and therefore will trigger a potent and specific immune response to the 
pathogen.  
In the first part of the thesis, a HEK-293 cell line stably expressing HA and NA under the 
regulation of a cumate inducible promotor was developed with the aim to produce influenza 
VLPs. Our observations after transfecting the 293HA-NA cell line with a plasmid containing M1 
influenza matrix protein support the previous results (Chen et al., 2007) that M1 by itself is not 
the driving force of influenza virus budding. M1 did not increase protein release in comparison 
with the co-expression of HA and NA alone. In contrast to M1, the potency of Gag of HIV-1 as a 
powerful protein to promote influenza VLPs formation in mammalian cells was demonstrated in 
the present thesis.  The transfection of 293HA-NA cells with Gag increased the production of 
VLPs antigenic proteins by 7-fold compared to its counterpart M1. The VLPs production process 
using the stable cell line 293HA-NA with transient transfection of a Gag containing plasmid was 
validated in a 3L-bioreactor. The influenza Gag-VLPs produced in the bioreactor were efficiently 
semi-purified by TFF at 1000 KDa cut-off with a recovery efficiency of 45%. Ultrafiltration 
membranes with a pore size as large as possible, but still capable of fully retaining the product 
must be selected for the concentration and semi-purification of VLPs, since more contaminants 
can be eliminated in the permeate. The VLPs production process in the 3L-bioreactor after 
transient transfection of 293HA-NA stable cells with the Gag-containing plasmid yielded 
138µg/L of HA, 6.5 µg/L of NA and 6x1011 Gag-GFP fluorescent events/L as measured by the 
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SRID, Dot-Blot and flow cytometry quantification values, respectively. The ratio of NA:HA in 
the VLPs was determined as 1:40. Finally, the intranasal immunization of mice with influenza 
Gag-VLPs induced strong antigen-specific mucosal and systemic antibody responses, and 
provided full protection against a lethal intranasal challenge with the homologous virus strain. 
In the second part of the thesis, having demonstrated the immunogenicity and protective efficacy 
of the VLPs, we aimed to streamline and make the VLPs production process more scalable. To 
this end, the Gag-GFP gene was put under the cumate inducible promoter CR5 and was stably 
transfected in the cell line 293HA-NA. This obviated the need for the transient transfection step, 
which is technically cumbersome to perform at large scale. Once the best producer cell clone of 
293-HA/NA/Gag-GFP was selected, the goal was to increase the cell density at the time of 
induction to improve the volumetric yield of VLPs. After culture media selection and assessing 
the impact of medium replacement at small scale, we performed a perfusion run in a 3L-
bioreactor. By increasing the cell density to 1.4x107 cells/ml at the time of induction, the 
volumetric yield of VLPs proteins increased by 60-fold (Gag-GFP fluorescent events/ml), 17-fold 
(HA µg/L) and 102-fold (NA (µg/L) compared to the batch control.  The 9.5L harvest broth 
collected from the bioreactor was clarified by normal filtration without the need of centrifugation 
steps since the VLPs containing supernatant is directly separated from the cells through the 
retention device. This fact is highly advantageous for large scale manufacturing, since large 
capacity centrifuge can be costly. The yields of VLPs proteins obtained in the 3L-perfusion 
bioreactor were 194 µg/L in terms of HA concentration measured by SRID, 3.1x1011 Gag-GFP 
events/L and 41 µg/L of NA quantified by Dot-Blot. Performing one 3L-bioreactor in perfusion 
mode with the stable cell line 293-HA/NA/Gag-GFP allowed to generate 5-fold more VLP 
antigenic protein HA than what was produced with the 3L- batch bioreactor using transient 
transfection.  
Finally, considering the great concern associated with the heterogeneous composition of 
enveloped VLPs containing endogenous HCPs, DNA and RNA and the co-production with 
extracellular vesicles (EVs) of similar size, in the present thesis the proteomic composition of 
VLPs and EVs produced from HEK-293 was identified by n-LC-MS/MS. A total of 73 host cell 
proteins were identified in the VLPs, while 98 were detected in the extracellular vesicles. From 
that, 32 host cell proteins were unique of VLPs and 41 proteins were common between the two 
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particles. The indentified proteins were mostly involved in cell signalling pathways, protein 
translocation, folding and were associated to the cell cytoskeleton and nucleic acids.  
 Recommendations for future studies 
The work performed in this thesis has also highlighted some critical aspects that call for more in 
depth-investigations: 
 Link reporter genes to viral recombinant proteins involved in VLPs formation. This will help 
to develop more straightforward methods for the online monitoring of VLPs by using 
sensitive probes. 
 Perform in vivo immunization of VLPs in other animal models like ferrets, use of lower 
doses, test the effect of different adjuvants and assess the efficacy of the VLPs produced with 
the 3L-perfusion bioreactor. Ferrets are better than mice as animal models for influenza since 
they have similar lung physiology than humans, developing similar clinical signs and 
transmissibility of the virus. 
 Perform further optimization of the production process by studying metabolic fluxes and 
designing a rational fed-batch strategy that can improve the production. Also, different cell 
densities at the time of induction can be studied in the perfusion process to evaluate the 
effect of this parameter on the VLPs production 
 Characterize the RNA, DNA and lipid composition of VLPs and exosomes produced in 
HEK-293 cells in order to have a complete description of the uptaken elements and ensure 
the safety of our vaccine candidate. 
 Perform biophysical characterization of the VLPs and EVs (Dynamic light scattering (DLS), 
Nanoparticles tracking analysis (NTA), Atomic force microscopy (AFM) or Scanning 
electron microscopy (SEM))   
 Develop new affinity chromatography methods to purify VLPs and EVs by binding 
antibodies against the proteins uniquely identified for both nanoparticles species in the 
present thesis.(e.g. make an immunoaffinity matrix by immovilizing an anti-nucleoline 
antibody, then pass the VLPs concentrated by TFF, wash and elute to recuperate the VLPs)   
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 To speed up the production process, other different approaches can be used: 1) Develop a 
stable cell line using CRISPR technology such that the variable antigenic proteins can be 
inserted and removed without the need to develop a new cell line from the beginning. 2) 
Develop a stable cell line expressing Gag protein and construct a plasmid/plasmids with 
enzymatic restriction sites that allow a fast removal/insertion of the antigenic proteins. 
 Use this VLPs platform, where Gag protein of HIV acts as a core protein and the VLPs are 
produced in HEK-293 cells, for presentation of antigens of other diseases and for 
presentation of universal epitopes against influenza 
 Perform stability studies of the VLPs and test different buffer formulations for better protein 
and structure conservation.  
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